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Abstract 
 
Vigabatrin, a GABA (γ-aminobutyric acid) agonist is a drug widely 
prescribed in Europe and Asia between 1989 and 1997 for drug resistant, 
partial epilepsy and has been associated with visual field defects. 
Uncertainity in the effect of Vigabatrin on vision resulted in decreased 
prescriptions. However, there has been poor reproducibility in previous 
studies due to many factors, especially poor sensitivity and specificity of 
tests for Vigabatrin associated visual dysfunction. The wide field multifocal 
electroretinogram (WF-mfERG) can objectively measure discrete areas of 
retinal function up to 90 degrees. The results of 204 patients with epilepsy 
divided into four groups are presented. A subgroup of 89 patients had repeat 
investigations. The patients were divided into four groups.  
Group 1.The Vigabatrin group comprised patients who had been taking 
Vigabatrin for at least 1 year (56 patients).  
Group 2. Forty nine patients who had previously taken Vigabatrin for at least 
1 year but had stopped taking this treatment for at least 2 years comprised 
the ex-Vigabatrin group.  
Group 3.The GABA group had 46 patients who used other anti-epileptic 
drugs (AED) with GABA action other than Vigabatrin. 
Group 4. Fifty three patients who had never used an AED with GABA action 
including Vigabatrin made up the non-GABA group.  
Surprisingly, the percentage of patients with visual field defects were high in 
all groups investigated (Vigabatrin group 59%, ex-Vigabatrin group 46%, 
GABA group 30.2% and non-GABA group 21.2%).  However, abnormal 
bilateral WF-mfERG responses were only found in the Vigabatrin group   2 
(48%) and the ex-Vigabatrin group (22%). The study suggests that there are 
probably different causes of visual field abnormalities in patients with 
epilepsy not related to Vigabatrin.  
We propose that the most sensitive and specific tests that can be used to 
detect visual dysfunction associated with Vigabatrin is the WF-mfERG 
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Chapter 1 
 
Summary 
   20 
Epilepsy is a common disabling neurological condition in the world.  
 
Epileptic  seizures  are  symptoms  experienced  or  demonstrated  in  someone  who  has 
episodes of abnormally increased electrical activity in the brain. In the brain regulatory 
inhibitory mechanisms normally prevent this excess activity. Such mechanisms include 
dampening  of  synaptic  conduction  by  neurotransmitters  such  as  γ-aminobutyric  acid 
(GABA).  Vigabatrin  enhances  GABA  inhibitory  action  by  irreversibly  binding  to  a 
degradatory enzyme (GABA-transaminase) increasing GABA levels in the brain (as well 
as other parts of the body, such as the retina) thereby decreasing the occurrence and spread 
of seizures in some patients. 
 
Epilepsy will not be fully controlled in 25-30% of cases. For everyone, the search for 
additional effective and well tolerated anti-epileptic drugs is an important one. 
 
Vigabatrin was found to be in an excellent drug in patients with drug-resistant partial 
seizures  and  in  infantile  spasms  and  was  widely  prescribed.  Since  1997,  seven  years 
following its licence being issued, there have been many reports of visual field defects 
occurring in some patients on Vigabatrin resulting in dramatic decrease in prescribing. 
 
A  literature  review  has  also  shown  discrepancy  on  the  aetiology,  prevalence  and 
contributing factors in patients with visual field defects. As will be explained Vigabatrin 
has complex actions on the retina that are reversible and irreversible, both with acute and 
chronic effects. Hence separating the chronic permanent changes which is predominantly 
represented by visual field defects from acute reversible changes is difficult.  
 
The clinical picture is further complicated by the difficulty in separating the actions of 
Vigabatrin from those of increased GABA levels since Vigabatrin increases GABA levels 
and it is difficult to separate the actions of these two compounds.  
 
Other unknown factors may prove to be important. A recent study by Izumi has indicated 
that high light levels may be significant.(1)  
 
There  are  other  problems:  people  with  epilepsy  have  poor  attention  and  concentration 
which may make subjective testing difficult.  
   21 
The  results  of  visual  field  testing  and  even  changes  in  objective  tests  such  as 
electroretinograms  (ERG)  and  multifocal  ERG  (mfERG)  reflect  the  multiple 
physiological/pathological processes occurring at the same time making it difficult to draw 
reliable conclusions form the data gathered. 
 
The ERG is a mass electrical response of the retina to light stimulation. The method of 
recording the electrical response is by stimulating the eye with a bright light source such as 
a flash produced by a Ganzfeld bowl. The intense flash of light elicits a biphasic waveform 
recordable at the cornea (a-wave and b-wave). Measurement of the amplitude and latency 
of the a-wave and b-wave using light flashes of different intensities in dark adapted and 
light adapted eyes provides information global retinal function. The international Society 
for Clinical Electrophysiology of Vision (ISCEV) sets standards for stimuli and recording 
responses. Responses are normally divided into rod, maximal, oscillatory potential, cone 
and flicker responses. Previous studies using the ERG to examine the retina in patients 
taking  Vigabatrin  have  shown  multiple  abnormalities  including  decreased  oscillatory 
potential  amplitude,  reduced  cone  b  wave  amplitude  and  decreased  flicker  amplitudes 
indicating global retinal dysfunction associated with Vigabatrin use. Unfortunately authors 
have disagreed on the significance of the ERG parameters in the development of visual 
field defects.  
 
Vigabatrin is as an effective AED but may be unsafe. Therefore we need to clarify the 
causes and possible prevention of the visual field defects.  
 
The National Institute on Drug Abuse is interested in evaluating the safety and efficacy of 
Vigabatrin for the treatment of cocaine and methamphetamine dependence. Studies with 
Vigabtrin have been fast tracked by the U. S. Food and Drug Administration (FDA). There 
are currently no medications approved by the FDA for the treatment of cocaine and/or 
methamphetamine dependence which have substantial negative public health impacts. We 
need to find an effective way ofpreventing the development of visual field defects. 
 
Vigabatrin may predominantly affect the peripheral retina. Multifocal ERG (mfERG) is an 
objective  technique  in which  simultaneous  recording  of  a collection of focal  electrical 
impulses  from  the  retina  corresponds  to  localized  areas  of  retinal  function.  Hence  the 
mfERG  can  differentiate  central  retinal  function  from  peripheral  retinal  function. 
Commercial mfERG systems can map discrete areas of retinal function but the field of 
view is limited to central 30 to 50 degrees. A custom built system by the electro-diagnostic   22 
Imaging Unit in Glasgow assesses up to 90 degrees field of view, the wide field mfERG 
(WF-mfERG).  
 
The mfERG evokes electrophysioloical responses using a stimulus consisting of multiple 
scaled  hexagonal  elements  which  are  independently  switched  between  low  or  high 
luminance  (black  or  white).  The  luminance of  each  run  is  controlled  by  mathematical 
series called m-sequences an array of ‘0’s and ‘1’s. The m-sequences enable each element 
to independently stimulate a focal area of the retina and each area of retinal function can be 
calculated from the global electric response generated from the cornea. Responses gives a 
‘map’  of  retinal  function  and  each  response  consist  of  multiple  waveforms,  N1  first 
negative deflection, P1 first positive deflection and N2 second negative deflection. The 
amplitude and latency of individual responses or the average of groups of responses are 
measured. 
 
The  first  report  in  the  literature  of  the  WF-mfERG  by  Parks  and  Keating  showed  an 
increase in implicit time in peripheral retinal responses. It was thought that a WF-mfERG 
parameter might be able to separate those with visual field defects from those without in 
patients who had taken Vigabatrin. (2) 
 
A larger study by APrks and Keating investigated 32 patients on Vigabatrin compared to 
34 patients with epilepsy who had never taken Vigabatrin. (3) 59% of the Vigabatrin group 
had visual field defects and none of the controls. The most consistent overall predictor of 
bilateral visual field defects was the difference between central and peripheral latency, 
abnormal if greater than 2 milliseconds. Using this parameter all patients with visual field 
defects showed abnormalities (100% sensitivity) and only 2 out of 13 patients without a 
field defect showed retinal abnormalities (86% specificity). 
 
This thesis concentrates on attaining knowledge of the effect of Vigabatrin on the retina 
allowing early detection of toxic effects. 
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Chapter 2  
 
Epilepsy 
 
2.1 Introduction 
 
Epilepsy should not be understood as a single disorder, but rather as a group of syndromes 
with vastly divergent symptoms but all involving episodic abnormal electrical in the brain 
that produces seizures of different types and severity. A careful history and appropriate 
investigations are essential for diagnosis. Epilepsy is usually controlled, but not cured, with 
medication,  although  surgery  may  be  considered  in  difficult  cases.  Not  all  epilepsy 
syndromes are lifelong – some forms are confined to particular stages of childhood. This 
section outlines the different types of epilepsy and the management of epilepsy including 
investigations and pharmacotherapy. 
 
2.2 Definition of epilepsy and seizures 
 
Epilepsy is a chronic, recurrent physical condition caused by a sudden, unprovoked, brief 
change  in  how  the  brain  works.  It  is  thought  to  occur  when  nerve  cells  in  the  brain 
discharges  electrical  impulses  at  a  rate  higher  than  normal.  This  “electrical  storm”  is 
abnormal and leads to seizures. 
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Seizures are sudden, uncontrolled waves of electrical activity in the brain which may cause 
involuntary movement, minor physical signs, abnormal feelings or loss of consciousness or 
a combination.(4) The type of symptoms and seizures depend on where the abnormalities 
take place in the brain, what its cause is, and such factors as the patient's age and general 
state of health. Seizures can be caused by head injuries, brain tumors, lead poisoning, 
maldevelopment of the brain, genetic and infectious illnesses, and fevers. In more than half 
of the patients with seizures, no cause can yet be found.  
 
2.3 Epidemiology  
 
Around 50 million people in the world have epilepsy. It is a common serious neurological 
condition with an annual incidence in developed countries of 50-70 cases per 100 000 
population.(5) In developing countries, the figure is higher due to more primitive obstetric 
services and greater likelihood of cerebral infection and head trauma. The prevalence of 
epilepsy is around 1% worldwide. The incidence varies greatly with age, with higher rates 
in early childhood, lower levels in early adult life and  a second peak in those aged over 65 
years.(6) 
 
 
2.4 Classification of Epilepsy 
 
1. Idiopathic and generalised. There is no seizure warning or underlying brain lesion and it 
is often associated with a family history.  
 
2. Symptomatic and localisation-related. This type of epilepsy is associated with aura, a 
specific site of onset and an identifiable cause.  
 
These two types can be differentiated by history and appropriate investigations such as 
electroencephalography (EEG) (see section 2.6.1) and brain imaging (see section 2.6.2). It 
is important to differentiate between the two types as they normally respond to different 
pharmacotherapy.  Investigations  are  useful  if  positive  but  may  be  negative  and  the 
diagnosis of epilepsy is often a clinical one. 
 
Common 
 
Occasional 
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Table 2.3.1 Factors lowering seizure threshold 
 
2.5 Classification of seizures 
 
According to the classification established by the International League against Epilepsy, 
seizures can be divided into two groups: partial seizures which arise from one small region 
of the brain and generalized seizures which arise from multiple brain areas simultaneously.  
 
Partial seizures originate in a focal region of the cortex and are divided into those that 
impair consciousness (complex partial) and those that do not (simple partial). Both types of 
partial  seizures  can  spread  rapidly  to  other  cortical  areas  through  neuronal  networks, 
resulting in secondary generalized tonic-clonic seizures.  
 
 
The following is an accepted classification of epileptic seizures by Brodie and Scachter.(7) 
 
Partial Seizures 
Simple - preservation of awareness. 
Complex - impairment of consciousness. 
Secondary generalised 
 
Generalized Seizures 
Absence - a brief loss of awareness 
Sleep deprivation 
Alcohol withdrawal 
Television flicker 
Epileptogenic drugs 
Systemic infection 
Head trauma 
Recreational drugs 
Menstruation 
 
Dehydration 
Barbituate withdrawal 
Benzodiazepine withdrawal 
Hyperventilation 
Flashing lights 
Diet and missed meals 
Stress 
Intense exercise   26 
Myoclonic - sudden and brief contractions of a single group of muscles or of the entire 
body 
Tonic - stiffening of muscles of the body, generally those in the back, legs, and arms 
Tonic-Clonic –  tonic phase; usually  involves  the  entire  body,  characterized by  muscle 
rigidity which causes the person to fall to the ground and may appear to cry out as air is 
expelled from their body, clonic phase; violent rhythmic muscle contractions causing the 
limbs to jerk 
Atonic - the loss of muscle tone, causing the person to fall to the ground 
 
Vigabatrin  has  been  found  to  be  effective  in  patients  with  pharmaco-resistant  partial 
seizures(8). Exact figures are difficult to obtain but in the Epilepsy Unit at the Western 
Infirmary in Glasgow approximately 6% of patients with epilepsy have been prescribed 
Vigabatrin at some time.  
 
Infantile  spasms  are  a  specific  type  of  seizure  seen  mainly  in  West’s  Syndrome,  an 
epilepsy syndrome of infancy and early childhood. The onset of infantile spasms in West’s 
syndrome is predominantly in the first year of life, typically between 3-6 months. These 
seizures typically clinically present as  a sudden bending forward and stiffening of the 
body, arms and legs and may be associated with arching of the torso. Spasms tend to begin 
soon after arousal from sleep. Individual spasms typically last for 1 to 5 seconds and occur 
in clusters, ranging from 2 to 100 spasms at a time. Infants may have dozens of clusters 
and several hundred spasms per day and are incapacitated. Infantile spasms usually stop by 
age 5, but are often replaced by other seizure types. West’s Syndrome is characterized by 
infantile  spasms,  hypsarrhythmia  (abnormal,  chaotic  brain  wave  patterns)  and  mental 
retardation. Other neurological disorders, such as cerebral palsy, may be seen in 30-50% of 
those with infantile spasms. Tuberous sclerosis is a rare, multi-system genetic disease that 
causes benign tumors to grow in the brain and on other vital organs such as the kidneys, 
heart, eyes, lungs, and skin. 
 
Vigabatrin is the drug of choice in patients with infantile spasms especially those with 
tuberous sclerosis.(9) 
 
 
 
 
2.6 Diagnostic Techniques   27 
 
2.6.1 Electroencephalography (EEG) 
 
Electroencephalography  (EEG)  is  the  neurophysiological  measurement  of  electrical 
activity in the brain obtained by recording from electrodes placed on the scalp or, in special 
cases, subdurally or in the cerebral cortex. These resulting traces represent a summation of 
post-synaptic potentials from a large number of neurons and represent voltage differences 
between different parts of the brain and not actual electrical currents.  
 
EEG  is  useful  as  a  tool  for  monitoring  a  patient’s  epilepsy.  It  can  be  also  used  as  a 
diagnostic tool in certain clinical situations such as to distinguish epileptic seizures from 
other  types  of  attacks,  for  example  psychogenic  non-epileptic  seizures,  syncope,  sub-
cortical movement disorders and also to categorize seizures for the purposes of treatment.  
 
Consequently  EEG  can  help  with  the  classification  of  epilepsy  and  support  the 
classification  of  partial  or  generalized  seizures.  However  a  standard  EEG  can  be  
insensitive(4).  Activation  techniques,  including  hyperventilation,  sleep  deprivation  and 
photic stimulation can be helpful in uncovering abnormalities. 
 
 A positive EEG is therfore helpful in confirming a diagnosis of epilepsy but a negative test 
does not rule it out.  
 
2.6.2 Brain imaging 
 
Brain imaging gives information on the structure of the brain.  
 
Computed Tomography (CT) scanning uses a series of x-rays of the head taken from many 
different directions and uses software that performs numerical integral calculations on the 
measured x-ray series to estimate the attenuation of an x-ray beam in a small volume of the 
brain. Cross sectional images of the brain are produced. A brighter area on the image 
represents denser tissue. 
 
Magnetic  Resonance  Imaging  (MRI)  uses  a  main  magnetic  field  and  radio-frequency 
waves to produce high quality two- or three-dimensional images of brain structures without 
the use of ionizing radiation (X-rays) or radioactive tracers. During an MRI scan, a large 
cylindrical magnet creates a magnetic field around the head of the patient. Radiofrequency   28 
impulses  are  transmitted  to  achieve  spatial  localization.  When  the  magnetic  field  is 
imposed, each point in space has a unique radio frequency at which the signal is received 
and  transmitted.  Sensors  read  the  frequencies  and  a  computer  uses  the  information  to 
construct an image. The detection mechanisms are so precise that a change in structure 
over  time  can  be  detected.  Images  of  both  surface  and  subsurface  structures  can  be 
recreated with a high degree of anatomical detail. MRI scans can produce cross sectional 
images in any direction i.e. transverse, sagittal and coronal. 
 
Neuro-imaging is essential in the appropriate evaluation of most patients with epilepsy, 
particularly  for  those  presenting  with  partial  seizures.  CT  and  MRI  both  allow  the 
identification of structural lesions. However, because of its superior ability to differentiate 
between different soft tissue structures in the brain,(10), MRI has higher sensitivity and 
specificity.   
 
 Pathological findings vary with age for example stroke and tumours are more common in 
the elderly. Among children, MRI images are particularly useful in identifying congenital 
abnormalities such as cortical migration disorder. 
 
2.7 Management of epilepsy  
 
The aim of epilepsy management is to prevent seizures without drug related side effects. 
 
Most patients experiencing more than one well-documented or witnessed seizure require 
treatment. Exceptions include patients with widely separated seizures or provoked seizures 
for  which  avoidance  activity  may  be  sufficient  prophylaxis  (e.g.  concomitant  illness, 
photosensitive epilepsy) and patients unlikely or unwilling to take medication (e.g. alcohol 
abusers and drug addicts).  
 
Management  mainly  consists  of  pharmacological  treatment  although  vagus  nerve 
stimulation and epilepsy surgery are useful treatments in selected patients. 
 
A single drug is normally introduced at low doses with increments over a number of weeks 
depending  on  the  urgency  and  the  type  of  anti-epileptic  drug.  This  is  to  establish  an 
effective  and  tolerable  regimen.(4)  This  helps  to  avoid  concentration-dependent  side-
effects, in particular central nervous system toxicity, the presence of which is likely to 
discourage the patient from persevering with long term therapy. An additional benefit of   29 
this  cautious  approach  is  that  it  allows  tolerance  to  develop  to  sedation  or  cognitive 
impairment. Such  a policy usually allows detection of potentially serious  idiosyncratic 
reactions such as rash, hepato-toxicity and blood dyscrasias. However there are exceptions: 
it took 8 years from the licensing of the drug Vigabatrin until the first reports of adverse 
effects on vision (see section 4.1).(11) 
 
A single anti-epileptic drug, rather than a combination of antiepileptic drugs, enhances 
compliance and provides a wide therapeutic window while producing complete seizure 
control in more than 70% of patients.(12) Measuring the serum blood concentration when 
steady  state  has  been  reached  confirms  appropriate  compliance  and  provides  a  useful 
baseline for further dosing if seizure control is not complete. 
 
Before prescribing a combination of AED therapy due to a lack of efficacy, the clinician 
considers possible reasons (listed below) for the lack of response of a patient’s seizures to 
treatment. Possible reasons are listed below.  
 
Some reasons for failure of a single AED: 
 
Wrong diagnosis 
Other medical causes e.g. syncope and cardiac arrhythmia 
Pseudo-seizures 
Underlying brain neoplasm such as meningioma 
 
Wrong drug 
Inappropriate for seizure type  
Kinetic/dynamic interactions 
 
Wrong dose 
Too low 
Side-effects preventing dose increase 
 
Wrong patient 
Poor compliance with medication 
Inappropriate lifestyle (e.g. alcohol abuse) 
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If  treatment  with  a  first  line  anti-epileptic  drug  as  mono-therapy  proves  ineffective, 
achieving  complete  seizure  control  with  additional mono-therapy  trials is  unlikely.(12) 
Some  patients  show  useful  improvement  in  seizure  frequency  or  severity  with  a 
combination of AED.  
 
2.8 Conclusion  
 
Epilepsy  is  a  common,  debilitating  condition.  Careful  history  and  appropriate 
investigations are essential so that appropriate treatment can be given. The goal of treating 
people with epilepsy is the maintenance of a normal lifestyle by complete seizure control 
without side effects. Vigabatrin has been shown to be very effective in West’s syndrome 
and drug resistant  partial seizures. Increasing the inhibitory neurotransmitters in the brain 
like GABA is one of the ways to stop seizures and GABA is discussed in chapter 3. 
Vigabatrin  may  also  reduce  seizures  by  other  actions  and  these  mechanisms  will  be 
discussed in Chapter 4. 
 
 
Chapter 3 
 
GABA (γ-aminobutyric acid) 
 
 3.1 Introduction 
 
GABA was identified in the brain in 1950(13)  and was first proposed to be an inhibitory 
neurotransmitter  in  1958.(14)  GABA  has  been  shown  to  be  the  principal  inhibitory 
neurotransmitter in the cerebral cortex and is present in up to 40% of all synapses(15) 
which maintain the inhibitory tone that counterbalances neuronal excitation.(16) When this 
balance is disturbed, seizures may ensue. 
 
A  number  of  pathological  conditions  are  associated  with  GABA-ergic  dysfunction 
including epilepsy, tardive dyskinesia and Huntington’s chorea.(17) GABA has also been 
implicated  in  chronic  drug  use,  producing  long-lasting  down-regulation  in  neurons 
associated  with  the  brain  reward  circuitry  and  reducing  dopamine  (another 
neurotransmitter thought to be involved in addiction) levels; hence Vigabatrin has been 
used with some success in cocaine addiction.(18) 
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GABA is also a major inhibitory neurotransmitter in the retina and is present on multiple 
retinal cell types.(19) GABA has also been proposed to be directly toxic to neurons in one 
study but these results could not be duplicated.(20)  
 
Vigabatrin causes a higher rise of GABA levels in the retina than in other parts of the 
nervous  system  (cortex  160%  of  control,  retina  221%  of  control)(21).  Neuro-retinal 
toxicity has been proposed to stem from the higher percentage increase  in retinal GABA 
levels(22). However, it is interesting to note that even at the highest dose of Vigabatrin in 
one study, actual retinal GABA concentrations reached only 50% of basal brain levels. The 
highest levels of GABA achieved are in the brain because the brain has the highest initial 
concentrations of GABA. It is possible that retinal ganglion cells are relatively sensitive to 
the effects of Vigabatrin when compared to the brain. 
 
 3.2 GABA synthesis 
 
Neither  GABA,  nor  its  precursor  glutamic  acid,  enters  the  brain  from  the  blood  in 
significant  quantities.  The  carbon  chains  of  both  neurotransmitters  are  derived  from 
glucose  via  glycolysis  and  the  entry  of  pyruvate  into  the  Kreb’s  cycle.(23)  GABA  is 
formed within GABA-ergic neuron axon terminals by carboxylation of α-ketoglutarate to 
glutamic acid  which  is then decarboxylated  by  glutamic acid  decarboxylase  (GAD)  to 
GABA (see figure 3.2.1). 
 
 
 
Figure 3.2.1 Synthesis of GABA via glycolysis and Kreb’s cycle   32 
(modified from www.neurosci.pharm.utoledo.edu/MBC3320/GABA.htm) 
 
GABA  transaminase  (GABA-transaminase)  is  a  pyridoxal  dependent  homodimer 
protein(made up of two identical, smaller molecules) known to be inhibited along with 
other similar transaminases by pyridoxal phosphate scavengers such as hydroxyalanine, 
hydrazines and in high doses by aminooxyacetic acid.(24) Other more selective blockers of 
GABA-transaminase include γ-acetylenic-GABA and ethanolamine-0-sulphate. Vigabatrin 
is poorly selective when compared with these.(25) 
 
3.3 GABA release 
 
There are two types of pre-synaptic GABA release, vesicular and non-vesicular. Vesicular 
release  is  calcium  dependent,  is  sensitive  to  tetanus  toxoid  and  is  triggered  by  high 
potassium concentrations. Non-vesicular release occurs as a consequence of  reversal of a 
GABA transporter in the cell membrane, is calcium independent and results in sodium 
influx. This type of release is thought to contribute to the ambient level of GABA in the 
synapses. 
 
3.4 GABA receptors 
 
The  effect  of  GABA  is  mediated  by  receptors  in  the  cell  membrane  and  results  in  a 
reduction  of  neuronal  excitability  by  the  generation  of  an  inhibitory  post  synaptic 
potential(IPSP),  a  negative  voltage  across  the  cell  membrane  resistant  to  further 
stimulation.  Three  types  of  GABA  receptors  have  been  identified  to  date  and  will  be 
discussed below 
 
3.4.1 GABAA receptors  
 
GABAA  receptors  are  ligand-gated  ion  channels  that  hyperpolarize  the  neuron  by 
increasing  inward  chloride  conductance  and  thus  have  a  rapid  inhibitory  effect(26) 
influencing the early portion of the GABA mediated IPSP. The GABAA receptor complex 
is  a  protein  complex  made  up  of  five  units  that  contains  binding  sites  for  GABA, 
barbiturates, benzodiazepines, picrotoxin and neurosteroids.(27) 
 
3.4.2 GABAB receptors  
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GABAB  receptors  are  G  protein  coupled  receptors  that  hyperpolarize  the  neuron  by 
increasing  potassium  conductance  or  decreasing  calcium  entry  in  the  cell  membrane 
thereby inhibiting the pre-synaptic release of other transmitters,(28) thus having a slow 
inhibitory effect.  GABAB  receptors are present on both excitatory and inhibitory axon 
terminals. Activation is associated with a decrease in neurotransmitter release and thus 
GABAB agonist drugs can be either antiepileptic(29) or proepileptic.(30) 
 
The role of GABAA and GABAB receptors in the generation of GABA mediated IPSP can 
be demonstrated. Bicuculline methiodide, a GABAA inhibitor inhibits the early portion of 
the IPSP whereas CGP-35348, a GABAB inhibitor, blocks the slow inhibitory effect seen 
in the later portion of the IPSP. Both drugs given together block the entire IPSP.(31) 
 
3.4.3 GABAC receptors  
 
GABAC  receptors  are  integrated  into  the  cell  membrane  and  are  ligand  gated.  These 
receptors stabilise membrane potential by increasing chloride conductance which permits 
chloride entry into cells mediating fast and sustained responses.  
 
Thus GABAA and GABAB receptors mediate inhibitory responses while GABAC receptors 
mediate excitatory responses. 
 
Although recent studies indicate a wide distribution of GABAC receptors in many parts of 
the  central nervous  system,(32)  these  receptors  are  most  prominently  expressed  in  the 
vertebrate retina.(33), play a role in retinal signal processing(33) and  play an important 
role in shaping signal transmission from bipolar cells to ganglion cells in the retina.(34)  
As GABAC receptors are concentrated in the retina, in the cone system it is one hypothesis 
that they may play a role in the side effects seen with Vigabatrin such as visual field 
defects though this has not been proven (see section 3.6). 
 
The characteristics of the GABA receptors are summarized in Table 3.4.1. 
  GABAA Receptor  GABAB 
Receptor 
GABAC 
Receptor 
Category  Ligand-gated 
channel 
G-protein 
coupled receptor 
Ligand-gated 
channel   34 
Subunits  Ά,β,γ,δ,ε  GBR1, GBR2 
(2 N-terminal 
variants) 
1,2,3 
Agonists    Muscimol,  
THIP (4,5,6,7-
tetrahydroisoxazolo[5,4-
c]pyridin-3-ol) 
Baclofen     
Antagonists  Bicuculline, 
Picrotoxin 
Phaclofen,  
CGP-35348   
TPMPA (1,2,5,6-
Tetrahydropyridin-4-yl) 
methylphosphinic acid),   
Picrotoxin 
Desensitization  Yes  No  No 
Modulator    Benzodiazepines 
Barbiturates 
Neurosteroid 
  Zinc 
 
Table 3.4.1 Characteristics of GABA receptors. 
 
 
 
 
 
 
 
 
 
 
 
3.5 Epilepsy and the role of GABA 
 
Experimental and clinical studies have provided evidence which indicates that GABA has 
an important role in the mechanism and treatment of epilepsy.    35 
 
1.  Abnormalities of GABA-ergic function have been observed in genetic and acquired 
animal models of epilepsy.(32, 33)  
2.  Reductions of GABA mediated inhibition have been reported in human epileptic 
brain tissue.(35) 
3.  GABA agonists suppress seizures and GABA antagonists produce seizures.(36) 
4.  Benzodiazepines  and  barbiturates  work  by  enhancing  GABA-mediated 
inhibition.(37) 
5.  Drugs that increase synaptic GABA are potent anticonvulsants.(36) 
 
3.6. GABA: its role in the retina and the development of retinal toxicity 
 
When administered systemically, Vigabatrin has been shown to cross the blood-retinal 
barrier and can be detected throughout the retina by immunocytochemical techniques.(38) 
The retina is approximately 0.5 mm thick and lines the back of the eye. The optic nerve 
contains the ganglion cell axons running to the brain and, additionally, incoming blood 
vessels that open into the retina to vascularize the retinal layers and neurons. A radial 
section of a portion of the retina reveals that the ganglion cells (the output neurons of the 
retina) lie innermost in the retina closest to the lens and front of the eye, and the 
photosensors (the rods and cones) lie outermost in the retina against the pigment 
epithelium and choroid. All vertebrate retinas are composed of three layers of nerve cell 
bodies and two layers of synapses. The outer nuclear layer contains cell bodies of the rods 
and cones, the inner nuclear layer contains cell bodies of the bipolar, horizontal and 
amacrine cells and the ganglion cell layer contains cell bodies of ganglion cells and 
displaced amacrine cells. 
A simple wiring diagram of the retina emphasizes only the sensory photoreceptors and the 
ganglion cells with a few interneurons connecting the two cell types such as seen in the 
figure below.   36 
 
Figure 3.6.1 Diagram of retina 
There are two main theories of retinal toxicity associated with Vigabatrin use: a direct 
action and an indirect action that may be due to increased GABA levels. 
 
Vigabatrin increases GABA concentrations in the retina more than in other tissues, such as 
in  the  brain.  GABA-transaminase  is  the  enzyme  which  degrades  GABA.  GABA-
transaminase is 22% of the level in rat cortex , while it is 260% of  the level control in the 
retina of rats with Vigabatrin use in one study(21). Hence GABA levels are increased to a 
greater degree in the retina as compared the brain by an unknown mechanism. 
 
Sills and Brodie have  surmised that  since there is  such a large percentage increase  in 
GABA  levels  in  the  retina  as  opposed  to  the  brain  that  GABA  is  implicated  in  the 
Vigabatrin associated retinal toxicity debate.  
 
There are other points to note. Importantly Sills has shown that  even at the highest dose of 
Vigabatrin,  actual  retinal  GABA  concentrations  reached  only  50%  of  basal  brain 
levels(22). So the higher percentage increase in the retina GABA levels still do not elevate 
GABA levels in the rat retina to higher levels than rat  brain GABA levels. 
 
Vigabatrin concentrations were also increased and found to be five times higher in the 
retina than any other brain region.(21) It is difficult to separate the action of these two   37 
compounds to determine if one, both or neither are responsible for Vigabatrin associated 
visual defects. In animal models it is difficult to control for GABA because GABA is 
broken down before therapeutic or toxic levels are achieved in the brain and retina. In 
acute  toxicology  studies  in  isolated  retina  slices  where  GABA  and  Vigabatrin  can  be 
applied directly to the retina,  Izumi has shown  light and Vigabatrin were found to be 
significant in causing retinal photoreceptor damage rather than GABA(1). 
 
GABA is found in bipolar, horizontal, amacrine and ganglion cells and has a role in the 
modulation  of  phototransduction  from  the  retinal  photoreceptor  cells  to  the  ganglion 
cells.(19)  Multiple  subtypes  of  GABA-ergic  retinal  cells  have  been  identified.  These 
include 1 type of rod bipolar cell, 8 to 11 types of cone bipolar cells and 10 to 20 amacrine 
cells.(39)  
 
Figure 3.6.2 shows a schematic diagram depicting the main GABA-ergic pathways in the 
outer retinas of vertebrates.(40)  
 
 
 
Figure 3.6.1 The main GABA-ergic pathways in the outer retina. 
(modified from webvision.med.utah.edu) 
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The main GABA-ergic elements are the horizontal cells which form a synctium by gap 
junctions (indicated by =). Horizontal cells and bipolar cells receive glutamatergic inputs 
from photoreceptors (red arrows). Horizontal GABA-ergic cell outputs indicated by solid 
arrows are directed onto photoreceptors (negative feedback) bipolar cells and horizontal 
cells themselves. After initial processing, the bipolar cells transmit to the inner retina and 
and to the brain (yellow arrow).   
 
Amacrine  and  horizontal  cells  contain  a  homogenous  population  of  GABA  receptors. 
Bipolar cells exhibit both GABAA and GABAC receptors with a much higher proportion of 
GABAA  on  cone  bipolar  cells  than  on  rod  bipolar  cells.(41)  One  of  the  tests  used  to 
monitor Vigabatrin effect on the retina is the ERG (explained in detail in chapter 8). One 
parameter that has been reported to be affected is the cone ERG b wave (a measure of 
Muller cell function with mainly cone system interaction that will be discussed more fully 
later  in  the  thesis).  Kapusta-Bruneau  reports  on  appropriate  activation  the  GABAA 
receptors decrease cone ERG b wave amplitude, whereas GABAC receptors increase cone 
ERG b wave amplitude(42) in isolated rat retinas. Coupland and Miller  have reported cone 
ERG  b  wave  reduction  in  people  on  Vigabatrin  with  visual  field  defects.  Therefore 
investigators  have  presumed  the  GABAC    receptors  in  the  cone  system  have  been 
selectively affected and it has been inferred that this may be due to this difference in 
distribution of GABA receptors.(43;44) 
 
3.7 Conclusion  
 
GABA has been shown to be a major, frequently inhibitory neurotransmitter in the brain 
and  retina.  The  manipulation  of  GABA  synthesis,  storage  and  breakdown  and  its 
interaction with 3 GABA receptors has had success in the management of epilepsy. The 
effects of increasing GABA concentrations in the retina are unknown. It is one theory that 
retinal toxicity is due to increased levels of GABA in the retina though Sils has shown in 
one  study actual retinal GABA concentrations reached only 50% of basal brain levels(22) 
although the percentage rise was higher in the retina.(21).  suggesting there may be other 
mechanisms such as a direct effect of Vigabatrin.  
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Chapter 4 
 
Vigabatrin 
 
4.1 Introduction 
 
Vigabatrin was the first ‘designer’ antiepileptic drug developed. It was manufactured to 
increase GABA levels in the nervous system and thus decrease seizures. Vigabatrin was 
licensed in the UK in 1989. It is a useful treatment for refractory partial seizures and is the 
drug  of  choice  for  infantile  spasms.  There  has  been  recent  interest  in  its  use  for 
amphetamine and cocaine addcition. However in 1997, Eke and co-workers reported three 
cases of bilateral concentric visual field constriction with Vigabatrin.(11)  More than 100 
research papers have since confirmed the link between Vigabatrin treatment and visual 
dysfunction. A variable prevalence (0.14% to 80%) of bilateral visual field defects (VFD) 
has been reported but most studies agree about 50% of patients on Vigabatrin develop 
visual field defects. (100;122;123) Patients may be asymptomatic but visual dysfunction 
may  be  progressive  and  irreversible  and  have  important  clinical  implications  such  as 
driving. 
 
4.2 Origin and design 
 
Vigabatrin was specifically designed to enhance GABA function in the CNS(45) and  was 
synthesized as a substrate for GABA aminotransaminase (GABA-transaminase) in 1977 by 
Jung et al at the Merrell laboratories in France (now Sanofi-Aventis, 2004).(46)   40 
 
4.3 Chemistry (pharmacology)  
 
Vigabatrin (4-amino-hex-5-enoic acid, γ-vinyl GABA, Sabril®) is an ethyl analogue of 
GABA (4-aminobutyric acid). The structure of Vigabatrin is shown in Figure 4.3.1 and 
compared with GABA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 4.3.1 Comparison of the chemical structure of Vigabatrin and GABA 
 
The only difference between the two molecules is that there is a vinyl function on the 
carbon bearing the amine group. Like GABA, it is a water soluble, polar molecule. The 
compound is a white to off-white crystalline solid with a melting point of 171-177 °C. The 
molecular weight is 129.16g/mol. 
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Vigabatrin exists as a racemic mixture and exhibits no optical activity (a racemate is a 
mixture of equal amounts of left- and right-handed stereoisomers of chiral (an object that is 
non-superimposable  on  its  mirror  image)  molecules.    The  two  isomers  rotate  plane-
polarised light in opposite directions. Therefore a racemic mixture does not rotate plane-
polarised light). The pharmacological activity and toxic effects of Vigabatrin have been 
shown to be associated with the (+) enantiomer (one of the mirror image forms of the 
molecule). The (-) enantiomer appears to be entirely inactive.(47) 
 
4.4 Mechanism of action    
 
Vigabatrin belongs to a class of enzyme activators that are called Kcat, suicide substrates or 
mechanism based inhibitors. Vigabatrin is converted in vivo to its active form by GABA-
transaminase,  the  enzyme  that  catalyzes  the  conversion  of  GABA  to  succinic 
semialdehyde.  Vigabatrin  irreversibly  inhibits  GABA-transaminase(48)  by  replacing 
GABA  as  a  substrate  for  GABA-transaminase.  Enzymatic  activation  produces  an 
intermediate which binds covalently to the active site, thereby consuming both enzyme and 
inhibitor  in an  irreversible  reaction.  GABA  levels  increase  in the brain  which  inhibits 
electrical activity thus decreasing seizures. 
 
The pharmacological action of Vigabatrin is related to the kinetics of GABA-transaminase 
so  a  concentration  effect  cannot  be  demonstrated.  For  this  reason  the  drug  can  be 
administered once a day despite its short elimination half life.  
 
A  single  parenteral  dose  of  Vigabatrin  (1500mg/kg)  reduces  mouse  brain  GABA-
transaminase activity to around 20% of control levels and consequently produces a 4-fold 
increase in whole brain GABA concentrations. This effect persists for over 24 hours, with 
GABA-transaminase activity and GABA concentrations only returning to normal upon the 
synthesis of new enzyme protein over a period of 4-5 days.(17) 
 
More  recent  experimental  studies  suggest  that  in  addition  to  an  effect  on  GABA-
transaminase, Vigabatrin also may block GABA uptake. This was shown using primary 
cultures of rat cortical astrocytes by Leach.(49) It has been suggested that Vigabatrin may 
induce tonic inhibition via GABA transporter reversal without increasing vesicular GABA 
release by Wu(50). However the concentration of Vigabatrin required to block GABA 
uptake (IC50 ~250µM) suggests that it may only occur at the highest therapeutic doses thus 
questioning its clinical relevance.    42 
 
Hanaya has shown GABA increased by inhibition of GABA-transaminase with Vigabatrin 
inhibits abnormal excitation of hippocampal CA3 neurons of the spontaneously epileptic 
rat (SER) via GABAA receptors.(51)   
 
It  is  important  to  note  that  alteration  of  GABA  may  not  be  the  only  antiepileptic 
mechanism  of  the  drug.  Vigabatrin  also  decreases  glutamate  in  the  hippocampus  and 
aspartate in the hippocampus, cortex and cerebellum by Halonen(52) which are excitatory 
neurotransmitters.  
 
4.5 Efficacy  
 
4.5.1 In vitro cultures  
 
At the cellular level Vigabatrin inhibits GABA-transaminase with an IC50 of 89µM in 
neurons and 132µM in glial cells ( IC50 is the concentration of an inhibitor that is required 
for 50% inhibition of its target). (53) 
 
4.5.2 In vivo  
 
Animal  models  for  seizures  and  epilepsy  have  played  a  fundamental  role  in  our 
understanding  of  the  physiological  and  behavioral  changes  associated  with  human 
epilepsy. In vivo animal models have been categorized into models of seizures and those of 
epilepsy. 
The following animal models have been tested with Vigabtrin: 
 
 Vigabatrin is devoid of activity in the maximal electroshock model (generalized tonic-
clonic model).(54)  
 
In the pentylenetetrazol test Vigabatrin has variable anticonvulsant effects observed when 
Vigabatrin  is  high  and  pentylenetetrazol  is  moderate  to  low  (generalized 
absence/myoclonic model).(55)  
 
Vigabatrin has efficacy only at high concentrations in audiogenic seizures in the DBA/2 
mouse and those induced by the inverse benzodiazepine agonist DMCM.(56)   43 
Vigabatrin  is  effective  in  blocking  seizures  induced  by  the  systemic  administration  of  
bicuculline and picrotoxin (antagonists of GABAA receptors).(57)   
 
Vigabatrin has variable anticonvulsant activity in the kindling model (partial seizures).(58)  
 
4.6 Pharmacokinetics  
 
4.6.1 Absorption 
 
At  therapeutic  doses  in  man  Vigabatrin  produces  dose-related  increases  in  CSF 
concentrations of free and total GABA, homocarnosine (the GABA-histidine dipeptide) 
and beta-alanine. These biochemical changes are consistent with an inhibition of GABA-
transaminase activity in brain.  
 
Racemate 
In all pharmacokinetic studies absorption was rapid with the peak concentration reached in 
the first 2 hr after dosing between 0.5 and 3g (59-61). The lag time (time delay between 
drug  administration  and  first  observed  concentration  above  the  lower  limit  of 
quantification (LOQ))was calculated to be between 2 and 30 min in one study(59) and 10 
to 16 min in another with the absorption half-life in the latter study ranging from 13 to 36 
minutes (61). The mean terminal half life was between 5 and 7 hr. (62) 
 
Approximately 60 – 80% of the drug was recovered unchanged in the 0 to 24 hr urine 
indicating a bioavailability of at least 60 -80 %. 
 
Enatiomers 
In  6  healthy  volunteers  Vigabatrin  single  dose  kinetics  were  determined  for  both 
enantiomers. (60) Peak plasma concentrations were reached for both at between 0.5 and 2 
hr  after  a  1,500  mg  oral  dose.  In  each  subject  the  (-)  and  (+)  enantiomer  peak 
concentrations were reached at the same time. The ratio of peak concentrations of (-) and 
(+) was 1.85. The plasma concentrations of the two enantiomers did not differ after 24 
hours.  
 
The mean terminal half life (t½), which is a measure of the time taken for a drug to leave 
the systemic circulation, for the (-) enantiomer was 485 minutes and 447 minutes for the 
(+) enantiomer.(60)   44 
 
Area under the curve (AUC) estimates bioavailability (fraction of administered dose that 
reaches systemic circulation) for non intravenous doses. AUC was 39.2 µmol min.ml
-1 for 
(-)  enantiomer  and  30.1µmol  min.ml
-1  for  (+)  enantiomer.  One  explanation  for  the 
discrepancy is that (+) enantiomer is used by GABA-transaminase as a substrate while the 
(-) enantiomer is inactive. 
 
Ultimately these absorption characteristics are unimportant as the anti-epileptic effects of 
Vigabatrin outlast the drug by several days. 
 
4.6.2 Distribution 
 
Vigabatrin is not protein bound.(63) It is a highly water soluble compound (33mg/ml) and 
has a wide distribution in the body with an apparent volume of distribution of 0.8 l/kg. 
(total body water is 0.6 l/kg ) A comparison with the extrapolated or initial volume of 
distribution with the steady state volume indicates that between 50-75% of the drug is 
outside the central blood compartment at steady state. 
 
In  man,  CSF  Vigabatrin  levels  have  been  analysed  showing  that  the  concentration  of 
Vigabatrin  in  the  CSF  was  10%  of  that  in  the  blood  indicating  blood  brain  barrier 
penetration. (64)  
 
Thus, with systemic availability upon oral administration, blood-brain barrier penetration 
and biochemical activity in the CNS, the prerequisites for potential uses of Vigabatrin in 
neurological disorders were demonstrated in clinical pharmacological studies. 
 
4.6.3 Accumulation 
 
It was initially thought that accumulation of Vigabatrin is unlikely. Accumulation did not 
occur  in  the  CSF  and  plasma  in  patients  treated  with  Vigabatrin  on  a  chronic  daily 
basis.(65) Surprisingly, one study in rats showed Vigabatrin concentrations in the retina 
were 18.5-fold higher than those in the brain.(21) The reasons for this large disparity is 
unknown but may suggest a different mechanism of Vigabatrin transport into the eye and 
may be linked with its toxic action on the retina.  
 
4.6.4 Metabolism   45 
 
The  majority  of  Vigabatrin  is  excreted  as  the  unchanged  drug.  There  have  been  no 
metabolites identified in humans (60). 
 
4.6.5 Excretion 
 
 Vigabatrin is eliminated primarily via the kidneys with about 65% of the administered 
dose found unchanged in the urine within 24 hours.  
 
In healthy volunteers the elimination half-life is 5-8 hr and the total clearance is about 1.7-
1.9 ml/min/kg with renal clearance accounting for 70% of the total clearance. Elimination 
is not influenced by the dose (0.5 to 3g) or by duration of treatment. (60) 
 
4.7 Pharmacodynamics 
 
Vigabatrin is a 50/50 mixture of (+) and (-) enantiomers. The pharmacological activity and 
the  toxic  effects  of  Vigabatrin  are  associated  only  with  (+)  enantiomer.(59)  The  (-) 
enantiomer appears to be entirely inactive. In most biologically active compounds, the 
inactive  enantiomer  is  considered  to  be  an  impurity  that  can  influence  the 
pharmacokinetics  and  action  of  the  active  enantiomer  as  well  as  contribute  to  the 
compound’s  toxicity.(60)  However  for  enzyme  inhibitors  such  as  Vigabatrin,  the 
pharmacokinetics of the drug itself are less important than for other drugs because GABA-
transaminase has a longer half life than Vigabatrin.(46) The pharmacological effects are 
determined by the half-life of the enzyme rather by the drug or the (+) enantiomer.  
 
4.8 Clinical use in epilepsy 
 
4.8.1 Short term add on  
 
At first, the efficacy of Vigabatrin was evaluated in two single blind pilot studies in Europe 
by Schechter and Gram.(66;67). Gram demonstrated a 50% reduction in median seizure 
frequency from placebo to active treatment period lasting 12 weeks.(67) Gram findings 
were correlated by Schechter in his study where 60% of the patients achieved complete 
seizure control, the active period being 4 weeks.(66) In the United States, a larger single-
blind,  placebo-controlled  multi-centre  study  in  89  patients  produced  similar  results  by 
Browne.(68)   46 
 
Several short-term, double blind, placebo-controlled crossover studies with Vigabatrin as 
add-on  therapy  have  been  reported.(69-72)  Vigabatrin  has  been  administered  in  doses 
ranging  from  2  to  4g  for  between  7  and  12  weeks.  Most  patients  had  drug  resistant 
complex partial seizures with or without secondary generalisation. In one of these studies 
Mumford  demonstrated  Vigabatrin  produced  a  greater  than  50%  decrease  in  seizure 
frequency in 46% of the total of 98 patients having only partial seizures.(73) In another 
study, Ring showed Vigabatrin responders were randomized into a double-blind placebo-
controlled  phase.  The  patients  on  Vigabatrin  maintained  a  55%  reduction  of  seizure 
frequency, whereas those on placebo experienced a 19% increase in seizure activity.(74)  
A multi-centre dose response trial in the United States of America compared treatment 
with 1g, 3g or 6g  of Vigabatrin to placebo and found a statistically significant decrease in 
seizures for those treated with 3g or 6g in patients with partial seizures.(75) 
 
4.8.2 Long term add on 
 
There have been several open-label follow up studies of Vigabatrin responders.(76-79) The 
antiepileptic efficacy and the good clinical tolerability are generally maintained during 
treatment  for  up  to  6  years.  The  treatment-related  withdrawal  rate  in  these  studies  is 
approximately 20% with the majority of patients treated for over 12 weeks discontinuing 
Vigabatrin mostly because of insufficient efficacy rather than side effects(80) before it was 
discovered that visual field defects were associated with Vigabatrin. 
 
4.8.3 Monotherapy 
 
In  an  open-label  monotherapy  study  comparing  initial  Vigabatrin  monotherapy  with 
carbamazepine (CBZ) monotherapy Kalviainen has shown 60% of patients in both groups 
have been treated successfully.(81) 
 
4.8.4 Studies in children   
   
Chiron followed the use of Vigabatrin in patients up to 24 months old with drug resistant 
infantile spasms.(82) During a mean follow up period of 3.2 months, 68% of the patients 
experienced a  greater than 50%  reduction  in  their  seizure frequency  and 43% became 
totally seizure–free. 
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4.9 Spectrum of activity in epilepsy  
 
4.9.1 Efficacy in relation to seizure type  
 
According to analysis of published clinical experience in 487 patients, Vigabatrin is more 
effective  against  partial  seizures  than  against  generalized  epileptic  syndromes.(83)    In 
children and mentally retarded patients there has been a trend towards greater response in 
partial epilepsies (45;84;85).  Vigabatrin is a drug of choice in the treatment of intractable 
infantile spasms.(82) 
 
Patients with mixed seizure types, EEG abnormalities, intellectual impairment and severe 
and frequent seizures are relatively resistant to Vigabatrin (83;86) but this is typical of all 
major  AED.  Vigabatrin  decreases  absence  seizures  and  myoclonic  epilepsy.(83;86;87) 
Exacerbation of seizures have also been reported in some patients with partial epilepsy(85-
87) and have been reported with all GABA-ergic drugs. 
 
4.9.2 Efficacy by dose 
 
The usual daily dosage of Vigabatrin used in clinical trials has been 2g to 4g for adults.  
 
In one of the early pilot dose-ranging studies a dose of 1g/day given over 2 weeks had 
some effect in reducing seizure frequency, whereas the effect was more marked during a 
2g/day period.(66) In another pilot study the reduction in median seizure frequency was 
similar for both the 1g and 2g/day periods.(67)  Some of these patients showed a further 
reduction in seizure frequency when the dose was increased to 3g/day. Both these pilot 
studies indicate a dose-linked efficacy that was reinforced by other studies.(69;70;73) 
 
However, doses beyond 4 g/day usually give no extra benefit.(75) These findings suggest 
that there is an optimally effective dosage or even a ceiling to effective dosage for an 
individual patient. Starting doses of 2g/day are recommended.(73) The starting dose is then 
titrated on an individual patient-by-patient basis to gain the best response.  
 
4.10 Toxicity 
 
4.10.1 Long term toxicity – pathological examination 
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Long term toxicity studies involve the chronic administration of the candidate compound 
to experimental animals for periods of up to one year. Thereafter the animals are subjected 
to intensive pathological examination. 
 
Vigabatrin has been the subject of several long term toxicity investigations comprising two 
studies in Sprague Dawley (albino) rats and one study in  Lister-Hooded rats(88;89) and 
four studies in beagle dogs.(88;90-92) 
 
In a rat model, Neal showed the spinal cord and brain show greater tolerance to the toxic 
action of Vigabatrin compared to the retina.(93) 
 
The two rat studies performed by Gibson and Butler employed Vigabatrin doses of 30 – 
300 mg/kg per day and were conducted for three and twelve months respectively. The rat 
toxicity  studies  revealed  significant  intra-myelinic  oedema  (vacuolisation)  in  the 
cerebellum, optic tracts, hippocampus and thalamus in albino rats.(88;89)  
 
The studies of Vigabatrin toxicity in the dog revealed significant intra-myelinic oedema in 
the fornix  columns, optic  tracts, thalamus, hippocampus  and hypothalamus.  (88;90-92) 
However, the distribution is limited to the brain and is reversible upon discontinuation of 
therapy as shown by Butler.(47) 
 
Butler concludes that in treated humans there has been no documentation of intra-myelinic 
oedema.(47;89)  Cohen  agrees  that  intra-myelinic  oedema  does  not  appear  to  be 
extrapolated to man.(94)  
 
There has been one post-mortem pathological report on a human treated with long term 
Vigabatrin  as  reported  by  Ravindran.  The  main  findings  of  the  visual  system  were 
peripheral retinal atrophy with loss of ganglion cells and loss of nerve fibres in the optic 
nerves, chiasm, and tracts. In this individual it would seem that there was injury within the 
ganglion cells in the retina.(95) However clinically, optic neuropathies result in loss of 
visual acuity, defective colour vision and abnormal visual evoked responses. Central visual 
acuity,  colour  vision  and  visual  evoked  response  have  been  reported  as  unaffected  in 
patients on Vigabatrin in several studies. It seems that in most patients the ganglion cell 
layer is not the primary area of pathology but may represent secondary changes. 
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Buncic has described in one clinical study a proposed ‘characteristic’ type of optic atrophy 
affecting predominantly the nasal part of the disc.(96) This pattern of nerve loss does not 
correlate  with  most  reported  visual  field  defects  in  patients  on  Vigabatrin  which  are 
predominantly nasal (100;122;123) (which would occur with predominantly temporal optic 
disc atrophy).  
 
Another study using optical coherence tomography suggested there was a reduction in the 
retinal  nerve  fibre  layer  in  patients  with  Vigabatrin  associated  visual  field  loss.  It  is 
difficult to make reliable measurements of retinal nerve fiber layer thickness in the same 
patient(97) and the study compared the retinal nerve fiber layer in patients without epilepsy 
making the conclusions suspect. However the study shows that vigabatrin does have a long 
term effect on the retina. Other studies have showed retinal degeneration was found to be 
dependent on light exposure.(88)  
 
Two studies, one the post mortem results as reported by Ravindran, the other using the 
wide  field multifocal  electroretinogram  as  reported  by  McDonagh  have  suggested  that 
Vigabatrin selectively affects the peripheral retina.(3;95) Jensen disputes this hypothesis 
and suggests that Vigabatrin associated retinal toxicity is diffuse, inducing subtle central 
visual dysfunction and more severe peripheral visual defects where cell density is lowest. 
However the study was done using the ERG which gives a global retinal response and so 
difficult to differentiate between peripheral anad central defects.(98) 
 
Wilson,  Arndt  and  Wong  suggest  that  the  visual  field  constriction  seems  to  be 
permanent.(99-101)  This  hypothesis  is  supported  by  the  degree  of  atrophy  seen  on 
pathological examination of nervous tissue of dogs given Vigabatrin. (95) Krakow refutes 
that visual field loss is reversible claiming in his patients visual field defects improved on 
discontinuing Vigabatrin.(102)  
 
There have been reports of visual field constriction  associated with other GABA-ergic 
drugs progabide and tiagabine.(103;104) These reports have largely been discounted by 
Kalviainen.(105)  
 
4.10.2 Short term toxicity 
 
The possibility of light levels being an important factor was raised by Butler in one study 
in which disorganization of the outer nuclear layer occurred in retinas of Sprague-Dawley   50 
(albino) rats but not Lister-Hooded (pigmented) rats.(89) Gibson corraborated in another 
study where no retinal lesions were identifiedafter administering Vigabatrin orally for 1 
year  to  Sprague-Dawley  rats.  This  study  hypothesized  that  light  has  a  critical  role  in 
Vigabatrin retinotoxicity.(88) 
 
A  recent  study  aimed  to  identify  factors  contributing  to acute  Vigabatrin neuro-retinal 
toxicity. Sprague-Dawley (albino) rats were used for in vivo and ex vivo experiments in 
light and dark environments by Izumi.  Retinas incubated with Vigabatrin under light had 
degeneration  of  photoreceptor  outer  segments,  loss  of  photoreceptors  and  structural 
disruption of outer limiting membrane and damage to Muller cells in all areas of the outer 
retina (i.e. not only in the periphery) which seemed to be time and dose dependent. Retinas 
incubated with no light with Vigabatrin and retinas incubated in the light or dark with 
GABA showed no change. This is a surprising result suggesting that photo-toxicity may be 
the main underlying pathological mechanism for Vigabatrin associated visual field defects 
and is unrelated to GABA.(1) 
 
Vigabatrin is not recommended in pregnancy because it is known to be teratogenic. Two 
cases  of  visual  field  defects  developing  in  children  with  intrauterine  dosing  has  been 
published by Sorri(106) suggesting that Vigabatrin has crossed the placental barrier. It is 
possible  the  field abnormalities  reported occurred  intrauterine or  the  changes  occurred 
postpartum when the infants were exposed to light. Harding disputes this in which he 
reported 5 children of 3 mothers with no effect of intrauterine vigabatrin exposure. (153) 
 
 
4.10.3 Aetiology – toxicity studies 
 
Several possible mechanisms of Vigabatrin toxicity have been proposed by Comaish and 
Izumi. These have included increased physiological effect of GABA, non specific actions 
e.g. increased α-aminoadipic acid, inhibition of mitochondrial ornithine aminotransferase, 
GABA shunt and glutamate excitotoxicity-metabolic dysfunction that may cause ischaemia 
and  accumulation  of  undesirable  metabolites,  apoptosis,  effect  on  glucose  metabolism, 
effect on oxidative damage(107) and recently photo-toxicity.(1) 
 
It is possible that Vigabatrin causes a decrease in cerebral and/or ocular circulation as the 
primary mechanism of pathology. Spanaki has described in one study a 13% decrease in 
global cerebral blood flow combined with an 8% decrease in cerebral metabolic rate for   51 
glucose  as  a  result  of  Vigabatrin  therapy.(108)  Raised  GABA  levels  may  have  an 
important role to play in exacerbating ischaemia. Edvinsson has shown GABA has a role 
in the regulation of vascular tone. Specific GABA receptors have been demonstrated both 
in vivo and in vitro as being functionally viable in eliciting a vasodilatory response in the 
presence of GABA.(109) In contrast Kelly has demonstrated in another study that systemic 
administration of GABA-ergic agonists in the rat model results in a reduction in cerebral 
glucose metabolism and a decrease in cerebral blood flow(110) probably due to increased 
CSF GABA levels. 
 
Retinal blood flow and pulsatile ocular blood flow are reduced in epileptic patients as 
compared to healthy volunteers as shown by Hilton and Hosking. (111;112) The reduction 
in  pulsatile  ocular  blood  flow  was  further  exacerbated  in  Vigabatrin  treated  epilepsy 
patients compared with those treated with conventional AED(112). Previously reported 
optic nerve pallor(11;113;114) and narrowing of retinal arterioles(115) may be indicative 
of  a  primary  ischaemic  mechanism.  This  effect  may  be  GABA-mediated,  due  to  pre-
existing ischaemia, due to reduced metabolic demands(112) or due to photo-toxicity. 
 
There  have  been  a  number  of  studies  investigating  the  effect  of  systemic  drugs  or 
vasoactive stimuli that have showed parallel changes in the brain and the eye(116;117). 
 
Physiologically a reduction in retinal and/or choroidal blood flow will have a direct effect 
on the health and functioning of the neural retina. In Vigabatrin patients, more pronounced 
toxic retinal effects and therefore a greater haemodynamic compromise may be expected. 
 
Vigabatrin effects on vision remain an enigma. It is likely that several cells and regions are 
affected. Genetically determined variations in local tissue, drug deactivations or clearance, 
most probably in the retina, are likely to play a role in determining who develops visual 
dysfunction. 
   
4.11 Adverse effects 
 
Vigabatrin is generally well tolerated in patients with epilepsy. Adverse events are mainly 
CNS related and probably a secondary consequence of increased GABA levels caused by 
Vigabatrin. The safety of Vigabatrin was evaluated in 2081 epileptic patients treated in 
clinical trials. The relationship of adverse events to Vigabatrin therapy was not clearly 
established  as  patients  were  taking  other  antiepileptic  drugs  concomitantly.  The  most   52 
frequently reported adverse events were somnolence (12.5%), fatigue (9.2%), and weight 
gain (5%).(80) 
 
Adverse events reported with a frequency of less than 1% include: anxiety, emotional 
lability,  behavioral disturbances  including  psychosis,  irritability,  tremor,  abnormal  gait, 
speech disorder, increased appetite, dyspepsia and constipation.(80) 
 
As with other antiepileptic drugs, some patients may experience an increase in seizure 
frequency with Vigabatrin treatment. 
 
Laboratory  data  indicate  that  Vigabatrin  treatment  does  not  lead  to  renal  or  hepatic 
toxicity. Chronic treatment with Vigabatrin may be associated with a slight decrease in 
haemoglobin, which rarely attains clinical significance.(80)  
 
4.12 Drug interactions 
 
Vigabatrin is neither protein bound nor metabolized and does not influence the cytochrome 
P450-dependent enzymes.(118)  Vigabatrin has limited ability to produce significant drug 
interactions.  Administration of  Vigabatrin causes  a 20%  decrease in plasma phenytoin 
concentrations but usually this interaction has been of limited practical significance. (118) 
There are no other known interactions with most concurrently used AED. 
 
4.13 Vigabatrin and Visual Field Defects  
 
4.13.1 Introduction 
 
Eke et al described 3 cases of severe visual field constriction in patients on Vigabatrin.(11) 
A number of studies have since linked visual dysfunction, often visual field defects with 
Vigabatrin use. The prevalence remains poorly defined with reports of visual field defects 
ranging from 0.3%(119) to 75% of patients treated with Vigabatrin.(120-122) Most reports 
claim at least 50% of patients have visual field defects. (101;123;124) It is not clear why 
some  patients  develop  visually  disabling  field  constriction  while  in  some  subjects  the 
visual field defects are mild and asymptomatic or undetectable; in one study 0.2% (1 out of 
713) patients using Vigabatrin had a symptomatic visual field defects. (101;123;124)  It is 
also unclear whether stopping the drug is the best way to manage patients with visual field   53 
defects  as  there  have  been  reports  of  sudden  death  associated  with  discontinuing 
Vigabatrin.(125) 
 
The most commonly described visual field defects is bilateral constriction present in both 
eyes, involving the nasal retina more than the temporal.(126) However, other descriptions 
such as generalised constriction have been described. (127) Some authors theorise there is 
not peripheral field constriction but a reduced sensitivity overall in the total visual field 
noticed more in the periphery because there are fewer cells in the periphery.(35)  
 
Many patients on Vigabatrin are asymptomatic. One of the possible reasons is there is a 
relative preservation of temporal fields in both eyes. The predominant area of field loss in 
most patients seem to be the nasal field where the visual fields of the two eyes overlap so 
the actual visual loss can be compensated for and allow patients to maintain good mobility. 
Also, patients unconsciously develop coping mechanisms to deal with peripheral field loss, 
such as turning their heads. 
 
4.13.2 Monitoring 
 
There are many difficulties in monitoring patients with epilepsy on Vigabatrin for visual 
field defects. 
 
Perimetry is a subjective technique requiring considerable attention and cooperation from 
patients. Patients with epilepsy can have delayed reactions or fluctuating attention due to 
seizure activity and drug treatment.(128) Therefore visual fields may not be reproducible. 
Lawden has shown in one study in patients with epilepsy  35% (11 out of 31) of patients 
were unable to complete visual field testing.(114) 
 
It is even debatable whether the best method to use is kinetic or static perimetry. Kinetic 
Goldmann perimetry allows examination to the extreme periphery of the visual field and 
measures  the  “true”  visual  field.  Graniewski-Wijnands  has  found  that  manual  kinetic 
perimetry was not the appropriate method of examination of the visual field in this patient 
group due to the length of time the test takes. Brain damage or lack of alertness secondary 
to Vigabatrin caused a delay in reaction time leading to a more concentric visual field 
constriction than detected with Humphrey Field Analyzer with Esterman strategy.(129) 
Also  Newman  showed  10%  of  patients  could  not  perform  kinetic  fields  because  of 
cognitive problems (130) and it is very operator dependent and not as quantitative as static   54 
Humphrey perimetry. Computerised static perimetry measures generalised sensitivity loss 
but has the advantage of improved repeatability and is non operator dependent. In this 
particular  patient  group  with  poor  attention,  computerised  static  perimetry  with 
repeatability indices seems to be the preferred method and was the method used in this 
study.  
 
In addition, in this study we could compare Humphrey perimetry (120° field of view) with 
wide field multifocal electroretinograms (WF mfERG), field of view 90°. 
 
A review of the literature shows that different methods of visual field examination were 
described and there were even different ways of calculating visual loss using the same 
method. It is difficult to compare these studies. 
 
Another confounding factor is the use of other anti-epileptic drugs that may be responsible 
for bilateral field defects. Hayashi in one study found a greater field constriction in patients 
on  Vigabatrin  and  valproate  (VPA)  than  Vigabatrin  and  carbamezepine  (CBZ).  It  was 
previously thought that VPA is likely to increase the inhibitory action of GABA in the 
retina(131) and this explains the additive toxicity when Vigabatrin is combined with VPA 
as compared with CBZ. However, the electroretinography results were the same for both 
groups and hence can not be attributed to retinal toxicity alone as described by Arndt(132). 
 
 4.13.3 Humphrey perimetry 
 
Prevalence  of  visual  field  defects  using  static  Humphrey  perimetry  in  patients  with 
epilepsy on Vigabatrin have varied from  33%(133) to 68%(134) but most studies show 
about 50% of patients have field defects.   
 
An over estimation of nasal visual field loss can be due to the test program used. The 
normal visual field extends 90 degrees temporally and 60 degrees nasally. A concentric 
loss of 20 degrees will show a field of 70 degrees temporally and 40 degrees nasally i.e. an 
apparent nasal predominant loss as described by Hardus.(135) 
 
4.13.4 Goldmann perimetry 
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The prevalence of visual field defects using kinetic perimetry in patients with epilepsy on 
Vigabatrin have varied from 20% (130) to  92%.(136) One study by Besch has found no 
difference between nasal and temporal fields.(137) 
 
Ultimately both static and kinetic perimetry are designed to quantify peripheral visual field 
defects. Johnson showed a high correlation between visual field constriction (i.e. kinetic 
perimetry)  and  generalized  sensitivity  loss  (i.e.  static  perimetry)  in  patients  taking 
Vigabatrin.(138)  
 
Patients are always excluded from these studies because they are unable to do Goldmann 
fields(136) or Humphrey fields. There is therefore a significant number of patients who are 
on Vigabatrin are who are unable to be monitored with visual field examination. 
 
4.14 Risk factors 
 
Vigabatrin  was  licensed  in  the  UK  in  1989.  There  were  no  reported  cases  of  visual 
dysfunction until Eke et al showed visual field constriction in 3 patients in 1997. The 
discovery of visual field defects took 8 years. It is possible that patients need to be exposed 
for a minimum length of time before damage occurs. But one also has to consider that 
defects  are  often  asymptomatic  and  that  because  this  is  a  difficult  group  in  which  to 
measure visual fields, visual defects may have went unnoticed for such a long time. 
 
In those patients on Vigabatrin with visual field defects Van der Torren and Johnson claim 
that there is no association with age, gender, duration of treatment or cumulative dosage 
and the severity of these defects. (134;138) However, Hardus claims those patients with 
the  largest  cumulative  dose  (>5kg)  had  a  slightly  higher  incidence  of  visual  field 
defects.(135)  Manuchehri  showed  a  correlation  with  visual  field  defects  once  a  total 
ingested dose of at least 1.5kg was achieved.(139) He theorised that there was a certain 
minimum load that needed to be achieved before visual field defects occurred. Van der 
Torren however postulated  that there is a correlation between the daily dose and visual 
field defects.(134) 
 
Some studies have found an increased incidence in male patients tested with up to 2:1 
relative risk.
 (126;128;140) Manuchehri found a correlation between number of cigarettes 
smoked and visual field defects.(139) 
   56 
4.15 Other anti-epileptic drugs (AED) 
 
Cases have been reported of visual field defects associated with other AED. These have 
included constricted fields with phenytoin(141), diazepam(142) and progabide.(104) Can 
such deficits be a relatively common side effect of anticonvulsant treatment or even a 
feature  of  the  natural  history  of  epilepsy?  There  have  been  attempts  to  quantify  the 
prevalence of visual field defects in patients with epilepsy by some authors but there has 
been some difficulty in the design and in most studies other visual pathway pathology was 
present.(143) Some studies have shown that other anti-epileptic drugs can cause visual 
field defects identical to those reported with Vigabatrin.(121) However, one other study 
claims that there is very little visual field constriction associated with antiepileptic drugs 
other than Vigabatrin (0 out of 39 patients in one study).(124) 
 
There  was  also  recent  concern  that  all  AED  with  GABA-ergic  action  would  cause 
peripheral  visual  field  defects  after  a  report  on  tiagabine  (TGB)  was  published.(144) 
However, other studies have shown this is not the case. One study that has compared 
gabapentin (GBP) and topiramate (TPM) and Vigabatrin showed that Vigabatrin was the 
only  drug  to  have  concentration-related  effects  on  enzymes  and  intermediates  of  the 
GABA shunt in rat brain and retina.(22) Vigabatrin produced a significant dose related 
increase  in  GABA  concentrations  and  decrease  in  GABA-transaminase  activity  in  all 
tissues  investigated.  This  effect  was  most  pronounced  in  the  retina  where  Vigabatrin 
concentrations were 18.5-fold higher than those in the brain.(22) Hence if the reason for 
visual field defects is related to GABA concentration as is suggested by the authors then 
Vigabatrin causes much higher concentrations in the retina than GBP and TGB. Of course 
there  may  be  other  factors  unrelated  to  GABA  that  are  more  important  such  as  light 
toxicity  (see chapter 3). Another study has showed  that TGB does not  precipitate  any 
significant neuro-retinal toxicity and does not appear to accumulate in the retina.(21) The 
results  of  these  pre-clinical  investigations  suggest  that  Vigabatrin  and  TGB  are 
pharmacologically distinct compounds with different anti-convulsant, neuro-retinal toxicity 
and pharmacokinetic profiles. It is possible that they will ultimately prove to have different 
clinical efficacies and spectra of activity.(48) 
 
Vigabatrin  is  not  metabolised  and  is  excreted  unchanged  in  the  urine  and  would 
theoretically not interact with any other drugs. One study has shown that patients using 
other  enzyme  inducing  drugs  show  a  shorter  half  life  for  Vigabatrin  than  healthy 
volunteers(145)  but  since  the  action  of  Vigabatrin  depends  on  the  rate  of  GABA-  57 
transaminase  being  regenerated  then  other  drugs  are  not  that  important  in  overall 
pharmacokinetics. Studies have shown that there is no significant contribution to visual 
field defects by any other concomitant antiepileptic drug.(135) 
 
4.16 Continuing or stopping the drug – visual fields 
 
Do visual field defects recover in patients who stop Vigabatrin? If loss is not reversible 
then do visual field defects stabilise or progress? (101; 127) 
 
The response to stopping Vigabatrin has been reported to be variable. Krakow,Dieterle and 
Versino in several papers have reported that visual field defects improve(102;102;146;147) 
on stopping Vigabatrin while Nousiainen in another paper have reported that visual field 
defects do not improve in the majority of patients on stopping Vigabatrin (148).  
 
Schmidt,  Graniiewski-Wijnands  and  Paul  in  other  studies  claim  that  there  is  no 
deterioration in visual field defects on continuing the drug (128;129;149) and therefore a 
“maximum” defect is achieved, dependent probably on genetic make up. Hardus presents a 
convincing case otherwise showing a gradual, significant progression of visual field loss in 
patients who continue using Vigabatrin.(150) 
Withdrawal of treatment in seizure-free individuals is sometimes not a preferred option as 
complications arise from failure to adequately manage these patients on alternative AED. 
Epilepsy control is important because uncontrolled seizures increase the risk of sudden 
unexpected death in epilepsy (SUDEP).(95;125)  
 
Other studies surprisingly suggest otherwise. Out of 75 patients in one study who had 
stopped Vigabatrin due to a visual field abnormality or concern over this potential adverse 
effect, the seizure control was no different or had improved in 66 (88%), while it had 
deteriorated  in  only  7  (9%)  as  reported  by  Nicolson.(140)  However,  this  was  a 
retrospective study and did not state how long these patients were on Vigabatrin to be 
included. 
 
4.17 Conclusion 
 
More  than  100  research  papers  have  linked  Vigabatrin  use  and  visual  field  defects. 
However the prevalence is variable due to difficulties in testing these patients. Visual field   58 
examination is subjective with poor reproducibility in this patient group. An improved 
method of monitoring visual problems is needed. 
 
My hypothesis as to why visual field defects occur in patients on vigabatrin is as follows. 
Vigabatrin has many influences on the visual pathway. For the purpose of this discussion 
these  changes  are  termed  reversible  and  irreversible.  Vigabatrin  results  in  reversible 
actions that can be acute and chronic. Vigabatrin also has been shown to have irreversible 
actions that can be acute and chronic such as loss in ganglion cells seen in pathology 
reports(95). Vigabatrin raises GABA levels and GABA will have acute and chronic actions 
which  are  very  difficult  to  distinguish  from  the  actions  of  Vigabatrin.  There  are  also 
unknown factors that Vigabatrin would affect. See Figure 4.13.1.1. 
 
 
 
 
 
 
 
 
 
Figure 4.13.1.1 The multiple effects of Vigabatrin (VGB) 
 
A review of the literature has not clearly defined into which “box” even visual field defects 
would go. Some papers claim that the visual field defects are irreversible whereas others 
claim that visual field defects are reversible. It is the same for other abnormalities detected 
in electrophysiological tests.(133;151) as will be discussed in Chapter 5. One hypothesis is 
that the wide field multifocal electroretinogram can better define the differences of these 
“boxes” with regards to management of these patients. 
 
It  is  unclear  what  the  contributing  factors  are  to  visual  field  defects  associated  with 
Vigabatrin use. What is clear is that only a certain number of people on Vigabatrin get 
visual field defects. Genetically determined variations in local tissue, drug deactivations or 
clearance,  most  probably  in  the  retina  may  explain  the  random  nature  of  Vigabatrin 
associated visual dysfunction. 
 
GABA  Acute 
Chronic 
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But how does the prevalence of visual field defects in patients on Vigabatrin differ from 
other epileptic drugs? The incidence of symptomatic and asymptomatic visual field defects 
has  not  previously  been  accurately  established  and  defined  in  patients  with  epilepsy. 
Several case reports have associated antiepileptic drugs other than Vigabatrin with visual 
field defects such as phenobarbitol and progabide(104). One study has a prevalence of 20% 
(out of 55 patients) but this was thought to be high due to occipital lobe lesions.(152) It is 
possible that the true incidence of pathological i.e. irreversible visual dysfunction is lower 
with Vigabatrin than previously thought. There was a 36% incidence of bilateral visual 
field defects in our patients with epilepsy not on Vigabatrin. 
 
Because we can not accurately define field defects on different visits because of problems 
with  reproducibility (for  all the above reasons),  it  will be unclear  if these visual field 
defects worsen or not thereby making managing these patients difficult. 
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Chapter 5 
 
Vigabatrin and electrophysiology  
 
5.1 Introduction 
 
Electrophysiological tests are an attractive method of examining patients with epilepsy as 
they provide an objective measure of visual function. As previously discussed, patients 
with epilepsy have difficulty with attention and concentration and therefore subjective tests 
such as visual fields (kinetic or static) may be unreliable and have artifacts.  Sadly, the 
literature does not agree on which electrophysiological tests are indicative of irreversible, 
pathological  visual  field  defects  that  occur  in  patients  on  Vigabatrin.  Reported 
abnormalities of electrophysiological tests will be reviewed in this chapter. If predictive 
retinal electrophysiological markers can be determined, it is possible that these changes 
can  occur before  visual  field defects become  irreversible,  allowing  an early  review  of 
treatment. Since electrophysiology is an objective measure of visual function it is vital in 
the monitoring of disease progression in patients with neuroretinal toxicity causing visual 
field defects. 
 
Ocular  electrophysiology  comprises  of  a  range  of  procedures  that  enable  the  visual 
pathway to be examined in an objective manner. Flash and/or pattern stimuli are presented 
to the patient and evoked responses are recorded by appropriate placement of electrodes. 
Various  tests  are  performed  to  investigate  different  parts  of  the  visual  pathway.  The 
electrooculogram (EOG) examines the retinal pigment epithelium. The ERG examines the 
global retinal responses of multiple cell types. The multifocal electroretinogram (mfERG)   61 
examines  focal  areas  of  retina.  The  visual  evoked  potential  (VEP)  is  an  evoked 
electrophysiological  potential  that  can  be  extracted,  using  signal  averaging,  from  the 
electroencephalographic activity recorded at the scalp. The VEP can provide important 
diagnostic  informationregarding  the  functional  integrity  of  the  visual  system.The  VEP 
examines the function of the optic nerves, optic radiations and occipital cortex.  
 
Electrophysiological disturbances in patients receiving Vigabatrin indicate a retinal locus 
of  abnormality.  It  has  been  proposed  that  Vigabatrin  has  many  effects  on  visual 
electrophysiology. (148;153) One effect is a transient, reversible (physiological) reduction 
in the EOG Arden index. The EOG is affected when patients are actively taking VGB 
possibly due to physiologically elevated retinal GABA levels. The  EOG Arden index 
returns  to  normal  when  the  drug  is  discontinued(151;154).  Another  consequence  is 
progressive ERG abnormalities which is thought to be associated with a risk of visual field 
loss and persists even when the drug is withdrawn.(43) However, the ERG abnormalities 
may  not  be  synonymous  with  the  mechanism  that  produces  the  visual  field 
abnormality.(151) 
 
The  International  Society  for  Clinical  Electrophysiology  of  Vision  (ISCEV)  EOG 
measures the variation of the standing potential of the eye between light (500 cd/m
2) and 
dark conditions. The ratio of the voltages between light and dark is known as the Arden 
ratio. It is a measure of function of retinal pigment epithelial cells and their interaction with 
photoreceptors.  
 
 The ISCEV standard ERG measures the mass retinal response to a stimulus of light and is 
divided into 5 trials. 
 
1. A rod response in the dark-adapted eye.  
2. A maximal response in the dark adapted eye.  
3. Oscillatory potentials.  
4. A cone response in the light-adapted eye.  
5. Responses to a rapidly repeated stimulus (flicker) 
 
The visual evoked potential (VEP) is an evoked electrophysiological potential that can be 
extracted  from  the  electroencephalographic  activity  recorded  at  the  scalp  with  scalp 
electrodes. 
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5.2 Aetiology – electrophysiology 
 
The  origins  of  electrophysiological  signals  remain  controversial.  However  some 
associations can be made with Vigabatrin effects on the retina.  
 
Vigabatrin seems to have an effect in the outer retina. Reduced Arden ratios have been 
found in up to 70% of patients as reported by Besch(137) suggesting dysfunction of retinal 
pigment epithelium.  A normal Arden ratio (light peak/dark trough) is greater than 1.5. 
   
Vigabatrin appears to have an effect in the mid and inner retina.(115;155;156) Krauss has 
reported loss of oscillatory potentials suggesting involvement of amacrine cells.(115)  
 
Decreased rod and cone b wave amplitude have been discovered by Van der Torren (134) 
suggesting dysfunction of Muller cells and bipolar cells.  
 
Muller cells and bipolar cells are involved in the generation of the b wave. Muller cells 
contain retinal GABA-transaminase and actively perform transmitter recycling. Vigabatrin 
is thought to inhibit GABA-transaminase in Muller cells and bipolar cells(93) Therefore if 
Muller  and  bipolar  cells  accumulate  Vigabatrin,  then  their  GABA  degrading  enzyme 
would be inhibited, hence increasing GABA levels and therefore increases in GABA levels 
may lead to a decrease in b wave amplitude.(43). 
 
Muller cell density decreases in the peripheral retina as compared to the central retina and 
this may be the reason that Vigabatrin can selectively damage the periphery. However this 
also applies to photoreceptor density. 
 
5.3 Electrooculogram (EOG)   
 
Studies claim that in patients on Vigabatrin, the Arden ratio is reduced by as much as 70% 
as reported by Arndt, Comaish and Hardus.(100;107;157) Researchers incuding Coupland, 
Lawden, and Harding claim that the Arden ratio of the EOG is affected only by the current 
use of Vigabatrin. (43;114;129;134;154) In one study Graniewski-Wijnands found that the 
EOG  showed  a  statistically  significant  improvement after  withdrawal  from  Vigabatrin. 
Abnormal EOG was present in 6/9 patients on Vigabatrin. All EOG became normal on 
stopping Vigabatrin.(129) Harding reported in another study in which clinically normal 
volunteers  were  given  Vigabatrin  for  9  days.  None  of  these  subjects  had  visual  field   63 
defects but all had reduced Arden index and decreased cone b wave latency that became 
normal on withdrawal of the drug.(151) Van der Torren showed a significant correlation 
with Arden ratio and cumulative Vigabatrin dose.(134) Conversely Arndt in one study has 
found a permanent change in EOG even after stopping Vigabatrin.(100) Van der Torren 
reported cumulative Vigabatrin dose had a significant correlation with EOG ratio and ERG 
rod and cone b wave amplitude.(134) 
 
5.4 Electroretinogram (ERG) 
 
5.4.1 Introduction 
 
Vigabatrin  causes  abnormalities  in  the  ERG.  However  Jensen  has  reported  that 
abnormalities are detected in patients with and without visual field constrictions.(98) The 
incidence of ERG abnormalities varies from 30% to 90%
  (134) in patients on Vigabatrin 
with visual field defects . These changes have been detailed below. 
 
5.4.2 Rod response  
 
Decreased b wave amplitude have been reported by Van der Torren in one study(134). The 
incidence has  ranged  from 33%  as  reported by  Coupland  (43)  to  38%  as  reported by 
Johnson.(138)  Harding  has  also  reported  increased  b  wave  latency  in  up  to  50%  of 
patients.(158)  
 
5.4.3 Maximal 
There have been reports of decreased amplitude of a wave by Hardus.(159) 
 
 
 
 
5.4.4 Oscillatory potentials (OP) 
Reduced oscillatory potential (OP) amplitudes have been described in several studies in up 
to 92% of patients including Krauss and Harding.(115;151) However, Daneshvar refutes 
this and have reported no change in OP but only 12 payients were tested in his study.(133) 
 
5.4.5 Cone response  
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The incidence of decreased b wave amplitude has been reported to vary between 30% 
(Krauss)  to  62%  (Harding).(115;151)  Studies  show  increased  photopic  b  wave 
latency.(155);132;137) Arndt postulates in one of these studies that increased photopic b 
wave  latency  correlated  significantly  with  severe  visual  field  constriction  and  this 
parameter can be used to detect retinal toxicity.(132) Johnson disputes this by showing that 
photopic b wave latency has become less delayed on stopping Vigabatrin(138) without 
improvement  in  visual  field  defects  and  concluded  there  is  no  relationship  between  
recovery of function and duration of treatment or cumulative dosage. Therefore the value 
of this test is debatable. 
 
Miller found the cone single flash and flicker have been affected more than rod single 
flash.(44) 
 
5.4.6 Flicker 
 
Studies have reported a decrease in flicker amplitude in up to 92% of patients with a cutoff 
in amplitude of 70µV in patients on Vigabatrin(137;138). Ponjavic has shown that 100% 
of patients with visual field defects on Vigabatrin had decreased 30Hz flicker amplitude  
while none had decreased flicker amplitude who did not have visual field defects.(160) In 
another  study  Johnson  found  there  was  no  improvement  in  amplitude  even  after 
discontinuation for 1 year.(138) Harding has reported delayed 30 Hz flicker in patients on 
Vigabatrin.(154) 
 
5.4.7 Visual field constriction and ERG changes 
 
Studies have shown that abnormal ERG potentials are significantly higher among patients 
with  visual  field  defects  than  those  without,  in  one  study  up  to  90%  of  patients  on 
Vigabatrin  with  visual field  defects had  ERG and  EOG  abnormalities. These  included 
reduced ERG cone b wave amplitude, reduced OP amplitude, increased cone  b wave 
latency (155) and reduced 30 Hz flicker amplitude which seemed to correlate with visual 
field loss(107)
 and was proposed could be used to detect retinal toxicity.(132)  
 
However, Jensen postulates the findings of abnormal visual field defects may not be equal 
to abnormal ERG(98)  and is supported by Lawden who has not found any link between 
visual field defects and ERG abnormalities.(114) 
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There has not been universal agreement to which ERG parameters are most sensitive and 
specific to visual field defects. Authors have disagreed and one of the common design 
flaws is insufficient control patients. However Harding has reported a study which have 
actively controlled for other antiepileptic drugs.(158) 
 
Some  studies  claim  that  central,  as  well  as  peripheral  retinal  function  is  affected  by 
Vigabatrin. Foveal ERG is proposed to test mainly central retina cone function. In one 
study 9 out of 11 eyes tested with foveal ERG showed normal or reduced amplitudes. 
However, it is difficult to position the stimulating beam precisely and steadily on the retina 
and these results are uncertain.(161) 
 
5.5 Visual evoked potentials (VEP) 
 
Multiple  studies  have  reported  abnormal  VEP  results  associated  with  Vigabatrin  use, 
though the prevalence has tended to be lower than that of visual field defects, abnormal 
ERG and abnormal EOG. The incidence of abnormal VEP has ranged from 7%(133) to 
22%.(44) Abnormalities include decreased amplitude and increased latency of responses. 
  
Because formal perimetry can rarely be done below a developmental age of 9 years a field 
specific  VEP  with a central (0 to 5)  radius and peripheral (30  to 60)  radius has been 
proposed(162) to be used in children (H-stimulus). Harding concluded that the different 
reversal rates of the central and peripheral checks allowed separate central and peripheral 
responses to be recorded by the electrodes on the skull. Though most of the children were 
able to comply with this test (35/39) only 12 children could have perimetry as well, giving 
values of 75% sensitivity and 87% specificity.(162) 
 
5.6 Continuing or stopping the drug -electrophysiology 
 
Electrophysiological tests measure the electrical signals generated by living cells of the 
eye.  If  use  of  Vigabatrin  results  in  the  death  of  these  cells  then  the  changes  in 
electrophysiology would be irreversible. However if Vigabatrin use results in cell damage 
which can recover when Vigabatrin is stopped, then abnormal electrophysiological test 
results could be reversible.    
 
EOG Arden index and ERG rod b-wave amplitude, rod b-wave latency time and cone ERG 
amplitude  and  latency  showed  a  significant  improvement  when  Vigabatrin  was   66 
discontinued  in  several  studies.(100;138;151)  However,  visual  field  defects  did  not 
improve in these studies on discontinuing Vigabatrin(158;163). This recovery effect is a 
strong argument for the hypothesis that the reduction in EOG and ERG b-wave amplitude 
is a reversible effect. There was no statistical correlation between recovery of function and 
either  duration  of  treatment  or  cumulative  dosage.(138)  Others  have  found  no 
improvement in rod and cone ERG amplitudes after stopping Vigabatrin.(43;138;149) 
 
The antiepileptic drugs carbamazepine and phenytoin have also been shown to decrease 
ERG  rod  and cone b  wave  and oscillatory  potential  amplitudes.  Bayer  and colleagues 
found that paradoxically that the addition of Vigabatrin to the medical regimen of these 
patients promoted the recovery of the b wave amplitude.(115) 
 
5.7 Conclusion 
  
Most researchers would agree that the EOG  is only transiently affected by Vigabatrin 
usage (the Arden index recovers on stopping). ERG abnormalities have also been reported 
in patients with visual field defects on Vigabatrin. These have included decreased b wave 
amplitude (rod response), reduced oscillatory potentials, decreased b wave amplitude (cone 
response), increase b wave latency (cone response) and a decrease in a flicker amplitude. 
Reduced  VEP  have  been  reported  with  VGB.  It  is  not  clear  if  electrophysiological 
abnormalities can be predictive to visual field defects.  
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Chapter 6 
 
Clinical findings 
 
6.1 Introduction 
 
A  number  of  patients  on  Vigabatrin  have  visual  complaints.  These  include  decreased 
central visual acuity (VA) and flashing lights.(120) Patients also complain of decreased 
peripheral  vision and have  symptoms such as tunnel vision and bumping  into objects. 
Some patients attribute decreased peripheral vision to clumsiness as a result of epilepsy. 
However many patients remain asymptomatic even though visual loss can be progressive. 
Peripheral visual field defects can be relevant to quality of life such as the ability to drive a 
car. This is one of the dilemmas in managing these patients on Vigabatrin. Many patients 
do not want to stop Vigabatrin even though there is visual dysfunction because they are 
seizure free. 
 
Various reports have described fundus changes such as pale optic discs that may explain 
visual field defects associated with Vigabatrin. As previously discussed it is difficult to 
decide where the primary pathology is located due to Vigabatrin and what is secondary. 
Other reports have found no correlation between visual field defects and fundus changes. 
 
6.2 Visual acuity 
 
In one study central visual acuity remained stable in all patients as measured by Snellen 
visual charts.(130) 
 
6.3 Colour vision 
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One study has reported colour defects ranging from 33% to 66% of people using various 
colour vision tests such as Isihara 38, Farnsworth D15-2 and Hardy Rand Rittler(161). One 
paper has reported a selective blue impairment that the author theorized was consistent 
with GABA-ergic inhibition at retinal level(164) while others have reported no change in 
colour vision on Vigabatrin with visual field defects.(130) 
 
6.4 Ophthalmic findings 
 
Studies have shown that abnormalities were found in up to 71% of subjects on Vigabatrin. 
These  include  retinal  artery  narrowing,  epiretinal  membrane,  abnormal  sheen  or 
pigmentation  in  the  macula,  optic atrophy  and  a decrease  in peri-papillary  nerve  fiber 
layer(44;126;165). Another study disputes this and has reported that there has not been any 
ophthalmic abnormality that could explain visual field loss.(135) 
6.4.1 Optic atrophy 
 
Several  papers  have  reported  incidences  of  optic  atrophy  with  Vigabatrin  use.(11;44) 
Indeed one of the few pathological reports available has documented loss of ganglion cells 
and  optic  atrophy.(95)  However  it  is  not  clear  if  loss  of  ganglion  cells  is  a  primary 
phenomenon or one secondary to other retinal pathology.  
 
One paper has reported a proposed a ‘characteristic’ finding associated with prolonged 
Vigabatrin use. This has been described as characteristic retinal atrophy with secondary 
“inverse”  optic  atrophy.  The  optic  nerve  is  paler  nasally  as  opposed  to  the  more 
characteristic temporal pallor hence the term “inverse” However this finding was found in 
only 3 patients out of 138 on Vigabatrin.(96)  
 
6.5 Studies in children 
 
Visual field testing of children is often difficult and sometimes impossible. There have 
been reports of children with visual field defects in the literature.(166;166). The prevalence 
of visual field defects may be lower in children than in adults. (167) 
 
In children the duration of AED therapy and the drug dose relative to body weight may 
differ considerably from those in adults and the maturing nervous system may respond to 
toxic substances in a very different manner. A major problem in estimating the prevalence   69 
of visual field defects in children is the lack of ability to cooperate reliably in visual field 
testing due to young age or developmental disability. 
 
Previous  reports  suggest  that  visual  field  defects  do  occur  in  some  Vigabatrin  treated 
children, however these studies have some practical problems: all study groups have been 
small and methods of visual field testing have varied even within one study(168-170). 
There are a lack of sufficient controls in studies(171) hampering the possibility of drawing 
conclusions that would be clinically relevant in children.(122) 
 
There have been two reports of recovery of visual field in children who stopped Vigabatrin 
but this may be due to learning artifact.
 (172). 
 
6.6 Conclusion 
 
No  consistent  clinical  observation  has  been  reported  which  is  specific  to  visual  field 
defects  associated  with  Vigabatrin.  Other  drugs  have  been  recognised  to  cause  retinal 
toxicity in the eye with characteristic clinical findings. By reviewing the retinal changes 
and test results of these drugs we may get an indication of the action of Vigabatrin in the 
retina. 
 
  
Chapter 7 
 
Retinal toxicity 
 
7.1 Introduction 
 
The development of retinal toxicity with medications has been an ongoing problem since 
Withering described digitalis-induced  xanthopsia in 1785. Ocular complications due  to 
pharmacologic  agents  are  numerous.(173)  This  section  describes  the  most  commonly 
encountered retinopathies associated with drugs. Visual field defects seen with phenytoin, 
diazepam and progbabide are discussed in section 4.15. 
 
7.2 Digitalis 
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It was suggested that the toxicity due to digitalis may be a result of inhibition of sodium-
potassium adenosine triphosphatase (Na
+, K
+-ATPase). Isolated photoreceptors exhibited 
concentration-dependent reductions in the magnitude of the light response during digitalis 
exposure, suggesting a reduction in the normal dark current. Cones were about 50-fold 
more sensitive than rods.(174) Therefore chronic inhibition of Na
+, K
+ -ATPase might 
degrade photoreceptor polarisation with the  greatest deterioration in the cone-mediated 
system.  Digitalis  toxicity  is  manifested  as  xanthopsia  (yellow  vision),  scintillating 
scotoma, blurriness, colour vision defects, often in the yellow-blue axis and pericentral 
scotomas  with  normal-appearing  retinas.  The  ERG  abnormalities  are  decreased  cone 
mediated  amplitudes  and  increased  photopic  b-wave  implicit  time(174;175).      Vision, 
colour vision and the ERG usually become normal with the cessation of therapy.(174;175) 
 
7.3 Quinine  
 
Over-dosage of quinine appears to be toxic specifically to retinal cells; photoreceptors, 
bipolar cells and ganglion cells. Occasionally bone spicule pigmentation occurs suggesting 
retinal pigment epithelium damage(176;177).  The initial appearance of the fundus may be 
normal or there may be mild venous distention and retinal opacification. Over the ensuing 
months optic atrophy and vascular narrowing appears probably secondary to the retinal 
toxicity. Long term visual field constriction normally occurs(176;177). There seems to be a 
late decline in ERG b wave amplitude suggesting on-bipolar cell damage that may be due 
to toxicity or ischaemia secondary to retinal vascular narrowing. Increased ERG b wave 
latencies and absent oscillatory potentials have also been described.(178)  
 
 
 
7.4. Tamoxifen 
 
Histopathological  examination  of  the  retina  of  a  patient  with  tamoxifen  retinopathy 
revealed nerve fiber layer and inner plexiform intracellular lesions 3 to 35 µm in diameter 
which appear to be the product of neuronal degeneration.(179) Tamoxifen can cause a 
crystalline retinopathy.(179) Decreased visual acuity secondary to optic neuropathy has 
also  been  reported.(180)  Visual  evoked  potentials  (VEP)  have  been  reported  to  be 
abnormal.(180) Reversibility of optic neuropathies has also been reported.(180) 
 
7.5 Retinal artery emboli (talc and steroid retinopathy)   71 
 
Embolic  retinal  vascular disease occurs from both chronic intravenous use of talc and 
cornstarch  contained  in  illegal  drugs  and  from  facial  injections  of  medication,  usually 
steroids that are inadvertently injected intra-arterially.(181) Injected talc particles may gain 
access to the ocular circulation through congenital shunts or by the chronic use of crushed 
talc  containing  tablets  in  the  presence  of  severe  pulmonary  obstructive  disease.  The 
particles  lodge  in  the  choriocapillaries  and  in  the  small  vessels  of  the  retina.(181) 
Embolisation of corticosteroid to the ipsilateral retinal choroidal circulation after injection 
of  periocular  and  facial  tissues  is  rare.  These  steroid  emboli  make  their  way  to  the 
ophthalmic artery through retrograde intra-arterial anastomatic connections after forceful 
injection  into  the  vasculature.(182)  Small  talc  particles  can  present  as  crystalline 
intravascular  emboli  and  are  often  associated  with  good  vision.  However  substantial 
ischemic damage to the macula can cause decreased visual acuity. Neo-vascularization at 
the  disc  and  the  retina  can  occur  leading  to  vitreous  haemorrhage  and  retinal 
detachment(181;183).  Occasionally bone spicule pigmentation occurs suggesting retinal 
pigment epithelium damage is present. Embolisation of corticosteroid to the ophthalmic 
artery is rare but visually devastating when it occurs.(182) 
 
7.6 Chloroquine and hydoxychloroquine 
 
Chloroquine and hydoxychloroquine have been useful in treating malaria and, in larger 
doses, collagen vascular disease. They cause a dose related pigmented retinopathy. Both 
drugs  apparently  have  a  selected  affinity  for  melanin,  but  the  earliest  histopathologic 
change,  even  before  RPE  damage  appears  to  be  membranous  cytoplasmic  bodies  in 
ganglion cells and degenerative cells in photoreceptor outer segments followed by oedema 
of the retinal pigment epithelium. Such changes are typical of cationic ampiphilic (One end 
of the molecule is hydrophilic (`water loving', polar) and the other is hydrophobic (`water 
hating,  non-polar))  drugs  that  interfere  with  phospholipid  breakdown,  probably  by 
damaging lysosomes.(184) 
 
Another factor compounding the toxicity of chloroquine and hydoxychloroquine is their 
very slow excretion rate. Small amounts of chloroquine are detectable in blood and urine 
as long as 5 years after the drug is discontinued.(185) This prolonged retention of the drug 
probably accounts for the reports of progressive and delayed onset retinopathy  despite 
discontinuation of therapy. 
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Hydroxychloroquine  seems  to  be  less  toxic  than  chloroquine.(186)  In  general  toxicity 
correlates with total dosage, although this may be less so in patients less than 40 years old 
who may have toxicity from lower doses.(186) 
 
The characteristic ocular signs of ocular toxicity include corneal whorl deposition, poliosis, 
and especially bulls’ eye maculopathy. The maculopathy begins as a pigmentary mottling 
that progresses to become a pericentral ring of depigmentation that is often horizontally 
oval.  There  is  also  often  peripheral  pigmentary  retinopathy  with  an  associated  loss  of 
peripheral visual field, occasionally leading to a mistaken diagnosis of retinitis pigmentosa 
or  rod/cone  dystrophy.  Visual  acuity  normally  decreases  with  worsening  of  the 
maculopathy. Other tests may show variable results especially in early, mild involvement 
including abnormal colour vision.(187) There may be central, pericentral and peripheral 
visual  defects(184;188).  Immediate  cessation  of  chloroquine  or  hydroxychloroquine 
therapy when toxicity is noted may produce clinical improvements, but the slow excretion 
of  these  drugs  usually  results  in  further  progression  of  symptoms.  Careful  clinical 
evaluation remains imperative because there is no treatment for the retinal toxicity. EOG 
Arden  ratio  can  be  reduced  in  patients  with  retinal  toxicity  with  chloroquine  and 
hydroxychloroquine.(187)  The  ERG  has  been  recorded  to  have  reduced  a  and b  wave 
amplitudes and increased latency as well as decreased oscillatory potentials.(189)  
 
Long-term hydroxychloroquine use may be associated with mfERG abnormalities. The 
mfERG appears to detect retinal physiological change earlier than visual acuity testing, 
color vision testing or Amsler grid testing.(190;191) 
 
7.8 Conclusion 
 
Retinal  toxicity  can  be  caused  by  a  variety  of  drugs,  commonly  digitalis,  quinine, 
chloroquine and hydroxychloroquine. The effect of AED such as Carabazepine, Phenytoin 
and Taiagabine are discussed in section 4.15. Different mechanisms have been proposed 
such  as  the  inhibition  of  Na
+,  K
+-ATPase  in  the  case  of  digitalis  and  disruption  of 
membranous cytoplasmic bodies in ganglion cells and degenerative cells in photoreceptor 
outer segments with hydroxychloroquine. Electrophysioloical tests provide an objective 
measure of  visual function and  are often  used in  diagnosis and monitoring  of  disease 
progression. 
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Chapter 8 
 
8.0 Multifocal Electroretinogram (mfERG) 
 
8.1 Introduction 
 
Recording of electrical impulses from the human eye was first reported in Scotland in 1877 
independently  by  Dewar  and  McKendrick  and  the  electroretinogram  (ERG)  has  since 
become  a  useful  diagnostic  tool  in  ophthalmology,  providing  information  on  retinal 
integrity.(192)  The ERG is a global retinal response produced by a summation of all the 
electrical responses of the different cells within the layers of the retina.   The  ERG is 
therefore  unable  to  detect  localised  areas  of  retinal  dysfunction.    Recent  advances  in 
electrophysiological techniques have enabled topographical maps of retinal function to be 
constructed, using a technique called multifocal electroretinography (mfERG), which was 
first described by Sutter and Tran.(193)   
 
MfERG enables the simultaneous recording of a collection of focal electrical impulses 
from  the  retina  that  correspond  to  localised  areas  of  retinal  function.    This  electro-
diagnostic technique facilitates a more in depth study of the normal physiology of the 
human retina and leads to better understanding of the effect of disease processes on retinal 
function.    In  contrast  to  the  standard  ERG,  the  method  of  stimulation  and  the  signal 
averaging  process  employed  enables  mfERG  to  provide  high  resolution  spatial  and 
temporal information on retinal processing.   
 
The mfERG allows for the simultaneous recording of many focal retinal responses in a 
relatively brief recording period.  
 
Since the first introduction to mfERG by Sutter and Tran in 1992(194), many commercial 
(VERIS™,  RetiScan™,  Metrovision™  and  AccuMap™)  and  non-commercial  systems 
have become available.(3;195)  The discussion of the mfERG technique in this chapter will 
concentrate on the VERIS™ and the non-commercial system developed in the Electro-
diagnostic Imaging Department in Glasgow(3;195). In general, all systems apply the same 
basic technique to obtain the mfERG response.  The systems stimulate the retina using a   74 
binary,  aperiodic  flash  stimulus  consisting  of  multiple,  independent  hexagonal  scaled 
elements. The on or off state of each element is controlled by a group of pseudorandom 
binary sequences called m-sequences. M-sequences are unique mathematically and allow 
various discrete, focal retinal areas to be stimulated, independently form one another. M-
sequences also allow the collection of these focal bits of retinal information from one 
“raw” signal collected from the eye.  
 
 
8.2 Technique 
 
Patient preparation will be described in the Methods section of this thesis 
 
8.2.1 Stimulus  
 
The technique of applying m-sequences to the recovery of small signals from noise has 
been used  extensively  in engineering  and physics  since  the early  1960's  and  was first 
applied  for  the  recovery  of  the  ERG  in  the  early  1970’s  and  1980’s  (196-200).  The 
technique  was  further  developed  to  provide  multiple  focal  responses  from  the  retina 
simultaneously.(201) 
 
The  mfERG  evokes  these  electrophysiological  responses  using  a  stimulus  generally 
consisting  of  multiple  hexagonal  scaled  elements,  which  are  independently  switched 
between low or high luminance (black or white). See Figure 8.2.1.1 
 
 
Figure 8.2.1.1 The hexagonal multifocal electroretinogram stimulus   75 
 
The stimulus delivery system can be a standard cathode ray tube (CRT) device, liquid 
crystal  display  (LCD),  light  emitting  diode  (LED)  or  scanning  laser  ophthalmoscope 
(SLO). In this study a custom built electrophysiological system was used to stimulate 90 
degrees of the visual field. This enabled wide field stimulation using a digital polysilicon 
projection system on a back projected screen. The main advantage of this technique is that 
peripheral retinal function can be assessed. This wide field stimulation is unique as no 
other multifocal system can stimulate more than 60 degrees of the visual field. The wide 
field system has been shown useful in the assessment of early retinal dystrophy and in 
selected cases of retinal toxicity(202;202-208;208-213). Patients on Vigabatrin appear to 
have selective peripheral retinal toxicity. Therefore wide field assessment has been a key 
element in the investigation of these patients in this study. 
 
The luminance of each element is controlled by m-sequences. A different sequence drives 
each element within the array. The sequences consist of an array of ‘0’s and ‘1’s. The 
stimulus is designed so that these sequences will switch the elements on and off at its 
driving frequency. In the case of the most commonly used stimulator (a computer monitor 
as with VERIS™) this driving frequency will generally be around 75 times per second 
(75Hz). Thus when the stimulus is active, it appears as a random flickering pattern.  
 
Typically this stimulus consists of either 61 or 103 elements. The scaling of each element 
is derived empirically to recover equivalent response amplitudes from all stimulated areas 
of the retina. This empirical scaling is influenced by photoreceptor topography, adaptation 
variation across the retina and the luminance topography of the stimulus. The intensity 
field of stimulation of the display varies depending on the stimulator used. Luminance 
intensity has ranged from 100-1000 cd/m
2 and a variety of stimulus sizes ranging from 30-
120 degrees of the visual field have been reported. 
 
8.2.2 The recording procedure   
 
As discussed previously the luminance of each element within the stimulus is controlled by 
individual m-sequences. These sequences consist of an array of ‘0’s and ‘1’s. The stimulus 
is designed so that these sequences will modulate the luminance (i.e. switch the elements 
on and off) at its driving frequency. In the case of the most commonly used stimulator (a 
computer monitor) this driving frequency will generally be around 75 times per second 
(75Hz).  Thus  when  the  stimulus  is  active,  it  appears  as  a  random  flickering  pattern.   76 
Although  each  element  independently  stimulates  a  focal  area  of  the  retina,  the  raw 
(uncorrelated)  response  recovered  will  represent  the  summation  of  retinal  responses 
generated at each individual area. Since each element is driven by its own independent 
orthogonal (modifying one sequence does not affect any other sequence) m-sequence this 
‘fingerprint’ sequence can be cross-correlated against the recovered mass response. The 
cross-correlation process in this binary system simply involves adding the relevant section 
of the global response when a particular stimulus element was at ‘on’ and subtracting the 
global response when the stimulus element was ‘off’. By repeating this process for each 
element at each stage of the recording process only the physiological responses that were 
modulated (and so related) to the sequence will be recovered. This provides the means of 
extracting  the  isolated  response  from  the  ‘global’  response.  Most  modern  computer 
systems with an appropriate signal processing card can acquire, digitise, store in memory 
and carry out this processing  in real-time and will produce a map of retinal function in 
around 8 minutes (see figure 8.2.2.1). This array of responses is usually termed the ‘ERG 
map’ or ‘trace array’. 
 
As the mfERG technique is still developing there are no international standards for the 
measurement  of  mfERG  responses,  although  the  International  Society  for  Clinical 
Electrophysiology of Vision (ISCEV) does provide some basic guidelines. (214)  
 
Figure 8.2.2.1 The mfERG Response 
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Figure 8.2.2.2 Focal waveforms in the mfERG response 
 
There  are  multiple  waveforms  in  each  multifocal  response.  Conventionally  these  are 
named N1, first negative deflection, P1, first positive deflection and N2, second negative 
deflection. See figure 8.2.2.2 
 
 
 
 
 
 
 
Figure 8.2.2.3 Parameters used to measure waveforms in mfERG response 
Multiple measures of retinal function can be calculated using the waveforms. Illustrated in 
figure  8.2.2.3  are  the  parameters  used  to  measure  P1  latency  and  P1  amplitude.  The 
commonest  way  of  analysing  mfERG  waveforms  is  by  looking  at  P1  amplitude  and 
latency. 
 
There are two responses that can be recorded from the mfERG. The first order response, 
which reflects responses evoked when presented with a high luminance and the second 
order  response,  which  reflects  responses  evoked  when  presented  with  a  change  in 
luminance.    In  reality  both  1
st  and  2
nd  order  responses  are  derived  from  the  same 
subcomponents  which  are  merely  added  and  subtracted  differently  (215;216).    Other 
authors  believe  that  the  2
nd  order  responses  are  non-linear  or  from  the  inner  retina. 
Evidence  from  animal  investigations  does  not  clarify  the  contributions  from  the  inner 
retina to a specific order of the response. It is also sometimes difficult to translate results 
from the animal model to humans.  
 
8.3 Clinical Application 
 
8.3.1 Introduction 
 
Normal Waveform
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P1 latency   78 
There has been a huge amount of published data on the mfERG. It is useful to categorise 
the clinical conditions into five categories. 
 
8.3.2 Vascular diseases of the retina 
 
Diabetes 
It has been shown that there is a reduction in first order mfERG responses before clinical 
changes were apparent and that implicit (latency) timing delays of the mfERG responses 
were  a  more  useful  indicator  of  diabetic  macular  oedema  than  mfERG  amplitude 
changes(217). 
 
Branch Retinal Artery Occlusion 
A small study on 3 patients showed a reduction in amplitude and delay in implicit time of 
the first order P1 and N1 mfERG responses in the affected quadrant compared with the 
vertically symmetrical unaffected quadrant(218). 
 
Central Retinal Vein Occlusion (CRVO)  
The mfERG is a useful investigative tool for differentiating CRVO in the acute phase. 
There is significant difference in the P1 amplitude and P1 latency between ischaemic and 
non-ischaemic CRVO(219).  
 
 
 
8.3.3 Retinitis Pigmentosa (RP) 
 
Implicit timing delays of  the mfERG responses in patients with RP could be a useful 
indicator of the disease and a useful parameter for monitoring the progression of RP. At 
advanced stages of RP, the standard Ganzfield ERG responses can be unrecordable. The 
spatial resolution of mfERG facilitates the recording of local electrical responses from the 
central retina in patients with advanced RP(220).   
 
8.3.4 Macular disease 
 
Age Related Macular Degeneration (ARMD) 
MfERG has been shown to be a sensitive tool in the assessment of patients with pre or 
early ARMD. In one study P1 amplitude and P1 latency of central mfERG responses were   79 
significantly reduced and delayed in  pre-ARMD and early ARMD eyes and also in the 
fellow  asymptomatic  eyes  when  compared  to  age-matched  controls.  Interestingly 
significant delays of the peripheral retinal mfERG responses were obtained from patients 
with  ARMD  using  wide  field  mfERG  suggesting  that  ARMD  globally  affects  retinal 
function.(221) 
 
Stargardt’s Macular Dystrophy (SMD) 
Macular mfERG response amplitudes were significantly reduced in patients with SMD and 
central mfERG amplitude reductions were detected even in patients with normal visual 
acuity and normal visual fields.(222) 
 
Best’s Disease (BMD) 
Central mfERG amplitude reductions that correlated significantly with visual acuity loss, 
were observed in a population of 18 patients with BMD, however, the mfERG reductions 
were much more marked than those observed in eyes with ARMD or Stargardts macular 
dystrophy(223).   
 
Central Serous Retinopathy 
The Electrodiagnostic Imaging Unit, Glasgow has tested 6 patients diagnosed clinically 
and  angiographically  with  unilateral  CSR,  using  multifocal  electroretinography 
(unpublished data).  They found that mfERG abnormalities of reduced amplitudes with or 
without implicit time delays were localised only to the areas clinically affected by the CSR 
and they did not find mfERG abnormalities in clinically normal areas of the affected eyes.  
Indeed, the electroretinographic responses from the clinically uninvolved eye were normal, 
supporting  earlier  work.  Conversely,  mfERG  abnormalities  observed  in  clinically 
unaffected areas of eyes with CSR and also in the contralateral normal eye despite the 
former findings and suggest a systemic aetiology to CSR suggesting that there is a pan-
retinal functional effect. The cause of this is unknown. 
 
 
 
 
8.3.5 Retinal toxicity 
 
MfERG  was  found  to  be  a  sensitive  indicator  of  retinal  dysfunction  in  patients  with 
chloroquine toxicity. The technique was more sensitive at detecting abnormalities of retinal   80 
function than standard ERG or routine clinical tests. (62) However, only three patients 
were assessed in this small study. 
 
The first reported case of a patient on Vigabatrin with visual field defects examined with 
mfERG was in 1998.(156) This case report concluded that both the ERG and mfERG were 
normal in a 17 year old on Vigabatrin for 18 months. The paper did not state if the patient 
was examined prior to Vigabatrin treatment so he may have had visual field constriction 
prior to starting Vigabatrin. The mfERG was performed using a conventional stimulus with 
only 50 degrees field of view and therefore the peripheral retina was not examined by 
mfERG.(156) 
 
The next reported case series of two patients in 1999 reported that there was a marked 
reduction in amplitude in peripheral responses of the mfERG with macular sparing.(114) 
Other studies have confirmed reduced mfERG amplitude, sometimes globally, including 
one study  where 12 out of 20 patients had reduced amplitude in first order kernel with 
conventional CRT monitors using a VERIS system with a 50 degree horizontal and 40 
degree vertical visual stimulus.(114;137;155) Some studies have stated that the pattern of 
reduced amplitude on mfERG was predominantly bi-nasal.
155  
 
One study in 12 patients has found no difference in amplitude of mfERG responses in 
those patients with visual field defects compared to controls.(160) The range of amplitude 
with  mfERG  is  wide  and  may  not  represent  the  most  sensitive  indicator  of  retinal 
pathology associated with Vigabatrin. 
 
The first report in the literature of the use of the wide field multifocal electroretinogram 
(WF-mfERG) was made in the literature in 2001.(2) This case report indicated that the 
WF-mfERG had good correlation with visual field loss in a patient on Vigabatrin. Retinal 
function as measured by the WF-mfERG was normal in the central retina. A delay in 
implicit timings occurred with eccentricity in both eyes.(2) 
 
A larger report in 32 adults on Vigabatrin was published in 2003.(3) These patients were 
matched with a cohort of patients who had never received Vigabatrin for age, sex and other 
anti-epileptic medication. There was no significant change in visual acuity or colour vision 
between the groups. 59% of the Vigabatrin group had visual field defects and none of the 
controls. Using WF-mfERG, all patients on Vigabatrin with visual field defects showed 
abnormalities  (100%  sensitivity)  and  only  2  out  of  13  patients  without  a  field  defect   81 
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showed retinal abnormalities (86% specificity). The most consistent overall predictor of 
bilateral visual field defects was the difference between central and peripheral implicit 
time. See Figure 8.1 and 8.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1 Plot of difference between central and peripheral implicit time of WF-mfERG 
responses in patients currently taking Vigabatrin Note the high correlation of WF-mfERG 
abnormalities  in  patients  with  bilateral  visual  field  defects.  Also  there  appears  no 
correlation of visual defect with accumulated dose. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.2 showing the difference in WF-mfERG between two patients with and without 
visual field defects. In the patient with visual field defects on Vigabatrin the peripheral 
responses are greater than 2msec delayed compared to the central responses. 
Vigabatrin pt without visual 
field defects 
Vigabatrin pt with visual 
field defects 
Average central 19 
responses 
Average peripheral 42 
responses   82 
 
8.4 Conclusion 
 
Vigabatrin (VGB) was the first in a series of new antiepileptic agents that arose from a 
period of unprecedented drug development for epilepsy in the 1980s and 1990s.  It was 
launched in the UK and Ireland in 1989 and exerts its effects by irreversible inhibition of 
the transaminase enzyme responsible for  inactivation of the inhibitory neurotransmitter 
GABA(46) VGB is an effective adjunctive treatment for complex partial seizures  
with or without secondary generalisation in adults as shown by Marson(224) and may be 
the  monotherapy  of  choice  in  some  children  with  infantile  spasms  as  reported  by 
Chiron.(82) The drug is now licensed in more than sixty countries.  Recently, VGB has 
received  “fast track” designation from  the  U.S. Food and Drug Administration for the 
treatment of cocaine and methamphetamine dependence. 
 
The initial barrier to marketing approval for epilepsy in the USA was an observation of 
white  matter  vacuolisation  by  Gibson  following  chronic  VGB  administration  to 
experimental  animals.(88)  This  pathology  has  never  been  reproduced  in  humans.(225) 
However, these concerns were compounded in 1997 with initial reports of bilateral visual 
field constriction in VGB-treated epilepsy patients by Eke.(11) Kalviainen suggested that 
this may be an issue for up to 40% of exposed individuals(120), despite the dearth of 
prospective studies or consideration of the inherent variability in the techniques employed 
in the assessment of visual fields.(97)   
 
As discussed in previous chapters, there have been limitations investigating patients on 
Vigabatrin with visual field defects (with selective peripheral retinal toxicity) with ERG 
alone  as  it  is  a  global  retinal  response  and  is  affected  by  the  reversible  actions  of 
Vigabatrin and increased GABA levels.  
 
The  wide-field  multifocal  electroretinogram  (WF-mfERG)  is  a  novel  ophthalmological 
tool  that  encompasses  up  to  90°  of  the  visual  field  and  can  thereby  identify  and 
differentiate dysfunction in both central and peripheral retina as described by Parks  & 
Keating.(195) This is in contrast to standard multi-focal electroretinography that reports 
only 40-50°
 of the central field. In comparison to perimetric methods for the assessment of 
visual fields, WF-mfERG permits investigation of causative electrophysiology rather than 
just  symptomatology.  We  have  previously  employed  WF-mfERG  to  identify  retinal 
dysfunction and by implication toxicity in VGB-treated epilepsy patients and demonstrated   83 
a partial concordance with data obtained from traditional perimetry(2;3). The current study 
was designed to distinguish retinal dysfunction from visual field constriction in a larger 
cohort  of  epilepsy  patients  in  relation  to  the  pharmacology  of  their  antiepileptic 
medications. 
 
 
 
 
 
 
 
 
 
 
 
Chapter 9 
 
Materials and Methods 
 
9. 1 Introduction 
 
Vigabatrin is an effective anti-epileptic drug for refractory partial epilepsy and the drug of 
choice  for  infantile  spasms.  Vigabatrin  seems  to  selectively  affect  the  outer  retina  in 
causing peripheral visual field defects. There are limitations in the current evaluation of 
these  patients.  Visual  fields  are  subjective.  Patients  with  epilepsy  often  have  poor 
concentration  and  attention,  making  repeat  visual  fields  poorly  repeatable  and 
reproducible. It is difficult to determine if there is progression of a vision defect if patients 
continue Vigabatrin. The ERG, though objective lacks spatial resolution. It is affected by 
the physiological effect of Vigabatrin itself and does not give a guideline to management. 
Conventional mfERG does not have  a wide enough field of  view to assess peripheral 
peripheral vision as the maximum area of examination is 60 degrees. Most other studies do 
not  seem  to  have  adequately  controlled  for  epilepsy  and  other  epilepsy  drugs  in  the 
examination of the visual system. During the study I was surprised to find even if patients 
have  documented  visual  field  defects,  patients  seemed  to  want  to  continue  taking 
Vigabatrin.  
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9.2 Aims 
 
 The aim of this study is to provide essential data to improve the management of patients 
taking Vigabatrin. This will include accurately quantifying the extent of retinal defects in 
patients,  assessing  visual  and  epilepsy-related  quality  of  life,  and  identifying  possible 
factors that may increase an individual's risk of developing retinal defects (i.e. other AED, 
occupation (indirect measure of light levels), site of epileptiform activity, smoking, alcohol 
etc).  The study also seeks to establish whether other GABA-ergic AED are implicated in 
causing retinal toxicity. 
 
9.3 Patients 
 
Two hundred and eighty three patients, aged 16 years or over, with partial-onset seizures 
attending either the Epilepsy Unit (Western Infirmary), Glasgow, Scotland or the Institute 
of Neurological Sciences (Southern General Hospital), Glasgow, Scotland were invited to 
participate in the study 2002 and 2006. Only patients that had read the patient information 
sheet and signed the consent form were recruited into the study. (see appendix 1) Each was 
currently taking, or had previously taken, Vigabatrin or alternative GABA-ergic or non-
GABA based AED for at least one year. All patients had CT and/or MRI scanning and 
were excluded if they had visual pathway pathology. Patients were not included if they had 
photosensitive  epilepsy,  significant  retinal  and/or  optic  disc  abnormalities,  including 
glaucoma, not associated with Vigabatrin therapy, were at risk of developing angle closure 
glaucoma,  a  previous  temporal  lobectomy  or  who  are  pregnant  Two  patients  who 
subsequently developed occipital infarction were excluded from analysis.  
 
Twenty one patients recruited were excluded from analysis for the following reasons: ten 
patients had a subsequent diagnosis of glaucoma (6 patients) or were found to have raised 
intraocular pressure and cupped optic discs (4 patients), two patients had a previous history 
of optic neuritis and were found to have pale optic discs on examination, four patients were 
unable to do visual field examination and WF-mfERG (there were no patients who could 
do a  visual field examination but not do  WF-mfERG examination), one patient had  a 
previous history of retinal vasculitis and had retinal scars on examination, one patient had a 
previous history of optic atrophy with bilateral pale optic disc and three patients refused to 
re-attend after equipment failure.  
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Three patients were excluded 
from analysis as they did not 
have  at  least  6/6  best 
corrected  visual  acuity  in 
both eyes. These included a 
decrease in central visual activity due to ophthalmic pathology such as opacity in the visual 
axis i.e. cataract (2 patients) and corneal dystrophy (1 patient). Fifty four patients failed to 
attend. One patient did not have repeat measurements as she had become pregnant. Two 
hundred and four patients were placed into four groups for analysis. Patients were matched 
for age, sex, duration of epilepsy and AED in each of the groups. 
 
The patients were divided into the following groups. 
 
1. Current Vigabatrin users. Patients had been on Vigabatrin for at least 2 years.  
 
2. Previous Vigabatrin users. Patients had used Vigabatrin for at least 1 year but had been 
off Vigabatrin for at least 2 years.  
 
3. Other GABA-ergic users. Patients had used another AED with GABA-ergic action.  
 
4. GABA naïve users. Patients had never used AED with GABA-ergic action.  
 
The final numbers that were analysed in the various groups were as follows. 
 
Groupings were performed to robustly control for the prevalence of visual field defects in 
patients with epilepsy not on Vigabatrin and for GABA-ergic AED. The groupings also 
allowed  analysis  to  identify  possible  factors  that  may  increase  an  individual's  risk  of 
developing retinal defects. 
 
 
 
 
 
Table 9.3.1 Numbers of patients in each group analysed 
 
9.4 Methods 
Current 
Vigabatrin 
n=56 
Previous 
Vigabatrin 
n=49 
Other 
GABA-ergic 
n=46 
GABA 
naïve 
 n=53   86 
 
Ethical approval was obtained from The West Ethical Committee, West Glasgow Hospitals 
University NHS Trust, (see Appendix 1) 
 
This research project complied with the Declarations of Helsinki. 
 
9.4.1 Medical history 
 
Demographic data such as age and address were noted. Patients were asked about current 
eye complaints, for example flashing lights, eye pain, floaters or decreased central vision. 
Decreased peripheral vision with symptoms such as bumping into objects was noted if 
volunteered and specifically asked for if not. Past ophthalmological history that can cause 
decreased peripheral visual field defects such as glaucoma or cataract was enquired about. 
Epileptic history included aetiological factors e.g. birth trauma, duration of epilepsy, type 
of epilepsy,  time since last fit, normal frequency of fits per month and past and current 
AED. If patients used to be or were currently on Vigabatrin, the dosage and duration of 
therapy were calculated. Medical conditions that affect the eye or brain such as diabetes, 
hypertension or brain tumours were verified. EEG findings and MRI/CT scan results were 
recorded. A note was made of any family history, smoking (cigarettes per day), alcohol use 
(units per week), diet (scale 0 to 5, 0 being the worse possible diet and 5 being the best 
possible diet) and occupation. 
 
9.4.2 LogMAR crowded test visual acuity (Keeler, Windsor, UK.) 
 
An assessment of a patient’s visual acuity gave a subjective measure of central vision. The 
logMAR flip chart has six selected letters which are of approximately equal legibility with 
all letters being symmetrical about the vertical mid-line. The following six letters were 
used X, V, O, H, U and Y. Each line in the chart contained 4 of the above letters to ensure 
a constant visual demand at each acuity level (as opposed to a Snellen chart which has 
different numbers of letters per line). This ensured that the only variable is the change in 
visual angle of the letters and permits low levels of the letter acuity to be measured with 
the same precision as higher acuity levels. Measured visual acuities ranged from 3/19 to 
3/1.5  (equivalent  to  6/38  –  6/3)  at  3  m  allowing  parametric  statistical  analysis  of  the 
complete distribution of acuity scores. The range could have been extended as required by 
changing the test distance. A regular geometric progression of letter sizes was employed 
whose ratio is equal to 
10√10
 or (0.1 log units) i.e. each new line in the chart was 0.1 log   87 
units smaller than the preceding one. Letters in each row were larger than those in the 
following smaller row by a factor of approximately 1.26.  
 
Artefacts  introduced  through  memorisation  and  intersession  variability  were  also  an 
important consideration and patients were closely monitored while reading the logMAR 
chart. 
 
The test was performed in an evenly well lit room at a test distance of 3m. The initial letter 
acuity level was determined using the screening cards, which were cards 1 to 3 in each of 
the crowded tests charts. Patients were encouraged to respond to each letter in the series 
until an error was made. The last successful response is used to determine the starting point 
for the measurement of line acuity. The appropriate card was then selected and the patient 
asked to identify each of the four letters presented. If the patient was able to correctly 
identify two or more letters on a line then the next card in the series was presented. 
 
The score for each eye was calculated using a single letter scoring system. Each line on the 
chart represents change of 0.1 log unit in the acuity level with each letter having a value of 
0.025 log unit, an example: a patient who reads correctly all of the letters on line 5 (0.4 log 
unit) and 1 letter on line 6 (-0.025 log unit for a single letter) was awarded a final score of 
0.375 log unit and a patient reading only 3 letters on line 5 (0.4 log unit) would have had 
the score for the missed letter (0.025 log unit) added to the line score giving a final score of 
0.425 log unit. See Figure 9.4.2.1 
 
 
 
Figure 9.4.2.1 the logMAR test card 
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The advantage of scoring each individual letter is that the scale is made four times finer 
than scoring simply by line. Comparison with Snellen are provided below (Table 9.4.2) 
 
Snellen 
(UK) 
Snellen 
(USA) 
logMAR 
 
6/38  20/127  0.8 
6/30  20/100  0.7 
6/24  20/80  0.6 
6/19  20/63  0.5 
6/15  20/50  0.4 
6/12  20/40  0.3 
6/9.5  20/32  0.2 
6/7.5  20/25  0.1 
6/6  20/20  0.0 
6/5  20/17  -0.1 
6/3.75  20/12.5  -0.2 
6/3 
 
20/10 
 
-0.3 
 
 
Table 9.4.2.1 Comparison between LogMAR and Snellen visual acuity 
 
The logMAR scoring system designates 6/6 a score of '0' and 6/60 a score of '1', with 
visual acuities less than 6/6 carrying a negative sign. Improvements in acuity result in a 
decrease in the score. 
 
9.4.3  Colour  vision  using  Hardy-Rand-Rittler  (HRR)  pseudoisochromatic  plates 
(Richmond International, Boca Raton, Florida USA) 
 
The HRR pseudoisochromatic plates were used as a qualitative diagnostic test to classify; 
 
1.  The type of colour vision defect whether protan or deutan, tritan or tetartan. 
2.  The degree of the defect whether mild, moderate or severe.  
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HRR plates have been shown to be effective in detecting acquired colour defects whereas 
other pseudoisochromatic plates such as Ishihara have been shown to detect predominantly 
congenital colour blindness.(226) 
 
The first four plates were demonstration plates and were not scored. These plates were 
used to detect malingerers or patients who were totally colour blind. Patients were allowed 
to name the symbols as they wished e.g. for “O” they may have said circle, ball or zero. 
Patients were instructed that symbols may appear in any of the four corners of the page and 
were asked to name each symbol and then trace them out. Patients were not allowed to 
trace out symbols before the symbol was named. Patients were then instructed that the test 
was made up of circles, triangles and crosses with two, one or none on a page. Some of 
them would be harder to see as they may be less strong in colour (see Figure 9.4.3.1). 
 
 
Figure 9.4.3.1 HRR screening plate. The correct response is “0” top left, “X” bottom right. 
 
The next six plates presented were screening plates. Only patients’ immediate responses 
were recorded. Plates were presented every 5 seconds. If patients correctly identified the 
objects in all six plates then they had normal colour vision and no more colour vision 
testing was done. If plate 1 or 2 was not correctly identified then the patient has defective 
blue-yellow colour vision (see figure 9.4.3.2) and plates 17 to 20 were then presented. If 
any of plates 3 to 6 were not correctly identified then the patient had defective red green 
colour vision and plates 7 to 16 were then presented (see figure 9.4.3.3).   90 
 
 
Figure 9.4.3.2 Plate 1 in HRR to test for blue – yellow colour defects 
  
Figure 9.4.3.3 Plate 10 in HRR to test for mild red green colour defects. 
 
For diagnosis of the type and extent of defects, plates 7 to 20 were used (see figure 9.4.3.4 
An error was a failure to see all symbols or citing an incorrect name or location of any 
symbol or an incorrect location.    91 
 
Figure 9.4.3.4 Scoring sheet for HRR 
(taken from Hardy-Rand Rittler scoring manual) 
 
Normal colour vision  
Patients with normal colour vision had correct responses to all six screening plates or made 
an error in the screening plates but none in the diagnostic plates, and had been given the 
screening plates again and made no error. 
 
Defective Colour Vision 
Red green deficiency patients were labeled depending on their responses to plates 7 to 16 
as protan (difficulty seeing red) or deutan (difficulty seeing blue). Blue yellow deficiency 
patients were labeled depending on their responses to plates 17 to 20 as tritan (difficulty 
seeing blue) or tetaran (difficulty seeing yellow). 
 
Extensive scattered errors throughout the various groups were likely due to malingering or 
total colour blindness. Three degrees of extent of defect were recognized: mild, medium 
and strong.  
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9.4.4 Pupil examination 
 
The size and shape of the pupils and their reaction to light and accommodation were noted. 
The swinging flashlight test was performed to examine for a relative afferent pupillary 
defect (RAPD). The patient was asked to fix his vision on an object in the distance. A 
strong light was shone in the right eye. The normal response is a bilateral contraction of 
both pupils. On moving the light to the left eye the normal response is no change in pupil 
size. If a patient had a RAPD then when the light was shone into the affected eye both 
pupils would dilate. Then on return of the light to the non-affected eye, both pupils would 
contract. RAPD occurs with unilateral retinal or optic nerve disease. 
 
9.4.5 Slit lamp examination 
 
The  slit  lamp  is  a  device  in  which  a  focused,  high  intensity  light  beam  (that  can  be 
narrowed into a slit) is used to illuminate the structures of the eye while the examiner looks 
at these structures with a magnifying scope. 
 
The eyelids were examined for lesions of the margins and subcutaneous tissues. The areas 
of the lacrimal sacs were palpated and an attempt made to express any contents up through 
the  canaliculi  and  puncta.  The  lids  were  then  everted,  and  the  palpebral  and  bulbar 
conjunctivae and the fornices were inspected for foreign bodies, signs of inflammation (eg, 
follicular hypertrophy, exudate, hyperemia, or edema), or other abnormalities. 
 
The cornea was closely inspected. If pain and photophobia made it difficult for the patient 
to open their eye, topical anesthesia could be added before examination by instilling one 
drop of 0.5% w/v proxymetacaine hydrochloride BP and 0.25% w/v Fluorescein Sodium 
BP. These drops allow the easier examination of corneal abrasions or ulcers more apparent. 
The patient would be asked to blink several times to spread the dye into the tear film and 
then the eye would be examined under good magnification and cobalt blue illumination. 
Areas where the corneal or conjunctival epithelium is absent would stain green. 
 
Once it was determined that patients were not at risk of developing narrow angle glaucoma 
and after visual field testing pupils were dilated with 1 drop of 1%  tropicamide w/v BP.   93 
Examination  of  the  eye  with  dilated  pupils  showed  opacities  of  the  cornea,  lens,  and 
vitreous as well as lesions of the retina and optic nerve in some patients. 
 
9.4.6 Intraocular pressure measurement (IOP) 
 
Intraocular  pressure  (IOP)  was  indirectly  measured  using  a  Goldmann  applanation 
tonometer on the slit lamp.  This is an instrument that measures intraocular pressure by 
determination  of  the  force  necessary  to  flatten  a  corneal  surface  of  constant  size  and 
eliminates the effects of scleral resistance. The device used a simple weighted lever system 
and eccentrically placed weights were varied until the applanated area of the cornea was 
flattened. This was a small corneal area (3mm) and the test was not uncomfortable for 
patients.  Fluorescein  dye  with  topical  anaesthesia  had  already  been  instilled  into  the 
conjuncticval sac before measurement of IOP. 
 
The weight required to flatten the cornea was directly converted to mm Hg by the device 
using the equation: 
  
P = W/A where P = Intraocular pressure 
W = weight applied 
A = area flattened. 
 
The procedure was repeated several times until two consecutive readings within 0.5 mm 
Hg were obtained. The normal range of IOP is 8 to 21mmHg. 
 
9.4.7 Visual fields examination 
 
The visual field was examined by automated static, three zone, suprathreshold perimetry 
using the Humphrey® Visual Field Analyzer (Humphrey systems Inc., Dublin, California, 
USA).  This  test  was  chosen  as  it  is  relatively  quick  to  perform,  is  less  likely  to  be 
influenced by fatigue than threshold testing (which takes longer to perform), encompasses 
a similar retinal field to the 90° WF mfERG and has been recommended as a screening 
instrument in Vigabatrin related visual field assessment.(126) Also, the visual field defects 
seen in patients with Vigabatrin are absolute scotomas. The added time to do a threshold 
test in this patient group was thought to be not worthwhile. 
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The Humphrey visual field device consists of a projection bowl on which test stimuli can 
be  presented  onto  the  surface  using  light  projections.  The  bowl  design  ensures  even 
background  illumination  of  a  known  intensity  which  was  consistent  between  repeated 
measurements over the period of this study.   
 
Static  suprathreshold  perimetry  employs  a  stimulus  intensity  that  should  be  seen 
everywhere  in  the  visual  field;  i.e.  it  is  above  the  predicted  threshold  value  for  each 
location. The stimulus that is presented is 6dB brighter than the expected age-dependent 
threshold at each point. The suprathreshold stimulus of light was presented as a small 
stationary  spot  of  white  light  for  a  short  period  of  time  superimposed  on  a  white 
background of uniform brightness. A hill of vision was assigned to the patient based on the 
patient’s age.  
 
A three zone test strategy was used. Every missed point is measured again at maximum 
intensity at 10,000 apostilbs to determine if the defect is absolute. The printout displays 
(X) for relative defects. Using this strategy, large areas of the visual field can be quickly 
examined.   
 
The  120  stimulus  locations  are  located  within  an  eccentricity  of  50°  nasally,  60° 
temporally,  40°  superiorly  and  55°  inferiorly  (see  Figure  9.4.7.1.).  The  stimulus  size 
subtended 0.43 degrees, was 4mm
2 and was white in colour. The stimulus duration was 200 
milliseconds and the background luminance of the bowl was 31.5 apostilbs for all visual 
field examinations. The normal test speed setting was used which automatically adjusted 
for slow responding patients. The fixation target used was a small yellow light in the centre 
of the bowl.  
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Figure 9.4.7.1 Stimulus locations for 120 degree visual field 
(Taken from Humphrey® Field Analyzer ΙΙ–i series User Manual) 
 
The  test  procedure  was  explained  to  all  patients  clearly.  All  questions  were  answered 
before starting. The following instructions were given; 
 
“This test will measure your central and side vision. It is always important that you look 
straight ahead at the steady yellow light. (The yellow fixation light was shown.) Other 
lights will flash one at a time off to the side. Some will be bright, some dim. Press the 
button whenever you see one of these lights. (The response button is presented to the 
patient.) You are not expected to see all of the lights so do not worry if you think you have 
missed some. If you want to rest, hold down the button, the test will resume when you 
release the button. We test one eye at a time. Blink normally so that your eye does not get 
dry.”  
 
The non-test eye was patched with temporary adhesive eye patches so that vision was 
completely blocked. The table, seat height and chin rest height were adjusted so that the   96 
patient was comfortable and relaxed while holding the button. The patient placed their chin 
on the appropriate side of the chin rest with their forehead against the forehead rest. The 
patient was aligned on the video eye monitor so that the pupil was centred on the target. 
The blinds were closed so that the room was dimly lit.  
 
The blind spot was monitored to determine reliability. The test programme periodically 
presented 5% of stimuli to the patient’s blind spot. Only if the patient indicated seeing the 
blind spot stimulus would the instrument record a fixation loss. If the patient was fixating 
well then they would not see the blind spot check stimulus. The blind spot test stimulus 
matches the test  stimulus size i.e. 4mm
2. A high fixation  loss score indicated  that the 
patient did not fixate  well or that  the blind spot was incorrectly located.  The printout 
showed  the  total  number  of  fixation  losses  followed  by  the  total  number  of  stimuli 
presented within the blind spot.  
 
Trial lens correction was used in all patients requiring near vision correction.  
 
 
 
 
 
 
 
 
 
 
Table  9.4.7.1 
Classification of degree of visual field loss is dependent on proximity to fixation of a 
cluster of four or more visual field defects. Values are degrees from fixation. 
 
All  visual  fields  were  assessed  masked  to  drug  history  by  two  experienced 
Ophthalmologists (PG and FD) with much experience of automated perimetry. Automated 
static threshold perimetry is a demanding visual task particularly in patients with cognitive 
impairment. Therefore patients who exhibited visual fields that manifested >50% fixation 
losses were deemed unreliable i.e. a greater margin of error was allowed in this patient 
group  because  of  attention  problems,  normally  only  up  to  33%  of  fixation  losses  are 
allowed.  
Classification  Temporal  Nasal  Superior  Inferior 
Normal   >60°  >50° 
 
>40°  >55° 
Mild  50 – 60°  36-50°  36-40°  45-55° 
Moderate  30-50°  20-35°  20-35°  25-45° 
Severe  <30°  <20°  <20°  <25°   97 
 
Using a modification of a previously described visual field defect classification by Wild 
(126), a cluster of four or more relative or absolute defects was described as an abnormal 
field defect. These defects were further classified as mild, moderate or severe depending 
on the proximity of the defect to fixation in each of the retinal quadrants. See Table 9.4.7.1 
 
Examples are given below of no, mild, moderate and severe visual field defects. See figure 
9.4.7.2 – 9.4.7.5 
 
 
 
 
Figure 9.4.7.2 No field defect (Humphrey 120 degree screening test) 
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Figure 9.4.7.3 Mild field defect (Humphrey 120 degree screening test) 
 
 
Figure 9.4.7.4 Moderate field defect (Humphrey 120 degree screening test)   99 
 
 
Figure 9.4.7.5 Severe field defect (Humphrey 120 degree screening test) 
 
9.4.8 Preparation for Electrophysiology 
 
Patients  are  seated  comfortably.  Clear  explanations  for  the  test  are  given.  Topical 
anesthesia  and  dilation  were  achieved  using  one  drop  of  0.5%  w/v  proxymetacaine 
hydrochloride BP and 2 drops of 1% tropicamide w/v BP into each eye. Reference skin 
electrodes were placed at the outer canthi of each eye and a ground or indifferent electrode 
was placed on the forehead using Neuroline® disposable skin electrodes. Contact DTL® 
electrodes were placed along the lower cornea of both eyes. 
 
9.4.9 Electroretinograms (ERG) 
 
ERG were performed in all patients to identify global retinal function. 
 
The ERG response is dependent on a number of variables including the type of electrode 
used. It is therefore important that every individual laboratory or clinic establish their own 
normative data. See figure 9.4.9.1 for our normative data set for the Espion Diagnosys 
electrophysiological system using DTL® and Neuroline® electrodes.     100 
 
 
  Amplitudes 
(micro Volts) 
Implicit times 
(ms) 
Rod  72-367  74-102 
Max A  165-291  15-17 
Max B  241-709  34-59 
Osc Pot  36-112  15-20 
Cone A  17-55  7-13 
Cone B  68-222  22-31 
Flicker  25-150  21-31 
Table 9.4.9.1 Normative data for Electro-diagnostic Imaging Unit 
 
By  appropriate  selection  of  background  light  levels,  stimulus  luminance,  dark  or  light 
adaptation  it  is  possible  to  obtain  a  set  of  responses  which  give  objective  and 
complementary information on the integrity of retinal processing.  The examples shown in 
this section were recorded from a patient in group 4 of this study using the disposable DTL 
Fibre  electrode.  In  the  description  of  the  responses  a  Standard  Flash  is  defined  as  a 
stimulus luminance level of 3.0 Cd.m
2.  
 
Response 1- The Rod Response 
This response was recorded using a dim flash of light in dark adapted eyes. The period of 
dark adaptation was 20 minutes. The stimulus intensity was 0.01 cd/m
2. Serial averaging of 
a number of responses was performed but inter  stimulus duration was not less than 2 
seconds  to  avoid  light  adapting  the  retina.  A  typical  response  is  shown  in  Figure 
9.4.9.2.The positive wave is known as the b-wave and is generated by the on-bipolar cells 
in the retina. As signals are passed to the on –bipolar cells from the rod system, a normal 
waveform indicates intact rod and on-bipolar cell function. The key measurement was the 
amplitude from baseline to the peak of the response. Time to peak was also of interest. 
 
Response 2-The Maximal Response 
This response was also performed on a dark adapted eye. In this case a bright flash of 
3cd/m
2 was used to evoke a response that is generated by both rod and cone systems. As 
this was a more intense flash of light inter stimulus duration was not less than 15 seconds 
to avoid light adapting the retina.  An example is shown in Figure 9.4.9.2. The trough is 
known  as  the  a-wave  and  is  generated  by  off–bipolar  cells  with  a  small  contribution 
directly from the photoreceptors. The positive component is the b-wave and this is mainly 
generated by off-bipolar cells. The a-wave amplitude is measured from the baseline to the 
trough and the b-wave amplitude from the a-wave trough to the response peak.   101 
 
Response 3-Oscillatory Potentials 
Oscillatory potentials are small oscillations on the rising edge of the b-wave. Stimulation 
was the same as for the maximal response but in order to emphasise the high frequency 
oscillations, a different amplifier filter bandwidth was used. Instead of 0.5 to 300 Hz a 
restricted  bandwidth of 75  Hz  –  300  Hz  was  used.  This  removed  the slow  frequency 
component giving the oscillatory potentials as illustrated in Figure 9.4.9.2. The oscillatory 
potentials are believed to originate in the inner retina with horizontal and amacrine cells 
the most likely generators. 
 
Response 4-Cone Response 
A 10 minute period of light adaptation to a background luminance of  30 cd/m
2 was done 
before  this photopic measurement  was performed. 3  cd/m
2    was used and  an example 
response is shown in Figure 9.4.9.2. This response is dominated by the cone pathway with 
the  a-wave  generated  by  the  off-bipolar  cells  and  the  b-wave  the  on-bipolar  cells. 
Waveform measurements are the same as in previous examples. 
 
Response 5-Flicker Response 
A pure response from the cone pathway was obtained using a fast flickering stimulus. In 
this case, the Standard Flash was used at a stimulation rate of 30 Hz. The rod system 
cannot respond at these frequencies therefore the flicker response is a pure cone pathway 
response. A normal flicker response is shown in Figure 9.4.9.2. 
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Figure 9.4.9.1 Normal ERG 
(taken from Electro-diagnostic Imaging Unit, Glasgow) 
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A summary table of stimulus intensity, background intensity and frequency is given below 
for the ERG parameters in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9.4.9.2 Stimulus intensity, background intensity and frequency of the ERG stimulus 
 
9.4.10 Wide field multifocal ERG (WF-mfERG) 
 
The WF-mfERG was performed in all patients immediately after the ERG was performed. 
The electrodes used for the ERG were also used to record the WF-mfERG response. 
 
The WF-mfERG was recorded using a custom built electrophysiological system. Wide 
field stimulation was achieved using a digital polysilicon projection system at a refresh rate 
of 75Hz. Maximal stimulus luminance was 1500 candelas per m
2. An array of sixty one 
empirically scaled hexagons  was used to stimulate 90 degrees of  the visual field. The 
hexagons  were scaled with eccentricity to take  into  account photoreceptor topography, 
photo-adaptive response profile and projection luminance gradient. Each hexagon OFF and 
ON  state  (black  and  white,  97%  contrast)  was  controlled  by  a  binary  m  sequence 
(explained in the introduction section).The duration of overall recording period was eight 
minutes, segmented into sixteen intervals each lasting thirty seconds. An amplifier gain of 
100,000 with an ADC digitisation rate of 1200Hz and a dual high/low pass filter of 3-
300Hz and 10-100Hz was used 
 
Parameter  Flash 
intensity 
(cd/m
2) 
Background 
intensity 
(cd/m
2) 
Flash 
Frequency 
(Hz) 
Rod  0.01  0  1 
Maximal  3  0  1 
Oscillatory 
potential 
3  0  1 
Cone  3  30  1 
Flicker  3  30  30.3   104 
Wf-mfERG responses were grouped concentrically into central (60 degrees) and peripheral 
(61 to 90 degrees) for analysis. See figure 9.4.10.1 
 
 
Figure 9.4.10.1 Groupings of central and peripheral responses for analysis of the WF-
mfERG. 
 
Responses were compared between the four patient groups for N1, P1 and N2 amplitude 
and latency. From previous studies the most consistent overall predictor of bilateral field 
defects was the difference between central and peripheral implicit times.(3) See figure 
9.4.10.2. 
 
60° central field 
90° peripheral field   105 
 
 
Figure 9.4.10.2 Typical examples showing responses from a patient on Vigabatrin with 
visual field defects compared to a patient on Vigabatrin without visual field defects. The 
traces from each retinal area are on the left while summed responses are on the right. In the 
patient  on  Vigabatrin  with  visual  field  defects  the  peripheral  responses  are  delayed 
compared to the central responses. 
 
9.4.11 Quality of life in epilepsy questionnaire (QOLIE 31 P) 
 
The Quality of Life in Epilepsy Inventory (QOLIE-31 P) contains seven multi-item scales 
that question the following health parameters: emotional well-being, social functioning, 
energy/fatigue,  cognitive  functioning,  seizure  worry,  medication  effects,  and  overall 
quality of life.(227) A QOLIE-31 P overall score was obtained using a weighted average of 
the multi-item scale scores. The QOLIE-31 P also included a single item that assesses 
overall health. The additional 7 preference items are scored separately and not combined 
with the main score. 
 
Pre-coded numeric values for responses on some QOLIE-31 P items are in the direction 
such that a higher number reflects a more favorable health state. For example, a circled 
response of '10' for item 1 corresponds to "Best Possible Quality of Life", while a circled 
response  of  '0'  corresponds  to  "Worst  Possible  Quality  of  Life."  However,  pre-coded 
numeric values for some other items on the QOLIE-31 P are in the direction such that a 
lower number reflects a more favorable health state. For example, a circled response of '1' 
for item 14 corresponds to more favorable quality of life, while a value of  '5' on this item 
  Central responses 
Peripheral responses 
Vigabatrin-treated patient with 
Vigabatrin-treated patient without  
visuavisual field defects   106 
corresponds to less favorable quality of life. As these examples also demonstrate, different 
items in the QOLIE-31 P have different ranges of precoded numeric values. After coding 
higher scores always reflect better quality of life (see appendix 3).  
 
A QOLIE-31 P overall score was derived by weighting and summing QOLIE-31 scale 
scores. QOLIE-31 P scale weights were derived from a regression analysis that used a 
summary  score  from  the  OOLIE-89.    The  QOLIE-31  overall  score  was  calculated  by 
summing the product of each scale score times its weight and summing over all scales. 
 
The QOLIE 31 P questionnaire and QOLIE 31 P scoring manual are in appendix 2. 
 
9.4.12 Visual function questionnaire (VFQ-25) 
 
The VFQ-25 is the product of an item-reduction analysis of the longer field test version of the 
survey  called  the  51-item  National  Eye  Institute  Vision  Function  Questionnaire  (NEI-
VFQ).(228)
  The survey measures the influence of visual disability and visual symptoms on 
generic health domains such as emotional well-being and social functioning, in addition to 
task-oriented domains related to daily visual functioning. Questions included in the VFQ-25 
represent the content identified during a series of condition-specific focus groups with patients 
who  had  age-related  cataracts,  glaucoma,  age-related  macular  degeneration,  diabetic 
retinopathy, or CMV retinitis.
  The VFQ-25 consists of a base set of 25 vision-targeted 
questions representing 11 vision-related  constructs, plus an additional single-item  general 
health rating question.  
 
The  VFQ-25  generates  the  following  vision-targeted  sub-scales:  global  vision  rating, 
difficulty with near vision activities, difficulty with distance vision activities, limitations in 
social functioning due to vision, role limitations due to vision, dependency on others due to 
vision,  mental  health  symptoms  due  to  vision,  driving  difficulties,  limitations  with 
peripheral and color vision , and ocular pain. Additionally, the VFQ-25 contains the single 
general health rating question which has been shown to be a robust predictor of future 
health and mortality in population-based studies. 
 
The VFQ-25 was scored by a two-step process. In step 1 original numeric values from the 
survey were re-coded following the scoring rules outlined in appendix 3. All items were 
scored so that a high score represented better functioning. Each item was then converted to 
a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points   107 
respectively. In this format, scores represented the achieved percentage of the total possible 
score, e.g. a score of 50 represented 50% of the highest possible score. In step 2, items 
within each sub-scale were averaged together to create the 12 sub-scale scores. Appendix 4 
indicates which items contributed to each specific sub-scale. Items that were left blank 
(missing data) were not taken into account when calculating the scale scores. Sub-scales 
with at least one item answered could be used to generate a sub-scale score. Hence, scores 
represented the average for all items in the sub-scale that the respondent answered. To 
calculate an overall composite score for the VFQ-25 the vision-targeted sub-scale scores 
were simply averaged excluding the general health rating question.  By averaging the sub-
scale scores rather than the individual items we gave equal weight to each sub-scale whereas 
averaging the items would have given more weight to scales with more items. 
 
9.4.13 Digital fundus photograph 
 
Every patient had digital fundus photography using the Oculab® digital imaging system 
with a Zeiss® F450 camera. Two photographs were taken: one with 50 degrees of view 
encompassing the optic nerve, macula and superior and inferior arcades, the other a 30 
degree close up of the macula. The fundus photographs of all patients were reviewed by 
two  experienced  Ophthalmologists  (PG)  and  (FD)  who  were  blinded  to  the  other’s 
assessment. Only agreed clinical findings were included in analysis. 
 
9.5 Statistical analysis 
 
Statistical  analysis  was  performed  following  advice  from  the  Robertson  Centre  for 
Biostatistics, University of Glasgow. 
Baseline  demographics  (visit  1)  and  clinical  characteristics  were  summarised  by  drug 
group.  Continuous variables were reported as mean (standard deviation (SD)) or median 
(as  appropriate)  and  range  (minimum-maximum).  Categorical  variables  are  reported  as 
number  and  percentage.    The  proportion  of  patients  in  each  of  the  drug  groups  with 
bilateral visual field defects at visit 1 was compared using the chi-squared test.  Unilateral 
visual field defects and bilateral and unilateral abnormal WF-mfERG were compared in a 
similar  manner.  Kappa  statistics  and  corresponding  95%  confidence  intervals  were 
reported for the agreement between visual field defects and abnormal WF-mfERG for both 
bilateral and unilateral effects.  
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ERG investigation variables at visit 1 were compared between patients with and without 
bilateral  visual  field  defects  using  Wilcoxon  rank  sum  tests.  Results  are  given  for  all 
patients and for each of the 4 drug groups separately. Each variable is also summarised by 
mean (SD) and median (Interquartile range (IQR)).  
 
The Wilcoxon signed rank test was used to compare the change in the difference between 
central implicit time and peripheral implicit time at visit 2 from visit 1 for all patients and 
by each of the 4 drug groups separately. The proportion of patients with visual field defects 
and abnormal mf ERG were compared between visit 1 and visit 2 using McNemar tests. 
Spearman’s rank-correlation coefficient was used to asses the association between number 
of monthly seizures and degree of Ptosis.  
  
The influence of baseline patient and clinical characteristics on bilateral visual field defects 
were examined using logistic regression models. Each of the variables was added into the 
model  univariately,  then  a  multivariate  stepwise  model  was  constructed  retaining  only 
variables significant at p<0.05. Odds ratios, 95% confidence intervals and corresponding p-
values are reported. 
 
Analysis of variance (ANOVA) was used to compare QOLIE-31 total score and subscales 
at visit 1 for the 4 groups. 
 
All statistical analyses were performed using SAS for windows version 8.2. All available 
data was used for each measurement. 
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10.1 Baseline Demographics 
 
Patients with epilepsy were grouped into four groups. Group 1 consisted of patients with 
epilepsy who had been Vigabatrin for at least 2 years and is named Vigabatrin group. 
Group 2 consisted of patients with epilepsy on Vigabatrin for at least 2 years and off 
Vigabatrin for at least 2 years and is named ex-Vigabatrin group. Group 3 consisted of 
patients with epilepsy on another anti-epileptic drug with a GABA-ergic action other than 
Vigabatrin and is named GABA group. Group 4 consisted of patients with epilepsy who 
have never been on Vigabatrin or GABA-ergic drugs and is named the non-GABA group. 
 
Patients were matched for age, sex and duration of epilepsy as far as possible and baseline 
demographics support this. (see Table 1) Since we had a limited population, sex of the 
patient  was not  as  important as  other epilepsy  drugs  or  duration of epilepsy.  Average 
monthly seizure frequency was 1 for Vigabatrin and ex-Vigabatrin groups and 0 for other 
GABA groups and other non-GABA group but ranged from 0 to 750 per month across all 
groups. 
 
The mean length of Vigabatrin therapy in Vigabatrin Group was 5.7 years, range 2 years to 
8 years. The mean Vigabatrin load was 5788g with the range 2765g to 21056g. 
 
A  number  of  patients  in  each  group  described  decreased  visual  acuity  on  ophthalmic 
history. Three patients were excluded from analysis as they did not have at least 6/6 best 
corrected visual acuity in both eyes. These included a decrease in central visual activity 
due to ophthalmic pathology such as opacity in the visual axis i.e. cataract (2 patients) and 
corneal dystrophy (1 patient). Similarly, anyone who had peripheral visual field defects 
which could be explained by ophthalmic pathology such as glaucoma, occipital lobe stroke 
or cataract was excluded from analysis (12 patients). Every patient had MRI scans of their 
visual pathway and were not included if there were any structural lesion that could affect 
the visual pathway (7 patients).   
 
There  was  an  equal  distribution  of  significant  medical  diseases  between  the  groups. 
Hypertension was the most common associated medical disease in all groups (n = 16). The 
most  common  associated  familial  diseases  were  epilepsy  and  glaucoma  and  were 
distributed between the groups. 
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By far, the most common additional anti-epileptic drug was carbamazepine (n = 126). 
There was a consistent distribution of anti-epileptic drugs across all groups. However on 
average patients in the Vigabatrin group and  
the ex-Vigabatrin group had used a greater variety of anti-epileptic drugs than those in the 
GABA group and the non-GABA group. This was expected as Vigabatrin is used mainly 
to  treat  refractory  seizures  in  this  patient  population  by  the  Epilepsy  Unit,  Western 
Infirmary Glasgow. Taking this into account, patients were matched as best possible for 
other anti-epileptic drugs used among the four groups as well as age, sex and duration of 
epilepsy. Patients in the Vigabatrin group and the ex-Vigabatrin group seemed to smoke 
more and drink less on average than patients in the GABA group and the non-GABA 
group, see Table 1. The GABA group and non-GABA group had the highest employment 
rate reflecting good seizure control. Monthly seizure frequency was on average 0. 
Characteristics 
 
Vigabatrin 
(n=56) 
Ex-Vigabatrin 
(n=49) 
 GABA 
(n=46) 
Non-GABA 
(n=53) 
Continuous variables         
Age (years)  39.9 (13.0), 
[12.1-70.5] 
43.9 (14.6), 
[16.4-81.3] 
46.7 (14.8), 
[16.3-79.8] 
43.8 (16.0), 
[17.4-85.8] 
Duration of epilepsy (years)  20.4 (9.9), 
[5.1-51.5) 
24.4 (12.2), 
[4.2-55.0] 
19.3 (12.8), 
[1.4-50.6] 
13.3 (10.0), 
[2.0-39.6] 
Female   29 (51.8)  35 (71.4)  25 (54.4)  36 (67.9) 
Monthly seizure frequency 
Median [range]  
1 [0-90]  2 [0-750]  0 [0-84]  0 [0-30] 
Length of Vigabatrin therapy 
(years) 
7.7 (3.7), 
[2.2-9.0] 
1.75(0.35) 
[1.0-1.9.0] 
-  - 
Actual load Vigabatrin (g) 
median [range] 
5788 
[2765, 21056] 
(not enough data)  -  - 
Categorical variables         
Ophthalmology history         
  Myopia  3 (5.4)  3 (6.1)  2 (4.4)  4 (7.6) 
  Presbyopia  0 (0)  2 (4.1)  10 (21.7)  9 (17.0) 
  Decreased central visual 
acuity 
5 (8.9)  7 (14.3)  9 (19.6)  7 (13.2) 
Medical history of :         
 Asthma  2 (3.6)  2 (4.1)  2 (4.4)  7 (13.2) 
 Diabetes  2 (3.6)  3 (6.1)  0 (0)  2 (3.8) 
 Hypertension  1 (1.8)  5 (10.2)  3 (6.5)  7 (13.2) 
 Ischaemic heart disease  5 (8.9)  2 (4.1)  2 (4.4)  1 (1.9) 
Family history of:         
  Epilepsy  3 (5.4)  8 (16.3)  1 (2.2)  7 (13.2) 
  Glaucoma  2 (3.6)  4 (8.2)  5 (10.9)  1 (1.9) 
Other anti-epileptic drugs:         
  ACETAZOLAMIDE  5 (8.9)  7 (14.3)  0 (0)  0 (0) 
  CARBAMAZEPINE  38 (67.9)  39 (79.6)  24 (52.2)  25 (47.2) 
  CLOBAZAM  10 (17.9)  17 (34.7)  5 (10.9)  0 (0) 
  GABAPENTIN  11 (19.6)  20 (40.8)  6 (13.0)  0 (0) 
  LEVETIRACETAM  8 (14.3)  19 (38.8)  16 (34.8)  0 (0) 
  LAMOTRIGINE  18 (32.1)  28 (57.1)  17 (37.0)  29 (54.7) 
  OXCARBAZEPINE  2 (3.6)  6 (12.2)  3 (6.5)  1 (1.9) 
 PHENOBARBITONE  8 (14.3)  12 (24.5)  7 (15.2)  0 (0) 
  PHENYTOIN  24 (42.9)  21 (42.9)  11 (23.9)  5 (9.4) 
  TIAGABINE  5 (8.9)  11 (22.4)  2 (4.4)  0 (0) 
  TOPIRAMATE  15 (26.8)  26 (53.1)  6 (13.0)  0 (0) 
  VALPROATE  18 (32.1)  25 (51.0)  25 (54.4)  0 (0) 
Current smoker  14 (25.0)  15 (30.6)  8 (17.4)  12 (22.6) 
Drinks alcohol  2 (3.6)  5 (10.2)  8 (17.4)  16 (30.2) 
Employment:         
  Employed/student  25 (44.6)  18 (36.7)  23 (50)  38 (71.7) 
  Retired  7 (12.5)  7 (14.3)  13 (28.3)  7 (13.2)   111 
  VGB Patient with no field defect 
  Central Responses 
 
Peripheral Responses   
VGB Patient moderate bilateral field defect 
  Unemployed  24 (42.9)  24 (49.0)  10 (21.7)  8 (15.1) 
 
Table 10.1.1 Baseline demographics  and clinical characteristics by  patient drug  group.  
Data are presented as mean (SD), [Range] for continuous variables and number (%) for 
categorical variables unless otherwise stated.  
 
 
10.2 Wide field multifocal electroretinogram (WF-mfERG) and visual field defects. 
 
As discussed previously, a typical WF-mfERG response from a Vigabatrin patient with no 
field abnormality and one with a moderate bilateral field abnormality is shown below. Note 
the delay (>2ms) between central and peripheral WF-mfERG response peaks in the patient 
with  a  moderate  bilateral  visual  field  defect.  A  bilateral  delay  of  greater  than  2 
milliseconds was the defining feature of retinal toxicity in this patient group. However, all 
parameters of anatomical and functional assessment of vision, such as fundus examination, 
visual field assessment and ERG in all patient groups were also analyzed and compared. 
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Figure 10.2.1 WF-mfERG differences in patients with and without visual field defects  
 
 
 
 
 
 
 
 
 
 
 
Table  10.2.1  summarises  the  comparison  between  bilateral  visual  field  defects  and 
abnormal WF-mfERG responses in all groups. 
  Vigabatrin 
(n=56) 
Ex-
Vigabatrin 
(n=49) 
GABA 
(n=45) 
non-GABA 
(n=53) 
Chi-squared 
test  
p-value 
(overall) 
Bilateral  visual 
field defects 
(mild,  moderate 
and severe) 
33 (64.7)  21 (45.6)  13 (30.2)
 *  11 (21.2)*
 ‡  <0.0001 
Bilateral 
abnormal  WF 
mf ERG 
27 (48.2)  11 (22.4)
 ±  0 (0)*
 †  0 (0)*
 †  <0.0001   113 
Table  10.2.1  Bilateral  visual  field  defects  and  abnormal  WF-mfERG  by  patient  drug 
groups.  
Date is presented as number (%).  N is the maximum number in each group. All available 
data used.  
*p<0.001 for pairwise comparison with Vigabatrin. 
± p<0.01 for pairwise comparison with Vigabatrin. 
† p<0.001 for pairwise comparison with Ex-Vigabatrin. 
‡ p<0.01 for pairwise comparison with Ex-Vigabatrin. 
Note: Due to multiple tests only p<0.01 (i.e. 0.05/6 =0.01) is considered to be statistically 
significant.  
 
Immediately, there are several striking observations. Only patients in Vigabatrin group and 
ex-Vigabatrin  groups  had  abnormal  bilateral  WF-mfERG  abnormalities  on  testing. 
Therefore, patients not exposed to Vigabatrin did not have abnormal bilateral WF-mfERG. 
This result is statistically significant. In contrast, in all groups a number of patients had 
bilateral visual field defects. In fact, the percentage in the groups not exposed to Vigabatrin 
was  much  higher  than  expected  in  the  GABA  group  (30.2%)  and  non-GABA  group 
(21.2%).  This  result  was  statistically  significant.    Therefore,  we  surmise  that  not  all 
bilateral visual field defects can be attributed to a retinal abnormality i.e. retinal toxicity. 
These results are presented graphically in Figure 10.2.2.  
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Figure 10.2.2 Graph  to show percentage of bilateral visual field defects and  abnormal 
bilateral WF-mfERG in each group. 
 
It  is  important  to note that  all  patients  analysed had normal  visual  pathways  on  MRI 
scanning hence no structural cause for visual field defects. Patients in all groups had visual 
field defects  even  those  not on  Vigabatrin.  Therefore,  visual  field defects may  not be 
specific to retinal toxicity associated with Vigabatrin.  
 
Let us assume that the visual field test is not as specific for retinal toxicity as compared to  
WF-mfERG (thus using the WF-mfERG as the “gold standard”), visual field defects has 
still proven to be sensitive in Vigabatrin group as only 2 patients out of 33 with abnormal 
WF-  mfERG  did  not  have  bilateral  abnormal  visual  field  defects  (93.9%  sensitivity). 
Specificity was 87.9%. 
   
It is also interesting that ex-Vigabatrin users still have abnormal WF-mfERG and visual 
field defects (up to two years after stopping Vigabatrin) suggesting irreversible damage in 
some patients and on-going retinal toxicity.  
 
 
 
 
 
 
 
Analysis was also done comparing right and left eye visual field defects and WF-mfERG 
and is illustrated below in Tables 10.2.2 and 10.2.3. 
 
  Vigabatrin 
(n=56) 
Ex-
Vigabatrin 
GABA 
(n=46) 
non-GABA 
(n=53) 
Chi-squared 
test p-value   115 
(n=49)  (overall) 
Left  eye  visual 
field defects 
37 (72.6)  22 (47.8)  19 (43.2)
 ±  17 (32.7)*  0.0006 
Left  eye 
abnormal  WF 
mf ERG 
32  (57.1)  12 (24.5) *  3 (6.5) *  3 (5.7) *
‡  <0.0001 
Table  10.2.2:  Left  eye  visual  field  defects  and  abnormal  WF-mfERG  by  patient  drug 
groups.  
Date is presented as number (%).  N is the maximum number in each group. All available 
data used.  
*p<0.001 for pairwise comparison with Vigabatrin. 
± p<0.01 for pairwise comparison with Vigabatrin. 
† p<0.001 for pairwise comparison with Ex-Vigabatrin. 
‡ p<0.01 for pairwise comparison with Ex-Vigabatrin. 
 
  Vigabatrin 
(n=56) 
Ex-
Vigabatrin 
(n=49) 
GABA 
(n=45) 
Non 
GABA(n=53) 
Chi-squared 
test p-value 
(overall) 
Right eye visual 
field defects 
40 (76.9)  23 (48.9)
 ±  18 (40.9)
 *  19 (36.5)*  0.0002 
Right  eye 
abnormal  mf 
ERG 
29 (51.8)  14 (28.6) *  1 (2.2) *
†  1 (1.9) *
†  <0.0001 
Table 10.2.3: Right eye visual field defects and abnormal WF-mfERG by patient drug 
groups.  
Data is presented as number (%).  N is the maximum number in each group. All available 
data used.  
*p<0.001 for pairwise comparison with Vigabatrin. 
± p<0.01 for pairwise comparison with Vigabatrin. 
† p<0.001 for pairwise comparison with Ex-Vigabatrin. 
‡ p<0.01 for pairwise comparison with Ex-Vigabatrin 
 
Retinal toxicity should largely be present in both eyes to the same degree if this is due to 
systemic toxicity. Interestingly, the presence of unilateral visual field defects is greater 
than in all groups. (Bilateral; GABA group 30.2%, non-GABA group 21.2%, Left; GABA 
group 43.2%, non-GABA group 32.7%, Right GABA group 40.9%, non-GABA group 
36.5%). There is greater variability in the groups when eyes are examined singly and could   116 
be due to the inherent poor attention and concentration in all patients with patients with 
epilepsy.  
 
There were greater numbers of patients with epilepsy with abnormal bilateral visual field 
defects than abnormal bilateral WF-mfERG. The WF-mfERG is an objective test. There 
will be patients with epilepsy who will do poorly on visual field tests because of poor 
attention and concentration, but by chance will have acceptable false negative and false 
positive rates. The data is suggesting that visual fields are not as specific to retinal toxicity 
as WF-mfERG. 
 
There are abnormal bilateral WF-mfERG results in both right and left eyes in other GABA 
and  other  non-GABA  groups  suggesting  bilateral  abnormal  WF-mfERG  rather  than 
individual WF-mfERG are more specific to retinal toxicity associated with Vigabatrin. 
 
Evaluating new technologies or tests raises the question of whether differences are due to 
the  technology  or  the  interpreters.  Kappa  is  widely  used  to  measure  inter-observer 
variability, that is, how often 2 or more observers agree in their interpretations. Simple 
agreement,  the  proportion  of  agreements  between  yes  and  no  is  a  poor  measure  of 
agreement because it does not correct for chance. Kappa is the preferred statistic because it 
accounts for chance. In statistical inference, one wishes to estimate population parameters 
using observed sample data. A confidence interval  gives an estimated range of values 
which is likely to include an unknown population parameter, the estimated range being 
calculated from a given set of sample data. 
 
Table 10.2.4  shows  agreement between  abnormal  WF-mfERG and  visual  field  defects 
using Kappa statistics and corresponding 95% confidence intervals. 
  
Visual field defects    
Abnormal WF-mfERG  Yes  No 
Kappa (95% CI) 
All patients                         Yes 
                                            No 
33 
45 
3 
111 
0.43 (0.31, 0.55) 
Vigabatrin only                  Yes 
                                            No 
23 
10 
2 
16 
0.53 (0.31, 0.75) 
Ex-Vigabatrin only             Yes 
                                            No 
10 
11 
1 
24 
0.45 (0.22, 0.69) 
GABA                                Yes 
                                            No 
0 
13 
0 
30 
N/A 
non-GABA                         Yes 
                                            No 
0 
11 
0 
41 
N/A 
Table 10.2.4: Agreement between bilateral visual field defects and abnormal WF mf-ERG   117 
Note:  Values  of between 0.41-0.60 moderate  agreement and  values between  0.61-0.80 
good agreement (see Altman D G Practical Statistics for Medical Research 1991) 
 
There is moderate agreement in Vigabatrin and ex-Vigabatrin groups. This was expected 
since  visual  fields  measure  a  complex  interplay  between  the  retina,  visual  pathway, 
processing areas of the brain, concentration and hand co-ordination whereas WF-mfERG 
measures  central  and  peripheral  retinal  function.  This  is  the  real  strength  of  the  WF-
mfERG in patients with epilepsy in this project. The WF-mfERG is an objective way to 
measure retinal function without interference in test results due to the cognitive problems 
of epilepsy.  
 
Similar results are detected on comparing individual eyes, see Tables 10.2.5 and 10.2.6. 
 
Visual field defects   Abnormal Wf-mfERG 
Yes  No 
Kappa (95% CI) 
All patients                         Yes 
                                            No 
43 
52 
4 
94 
0.42 (0.30, 0.53) 
Vigabatrin only                 Yes 
                                            No 
27 
10 
2 
12 
0.50 (0.27, 0.73) 
Ex-Vigabatrin only
             Yes 
                                            No 
12 
10 
0 
24 
0.56 (0.34, 0.77) 
Other GABAergic
              Yes 
                                            No 
2 
17 
1 
24 
N/A 
Other non-GABAergic
      Yes 
                                            No 
2 
15 
1 
34 
N/A 
Table 10.2.5: Agreement between left eye visual field defects and abnormal WF mf-ERG 
Note:  Values  of between 0.41-0.60 moderate  agreement and  values between  0.61-0.80 
good agreement (see Altman D G Practical Statistics for Medical Research 1991). 
 
Visual field defects   Abnormal mf ERG 
Yes  No 
Kappa (95% CI) 
All patients                         Yes 
                                            No 
40 
60 
3 
92 
0.36 (0.26, 0.47) 
Vigabatrin only                  Yes 
                                            No 
26 
14 
1 
11 
0.41 (0.20, 0.63) 
Ex-Vigabatrin only
              
Yes 
                                            No 
13 
10 
1 
23 
0.53 (0.30, 0.75) 
Other GABAergic
               Yes 
                                            No 
1 
17 
0 
26 
N/A 
Other non-GABAergic
       Yes 
                                            No 
0 
19 
1 
32 
N/A 
Table 10.2.6: Agreement between right eye visual field defects and abnormal bilateral WF 
mf-ERG.   118 
Note:  Values  of between 0.41-0.60 moderate  agreement and  values between  0.61-0.80 
good agreement (see Altman D G Practical Statistics for Medical Research 1991). 
 
 
 
 
 
 
 
There  has  been  controversy  surrounding  drug  load  as  a  contributory  factor  in  the 
development of retinal toxicity. Bilateral abnormal WF-mfERG is compared to drug load 
of Vigabatrin in Vigabatrin and ex-Vigabatrin groups in Table 10.2.7.  
Bilateral abnormal WF-mfERG  
Yes 
 
No 
Group 
N  Median [Range], g  N  Median [Range], g 
Wilcoxon  
p-value 
Vigabatrin  &  Ex-
Vigabatrin 
 
31  9012 [512-21056]  40  5065 [180-16875]  0.0035 
Vigabatrin 
 
27  9416 [893-21056]  29  5201[180-16875]  0.0081 
Ex-Vigabatrin 
 
4  7690 [512-9100]  11  4745 [3000-8612]  0.41 
Table  10.2.7  Comparison  of  actual  load  (g)  of  Vigabatrin  by  abnormal  bilateral  WF-
mfERG 
Note: For ex-Vigabatrin only 15/49 (31%) with information had actual load calculated. 
 
The  results  show  that  in  both  Vigabatrin  group and  ex-Vigaabtrin  group patients  who 
developed  bilateral  abnormal  WF-mfERG  had  a  higher  median  load  of  Vigabatrin. 
Vigabatrin group patients with abnormal WF-mfERG had a median dose of 9416g whereas 
those patients with normal WF-mfERG had a median dosage was 5201. Ex-Vigabatrin 
group patients with abnormal WF- mfERG had a median dose of 7690g whereas patients 
with normal WF-mfERG had a median dosage of 4745g.  
 
An arbitrary threshold of 8000g VGB was established, which did not correlate with the 
prevalence of visual field defects (x
2=2.710, p=0.100), but above which WF-mfERG 
abnormalities were significantly (x
2=9.046, p=0.003) more common.   119 
 
The accumulated load of Vigabatrin seems to be a significant factor in the development of 
retinal toxicity. Difficulties in identifying patients with retinal toxicity in previous studies 
may be due to the poor specificity of the tests used. 
 
It was often difficult in the ex-Vigabatrin group to work out actual drug loads as varying 
concentrations of Vigabatrin were given over varying times and often changes were not 
documented and so results were analysed only for confirmed drug loads. 
 
 
Comparison of actual load (g) of Vigabatrin to bilateral visual field defects with bilateral 
visual field defects is shown in Table 10.2.8. 
Bilateral visual field defects  
Yes 
 
No 
Group 
N  Median  [Range], 
g 
N  Median  [Range], 
g 
Wilcoxon  
p-value 
Vigabatrin  &  Ex-
Vigabatrin 
 
41  8225  [180-
21056] 
24  4878  [1500-
16875] 
0.058 
Vigabatrin 
 
33  8910  [180-
21056] 
18  4820  [1500-
16875] 
0.070 
Ex-Vigabatrin 
 
8  6527 [512-9100]  6  4878 [3000-8612]  0.75 
Table 10.2.8 Comparison of actual load (g) of Vigabatrin by bilateral visual field defects 
Note: For Ex-Vigabatrin group only 14/46 (52%) with information on visual field defects 
had actual load recorded. 
 
Note: even though visual field defects were classified as mild, moderate and severe the 
numbers  were  not  enough  to  perform  statistical  analysis  in  Tables  10.2.4  to  10.2.8.  
Yes/No to visual field defects were used for analysis. 
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10.3  Comparison  of  WF-mfERG  variables  between  patients  with  and  without 
bilateral visual field defects. 
  
 
 
 
 
 
 
 
Figure 10.3.1 a single WF-mfERG tracing. 
 
Table 10.3.1 explains the WF-mfERG terms. 
Investigation 
variable 
 
Explanation 
 Right P1 amp-c  Right  1
st  positive  peak  average  of  central  amplitude 
responses 
Right N1 imp-c  Right 1
st negative trough average of central implicit times 
responses 
Right P1 imp-c  Right  1
st positive  peak  average  of  central  implicit  times 
responses 
Right N1/P1-c  Ratio  of  1
st  negative  trough  to  positive  peak  of  central 
responses   
Normal Waveform
P1 amplitude 
P1 latency   121 
Right P1 amp-p  Right  1
st  positive  peak  average  of  peripheral  amplitude 
responses 
Right N1 imp-p  Right  1
st  negative  trough  average  of  peripheral  implicit 
times responses 
Right P1 imp-p  Right 1
st positive peak average of peripheral implicit times 
responses 
Right N1/P1  Ratio of 1
st negative trough to positive peak of peripheral 
responses   
Left P1 amp-c  Left  1
st  positive  peak  average  of  central  amplitude 
responses 
Left N1 imp-c  Left 1
st negative trough average of central implicit times 
responses 
Left P1 imp-c  Left  1
st  positive  peak  average  of  central  implicit  times 
responses 
Left N1/P1-c  Left  of  1
st  negative  trough  to  positive  peak  of  central 
responses   
Left P1 amp-p  Left  1
st  positive  peak  average  of  peripheral  amplitude 
responses 
Left N1 imp-p  Left  1
st  negative  trough  average  of  peripheral  implicit 
times responses 
Left P1 imp-p  Left 1
st positive peak average of peripheral implicit times 
responses 
Left N1/P1  Left  1
st  negative  trough  to  positive  peak  of  peripheral 
responses   
Table 10.3.1 Explanation of WF-mfERG terms 
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Table 10.3.2 summarizes the comparison of WF-mfERG variables between patients with 
and without bilateral visual field defects analyzing right and left eyes separately.  
Investigation 
variable 
 
Visual field defects 
(n= 78) 
No visual field defects 
(n=114) 
Wilcoxon 
p-value 
  Mean (SD)  Median 
[IQR] 
Mean (SD)  Median 
[IQR] 
 
 Right P1 amp-c  50.7 (24.3)  46 [35-60]  65.4 (28.2)  56 [46-82]  0.0002 
Right N1 imp-c  25.0 (2.0)  25 [24-26]  24.7 (2.7)  24 [23-25]  0.13 
Right P1 imp-c  40.5 (2.7)  40 [39-41]  40.5 (2.9)  40 [39-41]  0.57 
Right N1/P1-c  2.4 (0.5)  2.3 [2.0-2.7]  2.4 (0.5)  2.4 [2.2-2.6]  0.22 
Right P1 amp-p  31.1 (14.3)  28 [21-39]  46.5 (18.0)  42 [34-57]  <0.0001 
Right N1 imp-p  26.6 (2.1)  27[25-28]  26.2 (2.6)  26 [25-27]  0.017 
Right P1 imp-p  43.0 (3.2)  43 [41-45]  41.3 (2.6)  41 [40-42]  <0.0001 
Right N1/P1  2.1 (0.8  1.9 [1.7-2.2]  2.3 (0.4)  2.3 [2.0-2.4]  <0.0001 
Left P1 amp-c  49.9 (22.7)  45 [36-62]  65.8 (27.8)  60 [46-83]  <0.0001 
Left N1 imp-c  24.9 (2.2)  25 [24-25]  24.5 (1.8)  24 [23-25]  0.092 
Left P1 imp-c  40.6 (2.8)  40 [39-41]  40.3 (2.5)  40 [39-41]  0.33 
Left N1/P1-c  2.2 (0.5)  2.2 [2.0-2.4]  2.4 (0.7)  2.4 [2.2-2.6]  0.0016 
Left P1 amp-p  30.8 (14.3)  28 [21-38]  46.0 (18.5)  44 [33-57]  <0.0001 
Left N1 imp-p  26.5 (2.0)  26 [25-28]  26.0 (1.9)  25 [25-27]  0.020 
Left P1 imp-p  43.2 (3.2)  43 [41-45]  41.2 (2.5)  41 [40-42]  <0.0001 
Left N1/P1  2.1 (1.2)  1.9 [1.7-2.3]  2.2 (0.3)  2.2 [2.0-2.4]  0.0001   123 
Table 10.3.2 Comparison of WF-mfERG variables between all patients with and without 
bilateral visual field defects in 4 groups 
 
Significant  positive  correlation  occurred  with  Right  P1  amp-p,  Right  P1  imp-p,  Right 
N1/P1, Left P1 amp-c, Left P1 amp-p, Left P1 imp-p (P1- 1st positive wave, N1- first negative 
wave, imp- implicit time, amp – amplitude, -p – peripheral, -c- central see Figure 10.3.1). 
It is important to note that these variables are not specific to any group and by extension 
not specific to patients with epilepsy who were on Vigabatrin. Right N1/P1 and left N1/P1 
show p-values of <0.0001 indicating peripheral retinal function is decreased in patients 
with visual field defects. 
 
Analysis of Groups 1 to 4 with regard to WF-mfERG variables with and without bilateral 
visual  field  defects  are  summarised  in  Table  10.3.3  (Vigabatrin),  Table  10.3.4  (ex-
Vigabatrin),  Table  10.3.4  (GABA)  and  Table  10.3.5  (non-GABA).  There  is  no  other 
significant parameter of the WF-mfERG that correlates with bilateral visual field defects. 
 
Investigation 
variable 
 
Visual field defects 
(n= 33) 
No visual field defects 
(n=26) 
Wilcoxon 
p-value 
  Mean (SD)  Median [IQR]  Mean (SD)  Median [IQR]   
Right P1 amp-c  60.6 (25.8)  58 [42-74]  80.3 (31.9)  92 [52-99]  0.035 
Right N1 imp-c  25.0 (1.4)  25 [24-26]  24.9 (2.2)  24 [24-25]  0.36 
Right P1 imp-c  40.1 (1.9)  40 [39-40]  40.3 (3.0)  39 [39-40]  0.38 
Right N1/P1-c  2.2 (0.4)  2.2 [1.9-2.5]  2.3 (0.2)  2.3 [2.1-2.5]  0.55 
Right P1 amp-p  35.9 (15.5)  33 [25-48]  56.2 (22.5)  58 [42-72]  0.0027 
Right N1 imp-p  27.4 (1.8)  28 [26-29]  26.7 (2.1)  26 [25-28]  0.080 
Right P1 imp-p  43.8 (2.9)  44 [42-45]  41.5 (2.8)  40 [40-42]  0.0063 
Right N1/P1  1.8 (0.2)  1.8 [1.6-2.0]  2.0 (0.3)  2.1 [1.8-2.3]  0.0043 
Left P1 amp-c  57.9 (23.9)  56 [40-75]  76.2 (31.9)  79 [45-95]  0.049 
Left N1 imp-c  25.0 (1.6)  25 [24-25]  25.1 (2.1)  24 [24-26]  0.65 
Left P1 imp-c  40.3 (2.3)  40 [39-42]  40.8 (3.1)  40 [39-42]  1.00 
Left N1/P1-c  2.1 (0.5)  2.1 [1.8-2.3]  2.2 (0.3)  2.2 [2.1-2.5]  0.17 
Left P1 amp-p  34.6 (14.8)  32 [22-46]  54.7 (24.0)  54 [38-75]  0.0047 
Left N1 imp-p  27.1 (1.8)  27 [25-29]  26.8 (2.6)  26 [25-28]  0.26 
Left P1 imp-p  44.0 (3.0)  44 [42-45]  42.4 (3.3)  42 [40-43]  0.028 
Left N1/P1  1.9 (0.4)  1.8 [1.7-2.0]  2.0 (0.2)  2.0 [1.8-2.1]  0.035   124 
Table 10.3.3 Comparison of WF-mfERG variables between Vigabatrin patients with and 
without bilateral visual field defects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Investigation 
variable 
 
Visual field defects 
(n= 21) 
No visual field defects 
(n=28) 
Wilcoxon p-
value 
  Mean (SD)  Median 
[IQR] 
Mean (SD)  Median 
[IQR] 
 
Right P1 amp-c  41.8 (16.8)  43 [33-50]  53.6 (19.1)  50 [44-56]  0.021 
Right N1 imp-c  25.1 (2.7)  25 [23-26]  24.8 (1.2)  25 [24-25]  0.71 
Right P1 imp-c  39.7 (2.2)  40 [39-41]  40.5 (2.3)  40 [39-41]  0.49 
Right N1/P1-c  2.6 ( 0.6)  2.5 [2.1-2.8]  2.4 (0.3)  2.5 [2.2-2.6]  0.47 
Right P1 amp-p  24.0 (10.3)  20 [16-32]  38.0 (10.4)  37 [31-44]  0.0006 
Right N1 imp-p  26.2 (2.0)  25 [25-27]  26.0 (1.7)  26 [25-27]  0.86 
Right P1 imp-p  42.4 (2.8)  43 [41-44]  41.3 (1.9)  41 [40-42]  0.023 
Right N1/P1  2.1 (0.9)  1.8 [1.7-2.0]  2.2 (0.4)  2.3 [2.0-2.4]  0.019 
Left P1 amp-c  40.4 (16.1)  39 [30-46]  56.0 (17.4)  53 [48-62]  0.0021 
Left N1 imp-c  24.4 (1.7)  25 [23-25]  24.4 (1.6)  24 [23-25]  0.80   125 
Left P1 imp-c  40.0 (2.4)  40 [39-40]  40.1 (2.3)  40 [39-41]  0.86 
Left N1/P1-c  2.4 (0.7)  2.3 [2.0-2.6]  2.4 (0.3)  2.4 [2.2-2.6]  0.56 
Left P1 amp-p  23.5 (12.4)  21 [13-27]  38.9 (9.8)  40 [33-45]  0.0002 
Left N1 imp-p  26.3 (1.9)  26 [25-28]  25.7 (1.6)  26 [25-27]  0.29 
Left P1 imp-p  42.3 (2.8)  43 [40-44]  41.1 (2.1)  41 [40-42]  0.13 
Left N1/P1  2.4 (2.2)  1.7 [1.6-2.1]  2.2 (0.3)  2.2 [2.0-2.3]  0.011 
Table 10.3.4 Comparison of WF-mfERG variables between ex-Vigabatrin patients with 
and without bilateral visual field defects 
 
 
 
 
 
 
 
 
 
 
 
Investigation 
variable 
 
Visual field defects 
(n= 13) 
No visual field defects 
(n=32) 
Wilcoxon 
p-value 
 
  Mean (SD)  Median 
[IQR] 
Mean (SD)  Median 
[IQR] 
 
Right P1 amp-c  39.5 (18.3)  44 [29-91]  61.5 (25.0)  56 [44-79]  0.0090 
Right N1 imp-c  24.3 (1.4)  24 [24-95]  24.9 (4.3)  24 [23-25]  0.69 
Right P1 imp-c  41.3 (3.2)  40 [40-29]  41.1 (4.1)  40 [39-41]  0.61 
Right N1/P1-c  2.4 (0.4)  2.3 [2.2-28]  2.5 (0.7)  2.4 [2.0-2.7]  0.91 
Right P1 amp-p  28.2 (12.6)  29 [17-47]  45.9 (18.8)  43 [29-56]  0.0090 
Right N1 imp-p  25.5 (2.0)  25 [25-25]  26.4 (4.2)  25 [24-27]  0.99 
Right P1 imp-p  42.3 (4.0)  41 [40-43]  41.7 (3.8)  41 [40-43]  0.55 
Right N1/P1  2.7 (1.2)  2.4 [2.1-2.8]  2.2 (0.3)  2.2 [2.0-2.4]  0.35 
Left P1 amp-c  42.1 (14.6)  46 [37-32]  63.3 (27.2)  58 [45-85]  0.029   126 
Left N1 imp-c  24.7 (3.1)  25 [23-27]  24.4 (1.8)  24 [23-25]  0.78 
Left P1 imp-c  41.0 (3.3)  40 [39-45]  40.2 (2.5)  40 [39-41]  0.81 
Left N1/P1-c  2.3 (0.5)  2.3 [2.1-2.5]  2.6 (1.2)  2.4 [2.2-2.6]  0.30 
Left P1 amp-p  29.8 (11.0)  30 [20-52]  47.5 (21.4)  41 [32-62]  0.018 
Left N1 imp-p  25.2 (1.6)  25 [25-25]  25.9 (2.2)  25 [25-27]  0.54 
Left P1 imp-p  42.2 (3.3)  42 [40-41]  40.9 (2.7)  40 [39-42]  0.29 
Left N1/P1  2.3 (0.4)  2.3 [2.1-2.6]  2.2 (0.3)  2.2 [2.0-2.4]  0.35 
Table  10.3.5  Comparison  of  WF-mfERG  variables  between  GABA  patients  with  and 
without bilateral visual field defects 
 
 
 
 
 
 
 
 
 
 
 
Investigation 
variable 
 
Visual field defects 
(n= 11) 
No visual field defects 
(n=42) 
Wilcoxon 
p-value 
 
  Mean (SD)  Median 
[IQR] 
Mean (SD)  Median 
[IQR] 
 
Right P1 amp-c  51.9 (28.4)  41 [35-59]  69.0 (30.5)  57 [48-92]  0.050 
Right N1 imp-c  25.2 (2.8)  24 [24-29]  24.5 (2.1)  24 [23-25]  0.90 
Right P1 imp-c  42 (3.9)  40 [39-45]  40.1 (2.2)  40 [39-40]  0.18 
Right N1/P1-c  2.1 (0.3)  2.2 [1.9-2.4]  2.4 (0.4)  2.4 [2.2-2.6]  0.035 
Right P1 amp-p  33.9 (14.7)  26 [25-38]  47.7 (17.2)  42 [38-57]  0.0054 
Right N1 imp-p  26.6 (2.3)  26 [25-28]  25.8 (1.5)  25 [25-27]  0.46 
Right P1 imp-p  43.0 (3.8)  41 [40-47]  50.0 (1.9)  41 [40-42]  0.27 
Right N1/P1  2.2 (0.2)  2.2 [2.1-2.4]  2.4 (0.4)  2.4 [2.1-2.5]  0.39   127 
Left P1 amp-c  54.0 (29.8)  38 [36-71]  68.9 (30.1)  65 [45-86]  0.075 
Left N1 imp-c  25.9 (3.0)  25 [24-30]  24.4 (1.6)  25 [23-25]  0.19 
Left P1 imp-c  42.3 (3.7)  41 [40-46]  40.2 (2.5)  40 [39-42]  0.067 
Left N1/P1-c  2.2 (0.2)  2.2 [2.1-2.4]  2.4 (0.5)  2.4 [2.2-2.6]  0.070 
Left P1 amp-p  34.6 (16.0)  29 [26-48]  45.4 (16.2)  44 [34-52]  0.034 
Left N1 imp-p  26.8 (2.7)  26 [26-29]  25.8 (1.6)  25 [25-57]  0.19 
Left P1 imp-p  43.7 (4.0)  42 [41-47]  41.0 (2.0)  41 [40-42]  0.026 
Left N1/P1  2.2 (0.4)  2.1 [1.9-2.5]  2.3 (0.4)  2.2 [2.1-2.4]  0.29 
 
Table 10.3.6 Table shows comparison of ERG variables between other non-GABA patients 
with and without bilateral visual field defects 
 
 
 
 
 
 
 
 
 
 
10.4 Visual field defects and ERG 
 
Table 10.4.1  summarizes  the  comparison of  ERG  variables  between  patients  with  and 
without bilateral visual field defects analyzing right and left eyes separately. Significant 
positive  correlation  occurred  between  bilateral  visual  field  defects  and  oscillatory 
amplitudes, cone amplitude and flicker amplitude.  
 
Analysis of Groups 1 to 4 of to ERG variables with and without bilateral visual field 
defects are summarised in Table 10.4.2 (Vigabatrin Group), Table 10.4.3 (ex-Vigabatrin 
Group), Table 10.4.4 (GABA Group) and Table 10.4.5 (non-GABA Group).  
 
The conventional ERG responses, OP amplitude, cone B amplitude and flicker amplitude 
displayed  a  correlation  with  visual  field  abnormalities,  but  again  not  specifically  with 
bilateral  visual  field  defects  in  those  exposed  to  Vigabatrin.  This  was  surprising.  A 
possible  explanation  is  that  some  of  the  parameters  of  the  ERG  were  affected  by  the   128 
physiological neurological dampening caused by anti-epileptic drugs but were not specific 
to the pathological retinal toxicity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Visual field defects 
(n= 78) 
No visual field defects 
(n=114) 
Investigation variable 
 
Mean (SD)  Median [IQR]  Mean (SD)  Median [IQR] 
Wilcoxon 
p-value 
Right rod amp  149.3 (66.1)  138 [100-187]  180.8 (75.2)  166 [133-216]  0.0021 
Left rod amp  140.8 (57.4)  138 [97-181]  180.9 (78.3)  168 [131-217]  0.0003 
Right rod lat  90.2 (13.6)  91 [82-99]  86.8 (12.3)  86 [79-96]  0.025 
Left rod lat  88.9 (13.9)  89 [79-100]  86.6 (12.2)  86 [79-94]  0.14 
Right max A amp  184.1 (92.9)  164 [122-235]  185.4 (60.4)  180 [144-227]  0.28 
Left max A amp  180.9 (72.4)  180 [128-237]  186.8 (64.3)  178 [138-221]  0.67 
Right max A lat  18.3 (6.2)  17 [16-19]  17.2 (2.7)  16 [16-17]  0.060 
Left max A lat  17.5 (3.6)  17 [16-18]  17.0 (2.8)  16 [16-17]  0.068 
Right max B amp  299.4 (137.7)  265 [198-380]  331.6 (134.9)  306 [232-419]  0.076 
Left max B amp  299.4 (131.0)  266 [188-390]  337.9 (138.4)  310 [245-398]  0.038 
Right max B lat  45.5 (9.6)  45 [38-51]  44.4 (8.0)  46 [37-50]  0.64 
Left max B lat  45.6 (7.9)  46 [38-52]  44.7 (7.5)  47 [38-51]  0.51   129 
Right op amp  25.1 (14.5)  23 [16-31]  36.4 (16.8)  34 [24-45]  <0.0001 
Left op amp  24.2 (12.5)  22 [14-30]  37.5 (17.2)  37 [24-46]  <0.0001 
Right op lat  21.8 (3.6)  22 [18-25]  22.4 (3.6)  24 [19-25]  0.39 
Left op lat  21.8 (3.4)  22 [19-25]  22.4 (3.5)  24 [19-25]  0.31 
Right cone A amp  23.5 (11.3)  22 [16-29]  26.1 (10.1)  25 [19-32]  0.036 
Left cone A amp  23.9 (14.4)  22 [15-29]  26.9 (10.2)  26 [19-32]  0.0063 
Right cone A lat  12.7 (3.2)  13 [10-15]  12.2 (3.4)  13 [10-15]  0.61 
Left cone A lat  12.7 (3.7)  13 [10-15]  12.4 (3.3)  13 [9-15]  0.69 
Right cone B amp  78.9 (29.0)  76 [56-100]  107.8 (36.9)  102 [84-126]  <0.0001 
Left cone B amp  82.9 (35.0)  81 [59-103]  112.5 (41.3)  108 [82-142]  <0.0001 
Right cone B lat  29.0 (4.0)  30 [26-32]  28.8 (3.4)  29 [26-31]  0.47 
Left cone B lat  29.1 (3.8)  30 [26-32]  28.9 (3.2)  30 [26-31  0.46 
Right flicker amp  68.8 (33.8)  64 [46-89]  87.2 (30.8)  84 [61-107]  <0.0001 
Left flicker amp  70.1 (41.3)  64 [49-81]  93.6 (56.6)  82 [61-114]  <0.0001 
Right flicker lat  26.0 (4.3)  26 [24-29]  26.1 (2.7)  26 [24-28]  0.90 
Left flicker lat  26.3 (3.5)  26 [24-29]  25.9 (2.8)  26 [24-28]  0.46 
Table  10.4.1:  Table  shows  comparison  of  ERG  variables  between  patients  with  and 
without bilateral visual field defects.  
N is the maximum number in each group. All available data is used.  
 
 
 
 
 
 
 
 
 
Visual field defects 
(n= 33) 
No visual field defects 
(n=18) 
Investigation 
variable 
  Mean (SD)  Median [IQR]  Mean (SD)  Median [IQR] 
Wilcoxon 
p-value 
Right rod amp  156.5 (65.1)  145 [105-179]  212.3 (87.83)  200 [149-274]  0.018 
Left rod amp  153.6 (57.5)  152 [110-185]  208.4 (80.9)  184 [156-281]  0.024 
Right rod lat  90.3 (9.3)  92 [82-97]  82.6 (13.8)  82 [69-90]  0.060 
Left rod lat  89.7 (11.0)  92 [81-100]  82.6 (14.7)  83 [74-94]  0.096 
Right max A amp  223.0 (80.8)  224 [146-272]  238.1 (77.5)  233 [202-299]  0.60 
Left max A amp  220.2 72.6)  216 [173-260]  229.6 (79.4)  201 [171-281]  0.65 
Right max A lat  16.8 (2.3)  17 [16-18]  17.1 (2.1)  17 [16-18]  0.94 
Left max A lat  16.6 (2.6)  17 [16-18]  17.1 (3.0)  17 [16-17]  0.97 
Right max B amp  373.0 (134.9)  358 [271-475]  445.4 (173.5)  438 [299-588]  0.18 
Left max B amp  366.0 (122.0)  379 [256-432]  435.5 (167.9)  428 [290-529]  0.17 
Right max B lat  42.6 (11.8)  39 [36-45]  38.6 (8.8)  38 [36-42]  0.60   130 
Left max B lat  40.9 (7.6)  38 [36-43]  38.8 (9.2)  38 [36-43]  0.85 
Right op amp  24.6 (15.2)  22 [13-33]  37.3 (17.4)  39 [24-49]  0.014 
Left op amp  23.9 (14.0)  22 [12-31]  37.4 (18.5)  37 [22-49]  0.013 
Right op lat  20.3 (3.4)  19 [18-21]  18.4 (2.4)  18 [17-18]  0.0033 
Left op lat  20.5 (3.4)  19 [18-22]  19.2 (2.9)  18 [17-22]  0.077 
Right cone A amp  24.5 (9.9)  23 [17-31]  26.3 (9.6)  26 [22-34]  0.38 
Left cone A amp  24.1 (8.9)  24 [19-29]  24.3 (7.8)  23 [19-28]  0.91 
Right cone A lat  11.2 (2.6)  11 [10-14]  9.8 (2.8)  9 [8-11]  0.053 
Left cone A lat  11.2 (3.3)  10 [10-13]  10.4 (3.0)  10 [9-11]  0.31 
Right cone B amp  80.1 (33.4)  75 [56-100]  108.4 (35.9)  109 [93-114]  0.0051 
Left cone B amp  82.5 (34.0)  80 [59-103]  104.1 (36.6)  104 [73-119]  0.040 
Right cone B lat  27.5 (4.0)  27 [25-31]  26.8 (3.0)  26 [25-28]  0.43 
Left cone B lat  27.6 (3.6)  28 [26-31]  27.2 (3.5)  26 [25-28]  0.44 
Right flicker amp  68.9 (35.5)  60 [46-87]  77.7 (28.0)  81 [53-91]  0.17 
Left flicker amp  70.4 (47.9)  59 [49-73]  81.1 (38.8)  74 [55-107]  0.17 
Right flicker lat  24.8 (3.3)  24 [22-28]  24.8 (2.2)  24 [24-25]  0.71 
Left flicker lat  25.4 (3.8)  24 [23-29]  24.7 (1.9)  24 [24-25]  0.79 
Table 10.4.2 Table shows comparison of ERG variables between Vigabatrin patients with 
and without bilateral visual field defects.  
N is the maximum number in each group. All available data is used.  
 
 
 
 
 
 
 
 
 
 
Visual field defects 
(n= 21) 
No visual field defects 
(n=25) 
Investigation 
variable 
  Mean (SD)  Median [IQR]  Mean (SD)  Median [IQR] 
Wilcoxon 
p-value 
Right rod amp  126.4 (54.0)  112 [97-152]  160.4 (74.5)  148 [116-191]  0.044 
Left rod amp  115.0 (43.7)  104 [87-136]  161.5 (89.4)  157 [122-181]  0.010 
Right rod lat  86.9 (12.3)  90 [78-92]  88.0 (13.3)  88 [79-93]  1.00 
Left rod lat  89.6 (14.0)  89 [78-98]  86.4 (13.0)  85 [80-93]  0.38 
Right max A amp  133.5 (42.9)  144 [110-170]  156.9 (48.1)  147 [134-188]  0.20 
Left max A amp  139.3 (52.5)  143 [103-178]  163.4 (45.3)  158 [133-178]  0.13 
Right max A lat  18.3 (3.4)  18 [16-19]  17.1 (2.4)  16 [16-17]  0.096 
Left max A lat  18.7 (3.8)  17 [16-21]  16.7 (2.8)  16 [15-17]  0.020 
Right max B amp  235.1 (100.6)  223 [158-258]  271.4 (90.6)  263 [216-319]  0.086 
Left max B amp  222.9 (112.0)  184 [163-240]  282.3 (130.2)  252 [212-319]  0.017 
Right max B lat  46.5 (7.9)  47 [40-51]  48.0 (6.7)  49 [45-53]  0.39   131 
Left max B lat  48.2 (6.1)  49 [45-52]  47.6 (5.6)  49 [45-51]  0.70 
Right op amp  21.4 (6.9)  22 [17-27]  30.5 (14.0)  27 [23-39]  0.022 
Left op amp  20.0 (8.9)  19 [14-24]  32.3 (17.8)  27 [21-42]  0.0054 
Right op lat  23.0 (3.0)  24 [21-25]  23.7 (3.1)  24 [24-25]  0.94 
Left op lat  23.3 (3.2)  24 [24-25]  23.9 (2.8)  24 [24-25]  0.70 
Right cone A amp  18.6 (7.3)  18 [16-22]  24.6 (8.0)  24 [21-28]  0.016 
Left cone A amp  20.5 (15.0)  17 [13-23]  25.7 (10.1)  23 [18-30]  0.016 
Right cone A lat  13.1 (3.2)  14 [11-15]  13.4 (3.1)  14 [12-15]  0.67 
Left cone A lat  13.1 (3.1)  14 [12-15]  13.2 (2.8)  14 [12-15]  0.90 
Right cone B amp  73.2 (27.3)  65 [50-93]  98.4 (30.9)  93 [80-116]  0.0079 
Left cone B amp  70.8 (28.7)  68 [ 47-88]  100.4 (32.7)  101 [80-115]  0.0035 
Right cone B lat  30.6 (3.5)  31 [ 29-33]  29.1 (4.3)  31 [29-31]  0.24 
Left cone B lat  30.6 (3.2)  31 [29-33]  29.8 (2.6)  30 [30-31]  0.29 
Right flicker amp  62.1 (32.8)  63 [34-77]  79.5 (27.8)  73 [56-98]  0.038 
Left flicker amp  62.5 (34.4)  60 [40-69]  102.2 (95.2)  84 [62-103]  0.011 
Right flicker lat  27.6 (3.1)  28 [26-30]  26.8 (2.5)  27 [26-28]  0.29 
Left flicker lat  27.3 (3.2)  28 [26-30]  26.5 (2.6)  27 [26-28]  0.33 
Table 10.4.3: Table shows comparison of ERG variables between ex-Vigabatrin patients 
with and without bilateral visual field defects.  
N is the maximum number in each group. All available data is used.  
 
  
 
 
 
 
 
 
 
 
 
Visual field defects 
(n= 13) 
No visual field defects 
(n=30) 
Investigation 
variable 
  Mean (SD)  Median [IQR]  Mean (SD)  Median [IQR] 
Wilcoxon 
p-value 
Right rod amp  142.5 (73.7)  138 [90-169]  171.0 (73.5)  162 [111-209]  0.26 
Left rod amp  125.4 (50.5)  141 [111-145]  181.8 (84.1)  154 [128-226]  0.066 
Right rod lat  95.5 (22.8)  101 [95-108]  88.1 (12.3)  87 [80-99]  0.026 
Left rod lat  86.9 (21.8)  89 [82-98]  87.2 (13.6)  86 [79-92]  0.57 
Right max A amp  130.7 (56.8)  120 [111-148]  184.8 (54.0)  182 [139-227]  0.0087 
Left max A amp  150.4 (62.3)  147 [133-183]  189.5 (70.3)  184 [131-238]  0.15 
Right max A lat  18.5 (4.3)  18 [16-21]  17.2 (3.0)  16 [15-18]  0.26 
Left max A lat  17.8 (4.4)  17 [16-22]  16.6 (2.1)  16 [16-17]  0.18 
Right max B amp  197.2 (73.8)  188 [145-207]  324.4 (140.0)  291 [199-427]  0.0036 
Left max B amp  235.4 (84.0)  235 [182-283]  346.0 (148.8)  308 [250-398]  0.016   132 
Right max B lat  47.8 (7.4)  50 [44-53]  41.7 (8.0)  40 [34-49]  0.024 
Left max B lat  49.5 (7.6)  51 [47-54]  43.8 (8.0)  43 [36-52]  0.073 
Right op amp  22.8 (11.0)  21 [16-30]  39.7 (21.2)  36 [24-51]  0.0096 
Left op amp  24.1 (7.8)  22 [19-30]  40.4 (17.1)  38 [29-52]  0.0031 
Right op lat  23.1 (4.0)  24 [20-25]  21.8 (3.8)  24 [20-25]  0.52 
Left op lat  21.8 (2.6)  23 [20-24]  21.6 (3.8)  23 [18-25]  0.98 
Right cone A amp  24.6 (17.0)  22 [16-27]  22.8 (7.8)  21 [17-28]  0.84 
Left cone A amp  27.0 (24.5)  26 [12-28]  25.8 (9.4)  28 [18-31]  0.21 
Right cone A lat  14.5 (3.5)  14 [12-16]  11.3 (3.9)  12 [7-15]  0.036 
Left cone A lat  14.2 (4.3)  15 [14-16]  11.6 (4.1)  10 [9-15]  0.074 
Right cone B amp  73.4 (24.5)  73 [57-93]  101.7 (32.8)  100 [78-125]  0.013 
Left cone B amp  83.3 (31.4)  81 [67-106]  114.6 (43.3)  120 [82-146]  0.023 
Right cone B lat  29.8 (3.9)  31 [28-32]  28.6 (3.6)  29 [26-31]  0.24 
Left cone B lat  29.6 (4.2)  31 [28-32]  28.3 (3.8)  28 [25-31]  0.32 
Right flicker amp  77.4 (39.0)  67 [54-91]  83.1 (30.4)  76 [61-96]  0.62 
Left flicker amp  82.4 (38.4)  79 [62-95]  93.5 (44.7)  78 [60-115]  0.66 
Right flicker lat  25.5 (7.4)  28 [24-29]  25.9 (3.4)  25 [23-28]  0.48 
Left flicker lat  26.1 (3.8)  27 [24-28]  26.2 (3.4)  25 [23-29]  0.97 
Table 10.4.4: Table shows comparison of ERG variables between GABA patients with and 
without bilateral visual field defects.  
N is the maximum number in each group. All available data is used.  
 
 
 
 
 
 
 
 
 
 
Visual field defects 
(n= 11) 
No visual field defects 
(n=41) 
Investigation 
variable 
  Mean (SD)  Median [IQR]  Mean (SD)  Median [IQR] 
Wilcoxon 
p-value 
Right rod amp  179.4 (73.2)  187 [133-216]  186.5 (68.1)  162 [149-238]  0.96 
Left rod amp  169.6 (68.8)  181 [100-233]  179.9 (63.4)  170 [132-215]  0.91 
Right rod lat  89.7 (13.0)  89 [82-95]  86.8 (10.9)  86 [79-95]  0.50 
Left rod lat  87.4 (11.6)  87 [79-96]  87.9 (9.1)  88 [80-95]  0.76 
Right max A amp  227.2 (148.1)  171 [154-243]  180.2 (49.7)  178 [151-221]  0.60 
Left max A amp  178.1 (57.9)  201 [135-224]  180.3 (54.4)  181 [151-210]  0.80 
Right max A lat  21.9 (4.6)  16 [15-22]  17.2 (3.0)  16 [15-17]  0.61 
Left max A lat  17.9 (4.4)  16 [16-17]  17.5 (3.1)  16 [15-17]  0.89 
Right max B amp  321.6 (142.5)  294 [206-410]  323.7 (106.2)  315 [244-374]  0.86 
Left max B amp  321.1 (135.2)  315 [238-378]  322.9 (96.9)  325 [269-390]  0.62   133 
Right max B lat  49.3 (4.2)  50 [47-52]  46.7 (6.5)  47 [43-50]  0.12 
Left max B lat  50.6 (4.1)  52 [49-53]  46.4 (5.7)  49 [42-51]  0.0078 
Right op amp  36.5 (21.5)  35 [19-43]  37.3 (14.0)  36 [28-44]  0.54 
Left op amp  33.1 (15.0)  35 [21-44]  38.6 (16.3)  38 [26-49]  0.30 
Right op lat  22.7 (3.3)  24 [20-25]  23.8 (2.9)  24 [23-25]  0.59 
Left op lat  22.7 (3.1)  24 [21-25]  23.6 (2.8)  24 [23-25]  0.53 
Right cone A amp  28.9 (11.3)  27 [19-34]  29.3 (11.9)  28 [20-35]  0.89 
Left cone A amp  26.1 (11.1)  25 [ 17-33]  29.6 (11.6)  28 [23-35]  0.37 
Right cone A lat  14.3 (2.8)  14 [12-16]  13.3 (2.8)  14 [12-15]  0.42 
Left cone A lat  14.8 (38)  15 [12-17]  13.3 (2.5)  14 [12-15]  0.32 
Right cone B amp  92.8 (19.5)  99 [79-107]  117.8 (42.0)  108 [88-151]  0.13 
Left cone B amp  105.8 (45.1)  99 [68-131]  122.0 (45.0)  108 [89-149]  0.31 
Right cone B lat  29.6 (3.8)  30 [29-32]  29.5 (2.2)  30 [29-31]  0.71 
Left cone B lat  29.7 (3.8)  31 [29-32]  29.4 (2.7)  30 [29-31]  0.51 
Right flicker amp  71.1 (25.2)  73 [48-95]  99.2 (31.4)  103 [68-130]  0.016 
Left flicker amp  69.4 (36.6)  64 [40-89]  93.8 (37.3)  95 [ 66-120]  0.061 
Right flicker lat  26.8 (2.9)  26 [24-30]  26.4 (2.3)  27 [26-28]  0.90 
Left flicker lat  26.8 (2.4)  27 [25-30]  25.9 (2.8)  27 [24-28]  0.54 
Table  10.4.5:  Table  shows  comparison  of  ERG  variables  between  other  non-GABA 
patients with and without bilateral visual field defects.  
N is the maximum number in each group. All available data is used.  
 
 
 
 
 
 
 
 
 
10.5  Comparison  of  ERG  and  WF-mfERG  variables  between  patients  with  and 
without bilateral abnormal mf ERG.  
Table  10.5.1  summarizes  the  comparison  of  ERG  and  WF-mfERG  variables  between 
patients  with and without bilateral abnormal WF-mfERG analysing  right and left eyes 
separately.  This  was  done  to  identify  any  other  factors  that  might  be  significant  in 
identifying retinal toxicity. 
Abnormal WF-mfERG 
(n= 38) 
No abnormal WF-mfERG 
 (n=165) 
Investigation variable 
 
Mean (SD)  Median [IQR]  Mean (SD)  Median [IQR] 
Wilcoxon  p-
value 
Right rod amp  140.2 (57.2)  128 [96-175]  171.2 (74.8)  158 [117-209]  0.014 
Left rod amp  143.2 (52.2)  132 [98-183]  167.6 (75.4)  157 [121-210]  0.048 
Right rod lat  90.8 (11.9)  92 [82-97]  88.2 (13.2)  88 [80-98]  0.28 
Left rod lat  93.6 (13.9)  94 [83-104]  86.9 (12.7)  86 [79-95]  0.0076   134 
Right max A amp  204.0 (81.1)  199 [145-250]  177.2 (73.5)  165 [131-219]  0.054 
Left max A amp  206.6 (80.0)  210 [147-253]  177.2 (65.2)  168 [133-216]  0.031 
Right max A lat  17.6 (3.1)  17 [16-19]  17.8 (4.8)  17 [16-18]  0.16 
Left max A lat  17.8 (3.5)  18 [16-19]  17.3 (3.2)  16 [16-18]  0.13 
Right max B amp  322.0 (132.2)  296 [241-386]  311.7 (136.6)  278 [207-389]  0.45 
Left max B amp  318.7 (121.5)  302 [235-407]  318.0 (139.2)  285 [214-390]  0.71 
Right max B lat  42.1 (7.5)  40 [36-51]  45.6 (8.7)  47 [39-51]  0.023 
Left max B lat  42.6 (7.8)  41 [36-50]  45.9 (7.6)  48 [40-51]  0.019 
Right op amp  21.7 (10.4)  22 [14-28]  33.2 (17.3)  30 [21-41]  0.0002 
Left op amp  21.0 (10.6)  21 [12-25]  34.1 (16.8)  33 [21-44]  <0.0001 
Right op lat  20.7 (3.6)  20 [18-23]  22.5 (3.5)  24 [20-25]  0.0072 
Left op lat  21.4 (3.7)  20 [18-25]  22.4 (3.4)  24 [19-25]  0.17 
Right cone A amp  22.1 (7.5)  22 [16-27]  25.3 (11.1)  24 [17-31]  0.16 
Left cone A amp  23.8 (13.2)  22 [16-28]  26.0 (12.2)  26 [17-31]  0.10 
Right cone A lat  12.2 (3.1)  12 [10-15]  12.6 (3.4)  14 [10-15]  0.41 
Left cone A lat  12.2 (3.3)  12 [10-15]  12.6 (3.4)  14 [10-15]  0.38 
Right cone B amp  72.6 (27.2)  68 [50-96]  100.2 (36.3)  97 [76-117]  <0.0001 
Left cone B amp  71.9 (25.3)  72 [49-91]  105.2 (41.6)  99 [77-131]  <0.0001 
Right cone B lat  29.2 (4.2)  30 [26-32]  28.9 (3.5)  30 [26-31]  0.51 
Left cone B lat  29.3 (3.6)  30 [26-32]  29.0 (3.4)  30 [26-31]  0.55 
Right flicker amp  62.1 (31.3)  54 [35-85]  82.8 (32.5)  77 [58-102]  0.0004 
Left flicker amp  60.3 (29.0)  57 [39-72]  87.6 (54.1)  79 [56-107]  0.0002 
Right flicker lat  26.2 (3.5)  27 [24-29]  26.1 (3.4)  26 [24-28]  0.89 
Left flicker lat  26.6 (3.7)  27 [24-29]  26.0 (3.0)  26 [24-28]  0.29 
Right P1 amp-c  53.5 (24.2)  47 [35-70]  59.8 (27.8)  52 [42-75]  0.15 
Right N1 imp-c  25.4 (1.92)  25 [24-26]  24.7 (2.5)  24 [23-25]  0.0058 
Right P1 imp-c  40.0 (1.8)  40 [39-41]  40.6 (3.0)  40 [39-41]  0.83 
Right N1/P1-c  2.2 (0.4)  2.2 [2.0-2.4]  2.4 (0.5)  2.4 [2.1-2.6]  0.010 
Right P1 amp-p  29.8 (13.4)  28 [19-36]  42.1 (18.3)  40 [28-52]   <0.0001 
Right N1 imp-p  27.6 (1.9)  28 [26-29]  26.1 (2.4)  26 [25-27]  <0.0001 
Right P1 imp-p  44.2 (2.2)  44 [43-46]  41.6 (3.0)  41 [40-42]  <0.0001 
Right N1/P1-p  1.8 (0.4)  1.7 [1.6-1.9]  2.3 (0.6)  2.2 [2.0-2.4]  <0.0001 
Left P1 amp-c  50.3 (23.1)  44 [ 36-66]  60.3 (27.2)  54 [42-77]  0.026 
Left N1 imp-c  25.0 (1.6)  25 [24-26]  24.5 (2.1)  24 [23-25]  0.023 
Left P1 imp-c  40.3 (2.4)  40 [39-42]  40.5 (2.7)  40 [39-41]  0.93 
Left N1/P1-c  2.0 (0.6)  2.1 [1.8-2.3]  2.4 (0.6)  2.4 [2.1-2.6]  <0.0001 
Left P1 amp-p  28.1 (12.7)  26 [21-34]  41.9 (18.4)  40 [29-52]  <0.0001 
Left N1 imp-p  27.4 (1.8)  27 [26-29]  25.9 (2.0)  26 [25-27]  <0.0001 
Left P1 imp-p  44.5 (2.9)  44 [43-45]  41.5 (2.7)  41 [40-43]  <0.0001 
Left N1/P1-p  1.9 (0.5)  1.7 [1.6-2.0]  2.2 (0.8)  2.2 [1.9-2.4]  <0.0001 
Table 10.5.1 Table shows comparison of ERG and WF-mfERG variables between patients 
with  and  without  bilateral  abnormal  WF-mfERG.  N  is  the  maximum  number  in  each 
group. 
Parameters of the ERG that correlate with the presence of bilateral abnormal WF-mfERG 
were oscillatory potential amplitude and cone amplitude. Vigabatrin clearly exerts an effect 
on the global retinal response. It is unsure why these two parameters are the only ones 
affected. 
 
There may be other parameters of the WF-mfERG that indicates bilateral abnormalities 
other than the difference in P1 implicit times between central and peripheral responses. 
Each  of  the  parameters  of  the  WF-mfERG  was  analysed  to  see  if  it  corresponded  to 
bilateral abnormalities. These included the peripheral P1 amplitude, peripheral N1 implicit   135 
time, peripheral N1/P1 and central N1/P1. Mostly peripheral parameters are affected in 
patients  with  retinal  toxicity.  This  is  likely  to  be  due  to  selective  peripheral  toxicity. 
However, central N1/P1 is also significant for retinal toxicity. Other investigators have 
surmised  that  Vigabatrin  affects  the  retina  uniformly  but  there  are  reduced  cells 
peripherally then these are affected first and therefore a field defect results. The central 
responses  of  the  WF-mfERG  are  reduced  suggesting  that  there  is  involvement  of  the 
central retina and could be ‘physiological’ or ‘pathological’. 
 
Analysis of Groups 1 to 4 with regard to ERG and WF-mfERG variables with and without 
bilateral  abnormal  WF-mfERG  are  summarised  in  Table  10.5.2(Vigabatrin  group)  and 
Table  10.5.3  (ex-Vigabatrin  group).  In  group  1  patients,  peripheral  implicit  time  and 
peripheral N1/P1 in right eyes with bilateral abnormal WF-mfERG. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abnormal WF-mfERG 
(n= 27) 
No abnormal WF mf-ERG 
 (n=29) 
   
Investigation variable 
 
Mean (SD)  Median [IQR]  Mean (SD)  Median [IQR] 
Wilcoxon  p-
value 
Right rod amp  145.7 (60.2)  145 [96-175]  198.9 (81.2)  186 [132-266]  0.017 
Left rod amp  150.3 (55.4)  134 [104-185]  192.7 (73.9)  178 [152-246]  0.025 
Right rod lat  91.5 (11.9)  93 [82-99]  86.4 (12.5)  86 [80-98]  0.21 
Left rod lat  92.6 (13.9)  94 [82-103]  85.1 (12.9)  84 [77-94]  0.070   136 
Right max A amp  232.0 (76.3)  224 [171-276]  217.3 (81.7)  224 [144-286]  0.49 
Left max A amp  237.2 (68.6)  241 [195-269]  208.0 (81.4)  200 [138-263]  0.22 
Right max A lat  16.9 (2.2)  17 [16-18]  17.4 (2.5)  17 [16-18]  0.70 
Left max A lat  17.0 (2.8)  17 [15-18]  17.1 (3.1)  17 [16-18]  0.70 
Right max B amp  359.9 (131.7)  334 [256-433]  412.2 (166.6)  409 [271-512]  0.36 
Left max B amp  361.1 (113.0)  351 [256-425]  404.5 (162.2)  395 [283-487]  0.37 
Right max B lat  40.3 (6.6)  39 [35-44]  42.1 (13.3)  39 [36-45]  0.64 
Left max B lat  40.0 (6.3)  37 [36-44]  41.0 (10.1)  38 [36-43]  0.51 
Right op amp  20.2 (11.2)  20 [10-29]  34.7 (18.7)  33 [21-49]  0.0052 
Left op amp  21.0 (11.8)  22 [11-25]  35.3 (17.6)  36 [22-49]  0.0029 
Right op lat  19.7 (2.5)  19 [18-21]  20.0 (3.7)  18 [18-22]  0.62 
Left op lat  20.2 (2.7)  19 [18-21]  20.0 (3.6)  18 [18-22]  0.30 
Right cone A amp  22.4 (7.6)  23 [16-30]  26.9 (10.8)  26 [21-34]  0.15 
Left cone A amp  24.3 (10.7)  23 [19-28]  25.0 (9.6)  24 [19-29]  0.65 
Right cone A lat  11.3 (2.8)  11 [9-14]  10.4 (2.8)  10 [8-11]  0.16 
Left cone A lat  11.5 (3.3)  11 [10-14]  10.6 (3.2)  10 [9-11]  0.17 
Right cone B amp  70.0 (26.0)  72 [50-90]  106.2 (35.0)  106 [87-114]  0.0003 
Left cone B amp  71.0 (24.7)  70 [54-87]  105.1 (36.4)  102 [77-120]  0.0007 
Right cone B lat  28.0 (4.1)  28 [25-32]  26.8 (3.4)  26 [25-29]  0.20 
Left cone B lat  28.2 (3.5)  29 [26-31]  27.0 (3.6)  26 [25-29]  0.15 
Right flicker amp  60.8 (32.0)  52 [35-85]  80.1 (31.8)  80 [53-94]  0.016 
Left flicker amp  59.7 (31.1)  57 [37-72]  84.4 (50.2)  73 [55-107]  0.020 
Right flicker lat  25.1 (3.1)  24 [22-28]  24.8 (3.0)  24 [23-26]  0.71 
Left flicker lat  25.7 (3.7)  24  [23-29]  24.6 (2.8)  24 [23-26]  0.36 
Right P1 amp-c  57.1 (25.5)  49 [40-70]  75.1 (29.3)  70 [55-98]  0.019  
Right N1 imp-c  25.2 (1.5)  25 [24-26]  24.8 (1.8)  25 [24-25]  0.11 
Right P1 imp-c  40.2 (1.9)  40 [39-41]  40.2 (2.6)  40 [39-40]  0.45 
Right N1/P1-c  2.2 (0.3)  2.1 [1.9-2.4]  2.3 (0.3)  2.3 [2.0-2.6]  0.065 
Right P1 amp-p  32.0 (14.2)  28 [22-39]  52.8 (20.0)  54 [41-64]  0.0003 
Right N1 imp-p  27.8 (1.8)  28 [27-29]  26.7 (1.9)  26 [25-28]  0.0098 
Right P1 imp-p  44.5 (2.2)  45[43-46]  41.5 (3.0)  40 [40-42]  <0.0001 
Right N1/P1-p  1.6 (0.2)  1.6 [1.4-1.8]  2.1 (0.2)  2.1 [1.9-2.3]  <0.0001 
Left P1 amp-c  53.4 (23.9)  48 [37-67]  73.1 (27.2)  72 [56-90]  0.010 
Le41ft N1 imp-c  25.1 (1.7)  25 [24-26]  24.8 (2.0)  24 [24-25]  0.20 
Left P1 imp-c  40.4 (2.4)  40 [39-42]  40.5 (2.6)  40 [39-41]  0.82 
Left N1/P1-c  2.0  (0.4)  2.0 [1.8-2.2]  2.3 (0.4)  2.2 [2.1-2.5]  0.0057 
Left P1 amp-p  30.4 (13.2)  28 [21-35]  52.0 (20.2)  51 [40-66]  0.0002 
Left N1 imp-p  27.5 (1.9)  27 [26-29]  26.5 (2.2)  26 [25-28]  0.021 
Left P1 imp-p  45.0 (2.9)  45 [43-47]  42.1 (2.5)  42 [40-43]  0.0004 
Left N1/P1-p  1.8 (0.3)  1.7 [1.5-1.9]  2.0 (0.3)  2.0 [1.8-2.2]  0.0006 
Table 10.5.2:  Table shows  comparison  of ERG and WF-mfERG variables in Group  1 
patients with and without bilateral abnormal mf ERG N is the maximum number. 
 
 
 
 
 
Abnormal mf ERG 
(n=11 ) 
No abnormal mf ERG 
 (n=38) 
Investigation variable 
 
Mean (SD)  Median [IQR]  Mean (SD)  Median [IQR] 
Wilcoxon  p-
value 
Right rod amp  126.9 (48.7)  114 [90-165]  146.3 (70.9)  132 [104-181]  0.41 
Left rod amp  125.8 (40.6)  121 [95-139]  143.3 (80.3)  144 [94-165]  0.42 
Right rod lat  88.9 (12.3)  89 [80-92]  87.7 (12.7)  90 [78-94]  0.92 
Left rod lat  96.2 (14.1)  98 [85-110]  86.1 (12.2)  86 [79-93]  0.042   137 
Right max A amp  135.3 (43.1)  144 [107-174]  145.1 (49.4)  140 [126-172]  0.68 
Left max A amp  131.4 (52.4)  132 [103-152]  156.3 (46.7)  154 [120-180]  0.15 
Right max A lat  19.3 (4.4)  18 [16-21]  17.3 (2.3)  16 [16-18]  0.078 
Left max A lat  19.6 (4.5)  18 [16-23]  17.0 (2.7)  16 [16-18]  0.041 
Right max B amp  229.0 (78.5)  241 [139-269]  255.9 (99.4)  250 [177-310]  0.58 
Left max B amp  214.6 (68.1)  188 [163-284]  260.1 (133.2)  229 [174-309]  0.35 
Right max B lat  46.4 (8.2)  51 [38-54]  47.8 (6.8)  48 [43-52]  0.95 
Left max B lat  49.0 ( 7.5)  51 [43-54]  47.6 (5.0)  49 [45-51]  0.25 
Right op amp  25.3 (7.4)  25 [21-28]  26.1 (13.2)  24 [18-30]  0.89 
Left op amp  20.9 (7.6)  21 [14-30]  27.9 (16.7)  24 [15-37]  0.26 
Right op lat  23.4 (4.6)  24 [19-26]  23.4 (2.6)  24 [23-25]  0.88 
Left op lat  24.4 (4.3)  25 [24-26]  23.2 (2.6)  24 [23-25]  0.10 
Right cone A amp  21.4 (7.4)   22 [16-26]  21.6 (8.5)  22 [16-25]  0.90 
Left cone A amp  22.4 (18.6)  17 [15-20]  23.6 (10.4)  22 [17-30]  0.21 
Right cone A lat  14.2 (3.1)  15 [12-16]  13.0 (3.0)  14 [12-15]  0.27 
Left cone A lat  13.7 (2.8)  14 [13-15]  13.0 (2.9)  14 [12-15]  0.52 
Right cone B amp  79.0 (30.3)  67 [50-112]  88.9 (31.6)  88 [63-110]  0.36 
Left cone B amp  74.1 (27.7)  82 [47-94]  90.3 (34.5)  90 [64-115]  0.19 
Right cone B lat  32.1 (2.7)  33 [30-34]  26.2 (3.9)  30 [29-31]  0.020 
Left cone B lat  32.0 (2.1)  32 [30-34]  29.7 (2.8)  30 [29-31]  0.022 
Right flicker amp  65.4 (30.8)  77 [34-90]  72.8 (30.7)  66 [51-94]  0.58 
Left flicker amp  61.8 (24.4)  60 [40-76]  89.4 (82.0)  76 [55-97]  0.15 
Right flicker lat  29.1 (2.6)  30 [27-31]  26.7 (2.5)  27 [26-28]  0.016 
Left flicker lat  28.8 (2.6)  29 [27-31]  26.4 (2.7)  27 [25-29]  0.028 
Right P1 amp-c  44.8 (19.2)  43 [32-50]  48.1 (18.7)  48 [39-54]  0.37 
Right N1 imp-c  25.8 (2.8)  25 [24-26]  24.7 (1.6)  25 [24-25]  0.24 
Right P1 imp-c  39.6 (1.4)  40 [39-41]  40.3 (2.5)  40 [39-41]  0.78 
Right N1/P1-c  2.4 (0.4)  2.3 [2.0-2.7]  2.5 (0.5)  2.5 [2.2-2.7]  0.47 
Right P1 amp-p  24.6 (9.6)  20 [16-34]  33.0 (12.3)  32 [27-41]  0.068 
Right N1 imp-p  27.0 (2.0)   27 [25-29]  26.0 (1.6)  26 [25-27]  0.16 
Right P1 imp-p  43.4 (2.3)  43 [42-44]  41.3 (2.2)  41 [40-42]  0.017 
Right N1/P1  2.1 (0.5)  1.8 [1.6-2.7]  2.2 (0.7)  2.1 [1.8-2.4]  0.41 
Left P1 amp-c  42.4 (19.8)  37 [29-53]  49.1 (18.2)  48 [38-59]  0.22 
Left N1 imp-c  24.9 (1.4)  25 [24-25]  24.0 (2.3)  24 [23-25]  0.21 
Left P1 imp-c  40.0 (2.4)  40 [39-40]  40.2 (2.4)  40 [39-41]  0.98 
Left N1/P1-c  2.1 (0.3)  2.2 [1.8-2.3]  2.5 (0.5)  2.5 [2.2-2.6]  0.022 
Left P1 amp-p  22.4 (9.7)  21 [12-32]  33.7 (13.3)  35 [23-45]  0.018 
Left N1 imp-p  27.1 (1.8)  27 [25-29]  25.7 (1.5)  26 [25-27]  0.044 
Left P1 imp-p  43.4 (2.7)  43 [42-44]  41.2 (2.2)  41 [40-42]  0.024 
Left N1/P1  2.1 (0.8)  1.9 [1.6-2.6]  2.3 (1.6)  2.1 [1.7-2.3]  0.69 
 
Table 10.5.3: Table shows comparison of ERG and WF-mfERG variables between ex-
Vigabatrin with and without bilateral abnormal WF-mfERG. N is the maximum number. 
 
 
 
 
 
 
10.6 Difference in visual field defects between visit 1 and visit 2. 
 
Table 10.6.1 illustrates the difference in visual field defects between visit 1 and visit 2.    138 
 
Visit2   Visit 1 
Yes  No 
All patients                         Yes 
                                            No 
31 
3 
6 
49 
Vigabatrin only                  Yes 
                                            No 
18 
2 
0 
8 
Ex-Vigabatrin only             Yes 
                                            No 
8 
1 
1 
9 
GABA                               Yes 
                                            No 
2 
0 
0 
16 
non-GABA                         Yes 
                                            No 
3 
0 
5 
16 
Table 10.6.1: Comparison of number of patients with bilateral visual field defects at visit 1 
and visit 2 
 
In group 1, 18 patients had visual field defects at visit 1 and visit 2. There were no patients 
with a visual field defects at visit 1 without a visual field defects at visit 2. Two patients 
with no visual field defects at visit one had a visual field defects at visit 2. This statistic 
may  suggest 2  got worse based  on visual field defects. 8 patients  without visual field 
defects at visit 1 also had no visual field defects at visit 2. So in summary all patients with 
a visual field defects on visit 1 had a visual field defects on visit 2. Only 2 patients seem to 
get worse. These statistics were not significant. 
 
Similar findings were found in group 2. However 1 patient with a visual field defects at 
visit 1 did not have visual field defects at visit 2. Similarly in group 4, 5 patients with 
visual field defects at visit 1 did not have visual field defects at visit 2. This illustrates the 
lack of consistency of the visual field test as varying results are obtained at different visits. 
 
Table 10.6.2 and Table 10.6.3 summarizes with right and left eye visual field defects at 
visit 1 and visit 2. Results follow the same trend but are more consistent showing that 
bilaterally is more sensitive. 
Visit2   Visit 1 
Yes  No 
All patients                         Yes 
                                            No 
40 
4 
9 
37 
Vigabatrin only                  Yes 
                                            No 
20 
3 
1 
4 
Ex-Vigabatrin only             Yes 
                                            No 
10 
1 
0 
8 
Other GABAergic             Yes 
                                            No 
5 
0 
3 
11 
Other non-GABAergic      Yes 
                                            No 
5 
0 
5 
14   139 
Table 10.6.2: Table shows comparison of number of patients with left eye visual field 
defects at visits 1 and 2. 
Visit2   Visit 1 
Yes  No 
All patients                         Yes 
                                            No 
37 
5 
11 
37 
Vigabatrin only                  Yes 
                                            No 
22 
0 
2 
5 
Ex-Vigabatrin only             Yes 
                                            No 
8 
1 
1 
9 
Other GABAergic             Yes 
                                            No 
2 
1 
2 
13 
Other non-GABAergic      Yes 
                                            No 
5 
3 
6 
10 
Table 10.6.3: Table shows comparison of number of patients with right eye visual field 
defects at visit 1 and visit 2 
 
10.7 Difference in WF-mfERG between visits 1 and 2. 
   
See Table 10.7.1.  
 
Visit2   Visit 1 
Yes  No 
All patients                         Yes 
                                            No 
17 
1 
0 
75 
Vigabatrin only                  Yes 
                                            No 
13 
1 
0 
15 
Ex-Vigabatrin only             Yes 
                                            No 
4 
0 
0 
19 
Other GABA                    Yes 
                                            No 
0 
0 
0 
17 
non-GABA                        Yes 
                                            No 
0 
0 
0 
24 
Table 10.7.1 Comparison of number of patients with bilateral abnormal WF-mfERG at 
visit 1 and visit 2 
 
In the Vigabatrin group 13 patients had abnormal WF-mfERG on visit 1 and 2. One patient 
who had a normal WF-mfERG on visit 1 had an abnormal WF-mfERG on visit 2. There 
were no patients with abnormal WF-mfERG on visit one who did not have an abnormal 
WF-mfERG on visit 2. 15 patients did not have an abnormal WF-mfERG on visit 1 or 2.  
In the ex-Vigabatrin group 4 patients had an abnormal WF-mfERG on visit one and 2 and 
19 patients did not have an abnormal WF-mfERG on visit 1 and 2. In the other groups all 
the patients did not have an abnormal WF-mfERG on visit 1 and 2. 
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Table 10.7.2 and Table 10.7.3 shows of the comparison of patients with left and right eye 
abnormal WF-mfERG at visit 1 and visit 2.  
 
Visit2   Visit 1 
Yes  No 
All patients                         Yes 
                                            No 
18 
1 
9 
70 
Vigabatrin only                  Yes 
                                            No 
14 
0 
3 
13 
Ex-Vigabatrin only             Yes 
                                            No 
4 
0 
1 
18 
GABA                                Yes 
                                            No 
0 
1 
3 
15 
non-GABA                         Yes 
                                            No 
0 
0 
2 
24 
Table 10.7.2: Comparison of number of patients with left eye abnormal mf ERG at visit 1 
and visit 2 
 
For left eyes 14 patients had abnormal WF-mfERG on visit 1 and 2 and 13 did not have 
abnormal WF-mfERG on visit 1 and 2. However 3 patients did not have abnormal WF-
mfERG  on  their  2
nd  visit  even  though  they  did  on  visit  1.  The  numbers  for  the  ex-
Vigabatrin group are 4 patients with abnormal WF-mfERG on visit 1 and 2 and 18 did not 
have abnormal WF-mfERG on visit 1 and 2. 1 patient did not have abnormal WF-mfERG 
on their 2
nd visit even though they did on visit 1.       
 
Visit2   Visit 1 
Yes  No 
P-value* 
All patients                         Yes 
                                            No 
17 
4 
5 
68 
1.00 
Vigabatrin only                  Yes 
                                            No 
13 
3 
2 
11 
1.00 
Ex-Vigabatrin only             Yes 
                                            No 
4 
0 
2 
17 
0.50 
GABA                                Yes 
                                            No 
0 
1 
1 
15 
1.00 
non-GABA                         Yes 
                                            No 
0 
0 
0 
25 
- 
Table 10.7.3: Comparison of number of patients with right eye abnormal WF mf-ERG at 
visit 1 and visit  
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For right eyes 13 patients had abnormal WF-mfERG on visit 1 and 2 and 11 did not have 
abnormal WF-mfERG on visit 1 and 2. However 2 patients did not have abnormal WF-
mfERG on their 2
nd visit even though they did on visit 1 and 3 patients did not have 
abnormal WF-mfERG on visit 1 but had on visit 2. The numbers for the ex-Vigabatrin 
group are 4 patients with abnormal WF-mfERG on visit 1 and 2 and 17 did not have 
abnormal WF-mfERG on visit 1 and 2. 2 patients did not have abnormal WF-mfERG on 
their 2
nd visit even though they did on visit 1.       
 
 
 
 
10.8  Predictors  of  visual  field  defects  are  abnormal  wide  field  multifocal 
electroretinograms 
 
Predictors of visual field defects are shown below in Table 10.8.1. Predictors of abnormal 
wide field multifocal electroretinograms are shown below in Table 10.8.2.  
 
Univariate model   Multivariate stepwise model   Baseline characteristics 
Odds Ratio (95% CI)  P-value  Odds Ratio (95% CI)  P-value 
Continuous variables*         
Age (5 years)  0.98 (0.89, 1.08)  0.64     
Duration of epilepsy  
(5 years) 
1.05 (0.92, 1.19)  0.45     
Monthly  seizure  frequency  (5 
seizures) 
0.99 (0.96, 1.03)  0.59     
Categorical variables         
Drug group:         
  Vigabatrin  Referent  Referent 
  Ex-Vigabatrin  0.46 (0.20, 1.04)  0.29 (0.11, 0.73) 
  GABA  0.24 (0.10, 0.56)  0.23 (0.09, 0.57) 
  Other non-GABA  0.15 (0.06, 0.35) 
<0.0001 
0.13 (0.05, 0.33)  
0.0001 
Female   0.78 (0.43, 1.41)  0.40     
Current smoker  1.23 (0.62, 2.41)  0.55     
Drinks alcohol  0.45 (0.19, 1.07)  0.071     
Employment:         
  Employed/student  Referent     
  Retired  2.15 (0.94, 4.88)     
  Unemployed  2.71 (1.40, 5.27) 
0.0085 
   
Ophthalmology history of:         
  Myopia  0.47 (0.12, 1.78)  0.27     
  Presbyopia  0.89 (0.35, 2.26)  0.80     
  Decreased central VA  0.97 (0.41, 2.29)  0.95     
Medical history of :         
 Asthma  0.91 (0.29, 2.88)  0.87     
 Diabetes  1.48 (0.29, 7.53)  0.64     
 Hypertension  1.99 (0.71, 5.60)  0.19  3.38 (1.08, 10.59)  0.037 
 IHD  12.91 (1.58, 105.47)  0.017  10.53 (1.19, 93.55)  0.035 
Family history of:           142 
  Epilepsy  0.71 (0.25, 1.98)  0.51     
  Glaucoma  2.15 (0.66, 7.04)  0.21     
Other antiepileptic drug         
  ACETAZOLAMIDE  1.82 (0.53, 6.12)  0.34     
  CARBAMAZEPINE  0.87 (0.48, 1.57)  0.64     
  CLOBAZAM  2.37 (2.06, 5.39)  0.036     
  GABAPENTIN  2.28 (1.08, 4.79)  0.030     
  LEVETIRACETAM  1.04 (0.52, 2.11)  0.90     
  LAMOTRIGINE  0.90 (0.51, 1.61)  0.73     
  OXCARBAZEPINE  1.82 (0.53, 6.12)  0.34     
 PHENOBARBITONE  1.70 (0.71, 4.08)  0.23     
  PHENYTOIN  1.19 (0.63, 2.24)  0.59     
  TIAGABINE  1.15 (0.41, 3.23)  0.79     
  TOPIRAMATE  1.63 (0.82, 3.25)  0.16     
  VALPROATE  1.64 (0.90, 2.99)  0.11     
Table 10.8.1 Univariate and multivariate logistic regression for predictors bilateral visual field defects.Odds 
ratios (95% CI) represent 5 units increase.  Note for odds ratios if the 95% CI contains 1 then variable is non-
significant. 
 
Univariate model   Multivariate stepwise model   Baseline characteristics 
Odds Ratio (95% CI)  P-value  Odds Ratio (95% CI)  P-value 
Continuous variables*         
Age (5 years)  0.94 (0.83, 1.07)  0.34  0.85 (0.73, 0.99)  0.041 
Duration of epilepsy  
(5 years) 
1.22 (1.05, 1.41)  0.0091  1.31 (1.10, 1.56)  0.0025 
Monthly  seizure  frequency  (5 
seizures) 
1.00 (0.97, 1.03)  0.95     
Categorical variables         
Female   0.64 (0.31, 1.29)  0.21     
Current smoker  1.36 (0.62, 3.00)  0.44     
Drinks alcohol  0.12 (0.02, 0.92)  0.042     
Employment:         
  Employed/student  Referent     
  Retired  0.98 (0.33, 2.92)     
  Unemployed  1.91 (0.89, 4.11) 
0.21 
   
Ophthalmology history of:         
  Myopia  0.86 (0.18, 4.10)  0.85     
  Presbyopia  -  -     
  Decreased central visual acuity  0.69 (0.22, 2.12)  0.52     
Medical history of :         
 Asthma  0.78 (0.16, 3.66)  0.75     
 Diabetes  0.72 (0.08, 6.13)  0.76     
 Hypertension  0.60 (0.13, 2.76)  0.51     
 Ischaemic heart disease  0.47 (0.06, 3.81)  0.48     
Family history of:         
  Epilepsy  1.18 (0.37, 3.77)  0.78     
  Glaucoma  0.86 (0.18, 4.10)  0.85     
Other anti-epileptic drugs         
  ACETAZOLAMIDE  2.31 (0.66, 8.11)  0.19     
  CARBAMAZEPINE  1.44 (0.68, 3.06)  0.34     
  CLOBAZAM  2.32 (0.99, 5.43)  0.052     
  GABAPENTIN  1.52 (0.65, 3.56)  0.34     
  LEVETIRACETAM  0.65 (0.25, 1.67)  0.37     
  LAMOTRIGINE  1.11 (0.55, 2.24)  0.78     
  OXCARBAZEPINE  1.49 (0.38, 5.77)  0.57     
 PHENOBARBITONE  2.70 (1.10, 6.65)  0.030     
  PHENYTOIN  1.94 (0.94, 4.02)  0.075     
  TIAGABINE  3.61 (1.14, 8.80)  0.028  3.81 (1.25, 11.57)  0.018   143 
  TOPIRAMATE  2.33 (1.09, 5.00)  0.029     
  VALPROATE  1.86 (0.91, 3.83)  0.091     
 
Table 10.8.2 Univariate and multivariate logistic regression for predictors of abnormal 
WF-mf ERG 
* Odds ratios (95% CI) represent 5 units increase.   
10.9 QOLIE-31 P and VFQ-25 Questionnaire 
 
All available data was used, with n representing the number of patients who completed 
questionnaires and who had complied with both the field test and the WF-mfERG. For 
QOLIE-31 P questionnaire means (standard deviations, SD) are reported for each group 
and the p-value from either two sample t-test or ANOVA (>2 groups). For the VFQ-25 
questionnaire,  the  data  could  not  be  considered  normally  distributed  and  therefore 
alternative non-parametric tests were used. Medians (inter-quartile range, IQR) are quoted 
for each group and p-values from either the Wilcoxon Rank Sum test or the Kruskal-Wallis 
test (>2 groups).  
 
At visit 1 80% (45/56) of Vigabatrin group, 96% (47/49) of ex-Vigabatrin group, 98% 
(45/46) of GABA group and 98% (52/53) of non-GABA group completed quality of life 
questionnaires. 
 
  Vigabatrin 
(n=45) 
Ex-Vigabatrin 
(n=47) 
GABA 
(n=45) 
nonGABA 
(n=52) 
ANOVA 
 p-value 
Seizure Worry  59.4 (23.1)  49.7 (30.1)  55.4 (27.4)  60.6 (28.8)  0.21 
Overall 
Quality of Life 
62.4 (16.4)  60.7 (18.5)  63.5 (19.2)  68.0 (17.5)  0.20 
Emotional  
Well- being 
61.7 (20.2)  63.0 (16.8)  62.2 (20.3)  70.9 (17.1)  0.046 
Energy  52.5 (11.5)  51.0 (11.7)  50.0 (12.4)  52.6 (12.1)  0.67 
Cognitive  54.4 (24.5)  53.0 (25.0)  57.2 (23.8)  64.5 (25.2)  0.095 
Medicine 
Effects 
67.7 (22.3)  57.5 (24.3)  66.4 (23.5)  68.1 (25.6)  0.11 
Social 
Function 
62.7 (20.2)  56.5 (21.2)  64.0 (24.8)  72.7 (24.6)  0.0064 
QOLIE  58.9 (16.3)  56.0 (16.2)  59.5 (17.9)  66.4 (16.9)  0.018 
Table 10.9.1 Comparison of Quality of Life in Epilepsy questionnaire (QOLIE-31 P) at 
visit 1 between groups    144 
Data are presented as mean (SD) 
 
Overall QOLIE-31 P scores are highest in Vigabatrin and other non GABA group. Seizure 
worry, medicine effects and energy scored highest in these two groups as well. Emotional 
well  being  scores  were the  highest  in other non  GABA  groups  and  lowest  in  the  ex-
Vigabatrin group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10.9.2 shows the scores in patients with visual field defects and without visual field 
defects.  Overall  quality  of  life  is  lower  in  the  group  with  visual  field  defects  in  all 
categories except medicine effects.  
 
  Visual field defects 
(n= 70) 
No visual field defects 
(n=107) 
T-test  
p-value 
Seizure Worry  52.8 (28.3)  59.8 (26.9)  0.10 
Overall QOL  60.7 (17.6)  67.1 (17.3)  0.018 
Emotional  
Well- being 
59.3 (18.8)  68.7 (17.9)  0.0010 
Energy  50.1 (11.6)  53.0 (12.0)  0.11 
Cognitive  55.1 (24.9)  61.0 (24.4)  0.12 
Med Effects  65.6 (21.8)  65.4 (25.1)   0.94 
Social Function  58.5 (22.2)  69.6 (23.0)  0.0017 
QOLIE  56.8 (16.9)  64.1 (16.3)  0.0047   145 
Table  10.9.2:  All  patients:  Comparison  of  Quality  of  Life  in  Epilepsy  questionnaire 
(QOLIE-31 P) at visit 1 for bilateral visual field defects  
Data are presented as mean (SD). 
  
  Abnormal mf ERG  
(n= 32) 
No  abnormal  mf  ERG 
(n=156) 
T-test  
p-value 
Seizure Worry  60.1 (23.1)  55.6 (28.7)  0.40 
Overall QOL  62.3 (17.2)  64.0 (18.2)  0.63 
Emotional  
Well- being 
61.4 (19.3)  65.3 (18.8)  0.28 
Energy  53.4 (11.6)  51.2 (12.0)  0.35 
Cognitive  55.1 (25.6)  58.0 (24.9)  0.55 
Med Effects  66.8 (21.7)  64.7 (24.8)  0.66 
Social Function  59.9 (20.6)  65.0 (24.0)  0.26 
QOLIE  58.6 (16.4)  60.7 (17.4)  0.53 
Table  10.9.3:  All  patients:  Comparison  of  Quality  of  Life  in  Epilepsy  questionnaire 
(QOLIE-31 P) at visit 1 for bilateral abnormal mf ERG  
Data are presented as mean (SD). 
 
Table 10.9.3 shows the scores in patients with abnormal WF-mfERG and with normal WF-
mfERG.  Scores are higher  in patients  with abnormal  WF-mfERG  in  the  categories  of 
seizure worry, energy and medicine effects. 
 
 
In the Vigabatrin group all patients had lower scores for QOLIE-31 P in all categories with 
the exception of medicine effects if they had visual field defects. See Table 10.9.4. 
 
  Visual field defects 
(n= 27) 
No visual field defects 
(n=13) 
T-test  
p-value 
Seizure Worry  59.1 (25.1)  58.3 (20.8)  0.92 
Overall QOL  62.8 (16.7)  63.5 (14.3)  0.91 
Emotional  
Well- being 
61.2 (19.4)  60.8 (22.2)  0.95 
Energy  53.0 (12.7)  50.8 (11.1)  0.59 
Cognitive  59.3 (25.9)  47.0 (20.1)  0.14 
Med Effects  67.4 (22.5)  65.2 (23.8)  0.78 
Social Function  62.4 (21.7)  64.2 (19.7)  0.81   146 
QOLIE  60.2 (16.9)  56.9 (15.6)  0.55 
Table 10.9.4 Vigabatrin patients: Comparison of Quality of Life in Epilepsy questionnaire 
(QOLIE-31 P) at visit 1 for bilateral visual field defects  
Data are presented as mean (SD). 
 
In Vigabatrin group with QOLIE-31 P, all patients had lower scores in all categories if they 
had bilateral abnormal WF-mfERG. See Table 10.9.5. 
 
  Abnormal WF-mfERG 
(n= 23) 
No  abnormal  WF-
mfERG (n=22) 
T-test  
p-value 
Seizure Worry  61.4 (21.9)  57.3 (25.2)  0.56 
Overall QOL  64.1 (18.3)  60.6 (14.3)  0.48 
Emotional  
Well- being 
62.3 (20.2)  61.1 (20.6)  0.84 
Energy  53.9 (12.8)  51.1 (10.0)  0.42 
Cognitive  57.0 (27.2)  51.7 (21.6)  0.48 
Med Effects  69.8 (20.4)  65.6 (24.4)  0.53 
Social Function  62.8 (21.2)  62.6 (19.4)  0.98 
QOLIE  60.4 (17.2)  57.4 (15.5)  0.55 
 
Table 10.9.5 Vigabatrin patients: Comparison of Quality of Life in Epilepsy questionnaire 
(QOLIE-31 P) at visit 1 for bilateral abnormal WF-mfERG  
Data are presented as mean (SD). 
 
In  ex-Vigabatrin  patients  with  QOLIE-31  P,  medicine  effects  were  scored  higher  in 
patients with visual field defects than patients without visual field defects as were seizure 
worry. All other parameters were scored higher in the group without visual field defects. 
See Table 10.9.6. 
 
  Visual field defects 
(n= 19) 
No visual field defects 
(n=25) 
T-test  
p-value 
Seizure Worry  52.2 (29.5)  49.0 (31.2)  0.73 
Overall QOL  57.9 (14.7)  65.2 (20.2)  0.19 
Emotional  
Well- being 
59.5 (17.5)  67.1 (15.8)  0.14 
Energy  49.9 (10.2)  53.1 (12.1)  0.35 
Cognitive  53.7 (24.6)  54.7 (25.3)  0.90   147 
Med Effects  61.5 (24.5)  55.5 (25.3)  0.43 
Social Function  56.0 (19.3)  59.4 (22.3)  0.60 
QOLIE  55.3 (15.8)  58.4 (16.0)  0.53 
Table  10.9.6  Ex-Vigabatrin  patients:  Comparison  of  Quality  of  Life  in  Epilepsy 
questionnaire (QOLIE-31 P) at visit 1 for bilateral visual field defects 
Data are presented as mean (SD) 
 
  Abnormal WF-mfERG 
(n= 9) 
No  abnormal  WF-
mfERG 
(n=38) 
T-test  
p-value 
Seizure Worry  57.0 (27.0)  48.0 (30.9)  0.42 
Overall QOL  57.5 (13.9)  61.4 (19.5)  0.57 
Emotional  
Well- being 
58.9 (17.4)  64.0 (16.8)  0.42 
Energy  52.0 (8.2)  50.7 (12.4)  0.77 
Cognitive  50.4 (21.6)  53.7 (25.9)  0.73 
Med Effects  59.1 (24.3)  57.1 (25.6)  0.83 
Social Function  52.7 (18.1)  57.4 (22.0)  0.55 
QOLIE  54.1 (13.8)  56.4 (16.9)  0.71 
Table  10.9.7  Ex-vigabatrin  Comparison  of  Quality  of  Life  in  Epilepsy  questionnaire 
(QOLIE-31 P) at visit 1 for bilateral abnormal WF- mfERG  
Data are presented as mean (SD). 
 
 
 
In GABA patients with QOLIE-31 P, patients scored lower in all categories if they had 
visual field defects compared to not having visual field defects. See Table 10.9.8 
 
  Visual field defects 
(n= 13) 
No visual field defects 
(n=29) 
T-test  
p-value 
Seizure Worry  42.0 (31.3)  63.3 (23.2)  0.018 
Overall QOL  56.4 (23.0)  66.4 (17.3)  0.12 
Emotional  
Well- being 
51.3 (22.1)  66.6 (18.7)  0.026 
Energy  45.5 (12.7)  52.6 (12.3)  0.10 
Cognitive  46.8 (25.4)  63.4 (22.1)  0.038 
Med Effects  64.4 (21.0)  68.8 (22.6)  0.56   148 
Social Function  51.4 (27.4)  70.5 (22.2)  0.22 
QOLIE  49.8 (20.2)  64.6 (15.6)  0.013 
Table  10.9.8  Other  GABA  patients:  Comparison  of  Quality  of  Life  in  Epilepsy 
questionnaire (QOLIE-31 P) at visit 1 for bilateral visual field defects  
Data are presented as mean (SD) 
 
In other non-GABA patients with QOLIE-31 P, patients scored lower in all categories if 
they had visual field defects compared to not having visual field defects. See Table 10.9.9 
.  Visual field defects 
(n= 11) 
No visual field defects 
(n=40) 
T-test  
p-value 
Seizure Worry  51.3 (29.6)  64.6 (27.2)  0.17 
Overall QOL  65.2 (17.8)  69.9 (16.4)  0.42 
Emotional  
Well- being 
63.6 (14.3)  73.9 (16.3)  0.063 
Energy  48.7 (9.3)  54.1 (12.4)  0.19 
Cognitive  57.3 (22.7)  67.8 (24.7)  0.21 
Med Effects  69.8 (17.4)  69.1 (26.3)  0.93 
Social Function  61.7 (22.0)  77.2 (22.7)  0.050 
QOLIE  59.2 (13.3)  69.7 (15.7)  0.048 
Table  10.9.9  Non-GABAergic  patients:  Comparison  of  Quality  of  Life  in  Epilepsy 
questionnaire (QOLIE-31 P) at visit 1 for bilateral visual field defects 
Data are presented as mean (SD).  
 
 
 
 
 
Overall VFQ-25 scores are similar among all the groups tested. See Table 10.9.10 
  Vigabatrin 
(n=45) 
Ex-
Vigabatrin 
(n=47) 
 GABA 
(n=45) 
non-GABA 
(n=52) 
Kruskal-
Wallis 
 p-value 
General 
Health 
50 (50-75)  50 (25-50)  50 (50-75)  50 (50-75)  0.13 
General 
Vision 
80 (60-80)  80 (60-80)  80 (60-80)  80 (70-80)  0.59 
Ocular Pain  100 (88-100)  100 (75-100)  100 (75-100)  100 (75-100)  0.98   149 
Near 
Activities 
100 (83-100)  92 (83-100)  92(83-100)  100 (83-100)  0.70 
Distance 
Activities 
100 (92-100)  100 (83-100)  92 (83-100)  100 (92-100)  0.090 
Social 
Functioning 
100 (88-100)  100(100-
100) 
100 (88-100)  100 (100-100)  0.086 
Mental Health  94 (88-100)  94 (88-100)  100 (88-100)  94 (94-100)  0.63 
Role 
Difficulties 
100 (88-100)  100 (88-100)  100 (88-100)  100 (100-100)  0.52 
Dependency  100 (90-100)  100 (80-100)  100 (70-100)  100 (90-100)  0.61 
Driving  100 (75-100)  100 (80-100)  100 (90-100)  100 (90-100)  0.012 
Colour Vision  100  (100-
100) 
100 (80-100)  100 (100-100)  100 (90-100)  0.46 
Peripheral 
Vision 
100 (75-100)  100 (75-100)  100 (75-100)  100 (100-100)  0.014 
Visual 
Function 
95 (86-100)  94 (87-100)  95 (84-98)  95 (90-100)  0.62 
Table 10.9.10 Comparison of VFQ-25 questionnaire at visit 1 between groups 
 Data are presented as median (Interquartile Range). 
 
 
 
 
 
 
Scores are lower in patients with visual field defects in the categories of ocular pain, near 
activities, distance activities and mental health. Scores are lower in patients with visual 
field defects for peripheral vision and this result was clinically significant. Overall patients 
with visual field defects have a lower overall visual function score. See Table 10.9.11 
 
  Visual field defects 
(n=70) 
No visual field defects 
(n=107) 
Wilcoxon 
p-value 
General Health  50 (25-75)  50 (50-75)  0.27 
General Vision  80 (60-80)  80 (60-80)  0.063   150 
Ocular Pain  88 (75-100)  100 (88-100)  0.018 
Near Activities  92 (75-100)  100 (88-100)  0.011 
Distance Activities  92 (83-100)  100 (92-100)  0.016 
Social Functioning  100 (88-100)  100 (100-100)  0.0058 
Mental Health  94 (81-100)  100 (94-100)  0.0028 
Role Difficulties  100 (75-100)  100 (100-100)  0.042 
Dependency  100 (92-100)  100 (100-100)  0.013 
Driving  100 (100-100)  100 (80-100)  0.26 
Colour Vision  100 (100-100)  100 (90-100)  0.37 
Peripheral Vision  75 (75-100)  100 (100-100)  <0.0001 
Visual Function  93 (85-98)  97 (92-100)  0.0042 
Table 10.9.11 All patients: Comparison of VFQ-25 questionnaire at visit 1 for bilateral 
visual field defects  
Data are presented as median (Interquartile Range). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scores are lower in patients on Vigabatrin with visual field defects in the categories of 
ocular pain, mental health. Overall visual function in patients on Vigabatrin with visual 
field defects was lower than patients with no visual field defects though this result was not 
significant. See Table 10.9.12 
 
  Visual field defects 
(n= 33) 
No visual field defects 
(n=18) 
Wilcoxon 
p-value 
General Health  50 (25-75)  50 (50-50)  0.95   151 
General Vision  80 (60-80)  80 (80-80)  0.31 
Ocular Pain  88 (88-100)  100 (100-100)  0.082 
Near Activities  100 (83-100)  100 (83-100)  0.54 
Distance Activities  100 (92-100)  100 (92-100)  0.91 
Social Functioning  100 (100-100)  100 (100-100)  0.67 
Mental Health  94 (88-100)  100 (94-100)  0.28 
Role Difficulties  100 (88-100)  100 (88-100)  0.80 
Dependency  100 (90-100)  100 (100-100)  0.79 
Driving  100 (80-100)  100 (100-100)  0.62 
Colour Vision  100 (90-100)  100 (100-100)  0.53 
Peripheral Vision  100 (75-100)  100 (75-100)  0.95 
Visual Function  95 (90-100)  97 (88-100)  0.90 
 
Table  10.9.12  Vigabatrin  patients:  Comparison  of  VFQ-25  questionnaire  at  visit  1  for 
bilateral visual field defects  
Data are presented as median (Interquartile Range). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scores  are  lower  in  patients  in  ex-  Vigabatrin  group  with  visual  field  defects  in  the 
categories of near activities, mental health. Overall visual function in patients that were on 
Vigabatrin with visual field defects was lower than patients with no visual field defects 
though this result was not significant. See Table 10.9.13. 
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  Visual field defects 
(n= 21) 
No visual field defects 
(n=25) 
Wilcoxon 
p-value 
General Health  50 (25-75)  50 (25-50)  0.77 
General Vision  80 (60-80)  80 (60-80)  0.51 
Ocular Pain  100 (75-100)  100 (75-100)  0.67 
Near Activities  92 (75-100)  100 (83-100)  0.28 
Distance Activities  100 (75-100)  100 (92-100)  0.35 
Social Functioning  100 (100-100)  100 (80-100)  0.75 
Mental Health  88 (69-100)  100 (94-100)  0.079 
Role Difficulties  100 (88-100)  100 (88-100)  0.70 
Dependency  100 (92-100)  100 (100-100)  0.52 
Driving  100 (100-100)  100 (90-100)  0.23 
Colour Vision  100 (100-100)  100 (80-100)  0.20 
Peripheral Vision  100 (75-100)  100 (75-100)  0.27 
Visual Function  93 (85-99)  96 (92-100)  0.19 
 
Table 10.9.13 Ex-Vigabatrin patients: Comparison of VFQ-25 questionnaire at visit 1 for 
bilateral visual field defects  
Data are presented as median (Interquartile Range). 
 
 
 
 
 
 
 
 
 
 
 
 
Scores are lower in all categories in patients in GABA group with visual field defects 
except dependency, driving and colour vision. Overall visual function scores are lower in 
GABA group with visual field defects. (See Table 10.9.14)  
 
  Visual field defects 
(n= 13) 
No visual field defects 
(n=30) 
Wilcoxon 
p-value   153 
General Health  50 (25-50)  75 (50-75)  0.040 
General Vision  60 (60-80)  80 (60-80)  0.11 
Ocular Pain  88 (75-100)  100 (88-100)  0.10 
Near Activities  75 (58-83)  100 (92-100)  0.0009 
Distance Activities  75 (67-92)  100 (92-100)  0.0025 
Social Functioning  75 (75-100)  100 (100-100)  0.0025 
Mental Health  88 (50-100)  100 (94-100)  0.026 
Role Difficulties  75 (62-100)  100 (100-100)  0.010 
Dependency  100 (83-100)  100 (100-100)  0.065 
Driving  100 (100-100)  100 (92-100)  0.99 
Colour Vision  100 (75-100)  100 (100-100)  0.061 
Peripheral Vision  75 (50-100)  100 (100-100)  0.0002 
Visual Function  84 (74-93)  97 (90-98)  0.0041 
Table 10.9.14 GABA patients: Comparison of VFQ-25 questionnaire at visit 1 for bilateral 
visual field defects  
Data are presented as median (Interquartile Range). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scores are lower in the categories of ocular pain, near activities and mental health and 
overall  visual  function  in  patients  with  visual  field  defects  in  other  non-GABAergic 
patients. (See Table 10.9.15) 
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  Visual field defects 
(n= 11) 
No visual field defects 
(n=41) 
Wilcoxon 
p-value 
General Health  50 (50-75)  50 (50-75)  0.86 
General Vision  80 (80-80)  80 (70-80)  1.00 
Ocular Pain  75 (75-100)  100 (88-100)  0.022 
Near Activities  92 (83-100)  100 (92-100)  0.068 
Distance Activities  100 (92-100)  100 (92-100)  0.59 
Social Functioning  100 (88-100)  100 (100-100)  0.095 
Mental Health  94 (88-100)  97 (94-100)  0.70 
Role Difficulties  100 (88-100)  100 (90-100)  0.26 
Dependency  100 (92-100)  100 (100-100)  0.026 
Driving  100 (100-100)  100 (70-100)  0.061 
Colour Vision  100 (100-100)  100 (90-100)  0.24 
Peripheral Vision  100 (75-100)  100 (100-100)  0.044 
Visual Function  90 (88-96)  97 (93-100)  0.022 
Table 10.9.15 Non-GABA patients: Comparison of VFQ-25 questionnaire at visit 1 for 
bilateral visual field defects  
Data are presented as median (Interquartile Range). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scores are lower in the categories of ocular pain, near and distance activities, peripheral 
vision  and  overall  visual  function  in  patients  with  abnormal  bilateral  WF-mfERG  as 
compared with normal bilateral WF-mfERG. (See Table 10.9.16)   155 
 
  Abnormal mf ERG  
(n=33) 
No abnormal mf ERG 
(n=155) 
Wilcoxon 
p-value 
General Health  50 50-75)  50 (25-75)  0.30 
General Vision  80 (60-80)  80 (60-80)  0.27 
Ocular Pain  88 (88-100)  100 (75-100)  0.32 
Near Activities  92 (83-100)  100 (83-100)  0.69 
Distance Activities  92 (83-100)  100 (92-100)  0.21 
Social Functioning  100 (100-100)  100 (90-100)  0.56 
Mental Health  94 (88-100)  94 (88-100)  0.70 
Role Difficulties  100 (88-100)  100 (88-100)  0.26 
Dependency  100 (100-100)  100 (90-100)  0.92 
Driving  100 (70-100)  100 (100-100)  0.073 
Colour Vision  100 (80-100)  100 (100-100)  0.33 
Peripheral Vision  75 (75-100)  100 (75-100)  0.0036 
Visual Function  94 (85-99)  95 (88-99)  0.78 
Table 10.9.16 All patients: Comparison of VFQ-25 questionnaire at visit 1 for bilateral 
abnormal WF-mfERG 
Data are presented as median (Interquartile Range). 
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Scores are lower in the categories of ocular pain, distance activities and overall visual 
function in patients with abnormal bilateral WF-mfERG as compared with normal bilateral 
WF-mfERG in patients on Vigabatrin. (See Table 10.9.17) 
 
  Abnormal WF-mfERG 
(n= 23) 
No  abnormal  WF-
mfERG 
(n=22) 
Wilcoxon 
p-value 
General Health  50 (50-75)  50 (50-50)  0.13 
General Vision  80 (60-80)  80 (60-80)  0.94 
Ocular Pain  88 (75-100)  100 (88-100)  0.022 
Near Activities  100 (83-100)  100 (75-100)  0.43 
Distance Activities  92 (83-100)  100 (92-100)  0.43 
Social Functioning  100 (88-100)  100 (88-100)  0.93 
Mental Health  94 (88-100)  94 (88-100)  0.97 
Role Difficulties  100 (75-100)  100 (100-100)  0.13 
Dependency  100 (92100)  100 (100-100)  0.47 
Driving  100 (90-100)  100 (100-100)  0.53 
Colour Vision  100 (80-100)  100 (100-100)  1.00 
Peripheral Vision  75 (50-100)  100 (75-100)  0.28 
Visual Function  95 (85-100)  96 (88-100)  0.59 
 
Table  10.9.17  Vigabatrin  patients:  Comparison  of  VFQ-25  questionnaire  at  visit  1  for 
bilateral abnormal mf ERG  
Data are presented as median (Inter-quartile Range).   
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Scores are lower in the categories of general vision, near and distance activities, peripheral 
vision  and  overall  visual  function  in  patients  with  abnormal  bilateral  WF-mfERG  as 
compared with normal bilateral WF-mfERG in ex-Vigabatrin patients (See Table 10.9.18). 
 
  Abnormal WF-mfERG 
(n= 10) 
No  abnormal  WF-
mfERG (n=37) 
Wilcoxon 
p-value 
General Health  50 (25-75)  50 (25-50)  0.37 
General Vision  60 (60-80)  80 (60-80)  0.27 
Ocular Pain  100 (88-100)  100 (75-100)  0.52 
Near Activities  92 (83-100)  100 (83-100)  0.58 
Distance Activities  92 (75-100)  100 (92-100)  0.26 
Social Functioning  100 (90-100)  100 (100-100)  0.098 
Mental Health  94 (88-100)  94 (88-100)  0.99 
Role Difficulties  100 (88-100)  100 (88-100)  0.68 
Dependency  100 (80-100)  100 (100-100)  0.29 
Driving  100 (90-100)  100 (100-100)  0.48 
Colour Vision  100 (100-100)  100 (90-100)  0.72 
Peripheral Vision  88 (75-100)  100 (75-100)  0.59 
Visual Function  93 (88-99)  95 (87-100)  0.86 
 
Table 10.9.17 Ex-Vigabatrin patients: Comparison of VFQ-25 questionnaire at visit 1 for 
bilateral abnormal WF-mfERG  
Data are presented as median (Interquartile Range). 
 
10.10 Monthly seizures and ptosis 
 
Clinically, patients seemed to have a greater degree of ptosis if they were well controlled 
by their anti-epileptic medication and had fewer seizures per month. Table 10.10.1 shows 
that there is a relationship. 
 
Eye 
 
N  Spearman  rank  correlation 
coeffiecient 
P-value 
Left 
 
80  -0.033  0.77 
Right 
 
82  0.106  0.35   158 
Table 10.10.1: Association between number of monthly seizures and degree of Ptosis  
 
 
 
10.11 Conclusion 
 
There were no significant differences in basic demographic data (age, gender, duration of 
epilepsy, median monthly seizure frequency) between individual study groups. There was 
no evident selection bias on the basis of medical, environmental, and social variables, 
including family history of epilepsy and/or glaucoma, personal history of other chronic 
disease (asthma, diabetes, hypertension, ischemic heart disease), cigarette smoking, alcohol 
use, or levels of employment (data not shown). There were similarly no significant 
differences among study groups in terms of routine ophthalmological examination, visual 
acuity, or colour vision.  
 
Bilateral visual field constriction, as determined by static perimetry, was observed in all 4 
study groups the prevalence of which ranged between 59% in Group 1 patients who were 
being treated with VGB at the time of assessment and 21% in Group 4 patients who had 
never been exposed to any GABAergic AED. In contrast, WF-mfERG abnormalities were 
observed only in those patients who had been exposed to VGB, with a prevalence of 48% 
in current VGB patients and 22% in participants with previous exposure to the drug. A 
total of 21 VGB exposed patients (current and previous) demonstrated visual field defects 
(as determined by static perimetry) with no associated retinal dysfunction (as determined 
by WF-mfERG), whereas only 3 VGB exposed patients had demonstrable retinal 
dysfunction in the absence of apparent visual field constriction.  
 
Investigation of conventional ERG variables revealed bilateral reductions in the amplitude 
of rod, oscillatory potential, cone A, cone B, and flicker responses in subjects with visual 
field defects, compared to those without. These reductions were variously observed in 
patient Groups 1 to 3, but not in Group 4. Only those reductions in oscillatory potential and 
cone B amplitudes were common to all affected groups and in all cases statistical 
significance was lost when the data were corrected for multiple comparisons. In contrast, 
there was a selective association between the bilateral reduction in cone B amplitude and 
the presence of WF-mfERG abnormalities, which was exclusive to Group 1 patients 
(current VGB) and which was maintained in the face of correction for multiple testing. 
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An estimate of total VGB drug load was attempted for all participants in study Groups 1 
and 2, although only 15 of 49 patients in Group 2 (previous VGB exposure) had 
sufficiently detailed clinical records for a reliable figure to be calculated. There was no 
clear relationship between accumulated ingestion of VGB and the incidence of visual field 
constriction determined by static perimetry. However, patients with abnormal WF-mfERG 
findings had a significantly higher median VGB exposure than those with normal WF-
mfERG.  
 
Analysis of quality of life questionnaires completed at visit 1 revealed no significant 
differences in baseline visual health status (VFQ-25) or epilepsy-related quality of life 
(QOLIE-31) between individual study groups (data not shown). Participants with visual 
field constriction identified by static perimetry at visit 1 (irrespective of study group) 
reported a significantly lower peripheral vision score on VFQ-25 than those without visual 
field defects (p<0.05; data not shown). They also reported reduced emotional well-being 
(p<0.01), social functioning (p<0.05), and total QOLIE score (p<0.05) on QOLIE-31 
analysis (data not shown). These observations were made prior to initial ophthalmological 
testing and were independent of any confirmed visual field constriction or retinal 
dysfunction. No such associations were observed when visit 1 quality of life measures 
were compared on the basis of initial WF-mfERG findings (Tables 5 and 6).  
 
A total of 94 participants (29 in Group 1, 23 in Group 2, 18 in Group 3, 24 in Group 4) 
returned for repeat assessment (Table 7), with no significant or confounding changes to 
AED treatment regimen (other than modest dosage adjustments) in the intervening period. 
The median duration between visit 1 and visit 2 was 673 days [range 158 to 2066 days]. 
There were no differences in basic clinical demographics, routine ophthalmological 
examination, or the time since last study visit between study groups at repeat assessment 
(data not shown). Three patients with VGB exposure (2 in Group 1, 1 in Group 2) had de 
novo visual field constriction at visit 2, which had not been apparent at initial assessment. 
In contrast, six patients (1 in Group 2, 5 in Group 4), who had demonstrated bilateral field 
defects at visit 1, were subsequently reported as "normal" upon repeat investigation. Only 
one patient (Group 1) with a normal WF-mfERG at visit 1 had abnormalities on repeat 
testing 18 months later and none showed any apparent between-visits improvement (Table 
7). 
 
Participants who returned for repeat assessment completed further quality of life 
questionnaires with awareness of the outcome of initial ophthalmological investigation.   160 
These were analysed as both group data and individual paired data on the basis of outcome. 
Subjects with apparent visual field constriction at visit 1 (irrespective of study group) 
reported a significantly lower mean distance activities score on visit 2 VFQ-25 (p<0.05) 
and a significant reduction in mean emotional well-being on visit 2 QOLIE-31 (p<0.05) 
compared to those with normal perimetry (data not shown). There were no associations 
between quality of life measures recorded at study visit 2 and prior knowledge of retinal 
dysfunction identified by WF-mfERG at visit 1 (Tables 5 and 6). When analysed on an 
individual patient basis, there were no significant between-visit changes in VFQ-25 or 
QOLIE-31 measures that could be attributed to awareness of either visual field constriction 
or retinal dysfunction (data not shown).  
 
In the study it was thought that eyelid position correlated with seizure control i.e. the 
greater the ptosis then patients tended to have fewer seizures, though the relationship was 
not found to be statistically significant. Anti-epileptic drugs are designed to dampen 
neuronal activity and may reduce the neuronal input to the upper lid. Therefore, eyelid 
ptosis may be a useful clinical sign in compliance and efficacy of these drugs. 
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Chapter 11 
 
Final discussion 
 
11.1 Demographic data: controls 
 
Since  Eke  et  al  described  3  cases  of  severe  visual  field  constriction  in  patients  on 
Vigabatrin(11), a number of studies since linked visual dysfunction with Vigabatrin use, 
often visual field defects. The prevalence remains poorly defined with reports of visual 
field defects ranging from 0.3%(122) to 75% in patients treated with Vigabatrin.(120-122) 
This wide range is unlikely to be due to the varied effect of Vigabatrin effect on the retina 
but may reflect poor sampling in previous studies. Most papers describe at least a 50% 
prevalence of visual field defects. 
 
Why is the range so variable in different studies? This can be due to a number of problems 
with study design or sample selection. 
 
There have been few large scale studies to date to document the true prevalence of visual 
field defects in patients with different types of epilepsy such as reported by Wild and 
Martinez.(126;162) Cases have been reported of visual field defects associated with other 
anticonvulsant  drugs.  These  have  included  constricted  fields  with  phenytoin(141), 
diazepam(142) and progabide.(104) These defects may be a relatively common side effect 
of anticonvulsant treatment or even a feature of the natural history of epilepsy. 
 
It has been reported that other factors such as smoking “magnify” the peripheral retinal 
dysfunction seen with Vigabatrin (139). Many other “factors” have been reported in the 
literature to be important including cumulative drug dose.(127) 
 
In the study presented in this thesis, patients were divided into 4 groups.  These fours 
groups consisted of: patients on Vigabatrin for at least 2 years; patients on Vigabatrin for at 
least 1 year and off Vigabatrin for at least 2 years; patients on other GABA-ergic drugs; 
and patients on no GABA-ergic drugs as illustrated in Table 10.1.1. The patients in this 
study were matched closely for age, sex, AED and seizure control between four groups. 
Other factors thought to be important in developing visual field defects such as cumulative 
drug load could therefore be examined in detail with controls. One of the criticisms of   162 
some of the previous studies is a lack of adequate controls, though it was not known what 
factors are important in the development of toxicity. 
 
 
There are several important questions about Vigabatrin toxicity that have been answered 
by this study and the raw data has been summarized in the conclusions, Chapter 10. 
 
1.  Do visual field defects occur in other groups with epilepsy other than patients on 
Vigabatrin?  
2.  Do electrophysiological defects occur in all groups and if so which?  
3.  Can the WF-mfERG be used to diagnose and monitor progression of disease?  
4.  Is GABA or any other agents important in the development of retinal toxicity? 
5.  Do  visual  field  defects  worsen  when  continuing  on  Vigabatrin  and  are  they 
reversible on stopping Vigabatrin?  
6.  What factors are important in the development and progression of disease of the 
visual system associated with Vigabatrin use?  
7.  Do patients accept Vigabatrin associated visual field defects? 
 
11.2 Do visual field defects occur in other groups with epilepsy other than patients on 
Vigabatrin?  
 
Table 10.2.1  summarsied  the  results  in  patients  with and  without bilateral  visual field 
defects (visual field defects) in all groups.  
 
In  the  Vigabatrin  group,  33  patients  (64.7%)  had  visual  field  defects  assessed  by 
Humphrey 120 degree static perimetry which was the highest percentage of any of the 
groups (24 patients with predominantly bilateral nasal loss, 9 patients with symmetrical 
visual field loss).  Prevalence of visual field defects using static Humphrey perimetry in 
patients with epilepsy on Vigabatrin have varied from 33%(133) to 68%(134) but most 
studies show about 50% of patients have field defects. 64.7% was therefore within the 
range of previously reported studies. 
 
Bilateral visual field defects were present in all four groups.  The prevalence was highest in 
the  Vigabatrin  group  (64.7%)  followed  by  the  ex-Vigabatrin  group  (45.6%).  The 
percentage in the groups not exposed to Vigabatrin i.e. GABA-ergic and nonGABA groups 
were  much  higher  than  expected  (GABA  group,  30.2%,  non  GABA  groups  Group  4,   163 
21.2%). The field loss tended to be symmetrical in the GABA and non GABA group as 
opposed to predominantly bi-nassal which occurred with patients on Vigabatrin. However 
8 patients had predominantly bi-nasal defects in the ex-Vigabatrin group and 4 in the Non-
GABA group.This result was statistically significant. These patients had all had brain scans 
and full ophthalmic examination and were not included if there could have been a cause of 
visual field defects such as glaucoma. Therefore, visual field defects in all four groups can 
be divided into patients with a ‘real’ visual field defect (possibly due to their epilepsy) and 
patients with a ‘false positive’ visual field defect which was difficult to determine in this 
study. 
 
Visual  field  defects  can  occur  in  all  groups  with  epilepsy  irrespective  of  Vigabatrin 
exposure.  This  has  been  shown  in  other  reports  of  other  visual  field  defects  with 
phenytoin(141), diazepam(142) and progabide.(104) There are probably different causes of 
visual field abnormalities in patients with epilepsy that are not related to Vigabatrin use. 
Two possible reasons are that antiepileptic drugs generally act to dampen physiological 
responses in  the brain  and  in  the  retina therefore  they  are  likely  to decrease neuronal 
transmission in the retina and could cause transient visual field abnormalities causing a real 
field defect. Also patients with epilepsy have poor attention and concentration making it 
difficult for them to perform the subjective visual field test causing a false positive field 
defect. 
 
Undoubtedly being exposed to Vigabatrin increases the percentage of visual field defects 
in patients with epilepsy. It can be surmised in the group of patients exposed to Vigabatrin 
(Vigabatrin and ex-Vigabatrin) there there is a subset of patients with visual field defects 
due to retinal toxicity and a subset of patients who have visual field defects as a result of 
their epilepsy. These two groups may overlap. Hence, perimetry alone appears not to detect 
Vigabatrin associated retinal toxicity. 
 
11.3 Do electrophysiological defects occur in all groups and if so which? 
 
We know that visual field defects occur in all groups with epilepsy. One reason could be 
the poor response of patients with epilepsy leading to false positives in the field test. The 
ERG  is  an  objective  global  measure  of  retinal  function.  Is  the  ERG  specific  to  those 
patients  with  visual  dysfunction  due  to  Vigabatrin?  Comparison  was  made  of  ERG 
variables and patients with and without visual field defects and now is summarized in 
Table  10.4.1  analyzing  right  and  left  eyes  separately.  Significant  positive  correlation   164 
occurred between visual field defects and oscillatory potential amplitude, cone amplitude 
and flicker amplitude when all patients with visual field defects were examined.  
 
The four tables in section 10.4 (Table 10.4.2, 10.4.3, 10.4.4 and 10.4.5) showed correlation 
between  ERG  parameters  and  visual  field  defects  in  the  different  groups.  Oscillatory 
potential amplitude, oscillatory potential latency and cone b-wave latency correlated with 
visual field defects in the Vigabatrin group. Maximal a-wave latency, Maximal b-wave 
amplitude, oscillatory potential amplitude, cone a-wave amplitude and flicker amplitude 
correlated with visual field defects in ex-Vigabatrin groups. Maximal b-wave amplitude, 
oscillatory  potential  amplitude  and  cone  b-wave  amplitude  correlated with  visual field 
defects in GABA group. Bilateral flicker amplitude correlated with visual field defects non 
GABA groups.  
 
Reduced  oscillatory  potential  (OP)  amplitudes  have  been  described  (in  up  to  92%  of 
patients (115;151) on Vigabatrin) in several studies although one study has reported no  
change  in  oscillatory  potential  amplitudes(133).  In  this  study  there  was  a  positive 
correlation between visual field defects and OP amplitude in the Vigabtrin, ex-Vigabatrin 
and GABA groups suggesting a link with GABA not specific to Vigabatrin group only. 
 
The single flash cone and flicker reponses have been reported to be affected more than the 
rod single flash(44). In this thesis study there was no correlation between rod parameters 
and bilateral visual field defects in any of the groups studied.  
 
The incidence of decreased cone b-wave amplitude has been reported to vary between 30% 
and 62%(115;151) In this thesis study there is a positive correlation between visual field 
defects and cone b-wave amplitude in the GABA group but not in the Vigabatrin and ex-
Vigabatrin groups therfore agreeing with previous studies. (115;151) 
 
One study have reported increased cone b-wave latency.(155)  However, no significant 
relationship between cone latency and visual field defects was found in any of the groups 
in this thesis study. 
 
Studies have reported a decrease in flicker amplitude in up to 92% of patients with a cutoff 
in  amplitude  of  70µV  in  patients  on  Vigabatrin  (158;160).  In  this  study  there  was  a 
positive correlation between visual field defects and flicker amplitude in the non GABA 
group.    165 
 
The conventional ERG responses i.e. OP amplitude, cone b-wave amplitude and flicker 
amplitude displayed a correlation with visual field abnormalities. The visual field defects 
in all groups can be corroborated by objective tests suggesting that these defects are true 
and not false positives. A possible explanation is that these ERG responses and visual field 
results both represent similar changes occurring in the visual system. One theory is that 
physiological  neurological  damping  is  caused  by  all  anti-epileptic  drugs  and  in  some 
patients this is enough to have visual field defects and abnormal ERG.  
 
11.4 Can the WF-mfERG be used to diagnose and monitor progression of disease?  
 
 An abnormal WF-mfERG in patients with Vigabatrin retinal toxicity is one in which the 
difference  between  central  and  peripheral  implicit  time  is  abnormal  (greater  than  2 
milliseconds) in both eyes.(2;3)  It is the difference between central and peripheral retinal 
function that is specific to  Vigabatrin. One theory is that only  the peripheral retina is 
affected by Vigabatrin toxicity as suggested in previous studies. (3;95) Another study has 
suggested  that  Vigabatrin  associated  retinal  toxicity  is  thought  to  be  diffuse,  inducing 
subtle  central  visual  dysfunction  and  more  severe  peripheral  visual  defects  where  the 
density of the cells are the lowest.(98) Because the WF-mfERG measures discrete areas of 
retinal function we can objectively compare the periphery to the centre. Therefore if there 
is a difference in function we can us this test to monitor only those patients with visual 
field defects secondary to Vigabatrin. 
 
Table 10.2.1 showed the results in patients with abnormal WF-mfERG responses in all 
groups. Only Groups 1 & 2 had abnormal bilateral WF-mfERG abnormalities on testing. 
Patients not exposed to Vigabatrin did not have abnormal bilateral WF-mfERG. Table 
10.6.1 showed that no patient in the GABA-ergic or the non-GABA group with abnormal 
WF-mfERG on visit 1 or 2. These results are statistically significant. The WF-mfERG 
therefore seems to be the most specific test for Vigabatrin associated retinal toxicity. 
 
Visual  field  defects  are  not  as  specific  because  it  seems  that  visual  field  defects  are 
common  in  patients  with  epilepsy.  The  ERG  is  not  as  specific  because  it  is  a  global 
measure of retinal function and Vigabatrin seems to selectively affect the peripheral retina. 
It is the difference between central and peripheral function that is important. 
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All the patients with an abnormal WF-mfERG at visit 1 and visit 2 had visual field defects. 
Visual field defects appear to be the first clinical sign of Vigabatrin retinal toxicity. The 
WF-mfERG was 100% sensitive and 81% specific in detecting vigabtrin associated visual 
field defects. 
 
Table  10.5.1  summarized  the  comparison  of  ERG  and  WF-mfERG  variables  between 
patients with and without bilateral abnormal WF-mfERG. Right and left eyes were also 
analysed separately. This was done to identify any other factors that might be significant in 
identifying retinal toxicity.  
 
Significant parameters of  the  ERG that correlated with bilateral  abnormal WF-mfERG 
were oscillatory potential amplitude and cone b-wave amplitude. However Tables 10.5.2 
and 10.5.3 summarized the comparison of ERG and WF-mfERG variables between groups 
1 and 2. There was no statistically significant ERG parameter that correlates with bilateral 
abnormal WF-mfERG specific to each group. 
 
Significant  parameters  of  the  WF-mfERG  that  correlated  with  bilateral  abnormal  WF-
mfERG in all groups were peripheral P1 amplitude, peripheral N1 implicit time, peripheral 
N1/P1 ratio and central N1/P1 ratio. Mostly peripheral parameters were affected in patients 
with  retinal  toxicity  confirming  that  the periphery  is  selectively  affected  in  Vigabatrin 
associated retinal toxicity.  
 
Interestingly  central  N1/P1  is  also  significant  for  retinal  toxicity.  This  may  mean  that 
central visual function is subtly affected by Vigabatrin and can be picked up by the WF-
mfERG. 
 
In group 1 patients, peripheral implicit time and peripheral N1/P1 in right eyes correlates 
with bilateral abnormal WF-mfERG. No other WF-mfERG result correlates with bilateral 
abnormal WF-mfERG specific to each group. 
 
11.5 Is GABA or any other agents important in the development of retinal toxicity? 
 
The  manipulation  of  GABA,  a  major  inhibitory  neurotransmitter  in  the  brain  has  had 
success  in  the  management  of  epilepsy.  GABA-ergic  agents  increase  GABA  levels 
globally. Vigabatrin is the GABA-ergic agent that induces the highest percentage rise of 
GABA in the retina.(21) The side effects of increasing GABA concentrations in the retina   167 
are unknown but it has been suggested to lead to retinal toxicity.(43) It is difficult to 
separate the action of Vigabatrin and GABA. Is it Vigabatrin, GABA, both or neither is 
responsible for Vigabatrin associated visual defects? In animal models it is difficult to 
control for GABA. GABA is broken down before therapeutic or toxic levels are achieved 
in the brain and retina. In recent acute toxicology studies, in isolated retina slices, GABA 
was applied directly to the retina. Light and Vigabatrin were found to be more important 
than GABA(1) in causing retinal photoreceptor damage. 
 
In Figure 11.5.1, in the GABA group and non GABA group, there were no patients with 
abnormal  WF-mfERG.  Peripheral  retinal  dysfunction  appears  to  be  confined  to  the 
current/ex-Vigabatrin users and GABA does not therefore seem to be implicated in the 
development of peripheral retinal dysfunction.  
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Figure 11.5.1 Normal and Abnormal WF-mfERG in four groups tested 
 
 
 
 
 
 
11.6  Do  visual  field  defects  worsen  when  continuing  on  Vigabatrin  and  are  they 
reversible on stopping Vigabatrin?  
 
There  has  been  great  debate  about  improvement  in  visual  function  following 
discontinuation  of  Vigabatrin.  Several  papers  have  reported  that  visual  field  defects 
improve(102;102;146;147) on stopping Vigabatrin while other papers have reported that   168 
visual field defects do not improve in the majority of patients on stopping Vigabatrin(138) 
(148). So the visual field response to stopping Vigabatrin has been reported to be variable. 
This  may  be  due  to  visual  fields being  non-specific  in  diagnosing  Vigabatrin  induced 
visual dysfunction. 
  
Table 10.2.1 showed a smaller percentage of patients with visual field defects in the ex-
Vigabatrin group as opposed to the Vigabatrin group (45.6% ex-Vigabatrin versus 64.7% 
Vigabatrin). This supports the theory that some improvement in visual field defects occurs 
on stopping Vigabatrin. 
 
However, Table 10.6.1 illustrated the difference in visual field defects between visit 1 and 
visit 2 for the ex-Vigabatrin group. Most patients had similar findings between the two 
visits. 8 patients had visual field defects at visit 1 and 2. 9 patients had no visual field 
defects at visit 1 and visit 2. One patient that had a visual field defect at visit 1 did not have 
one at visit 2. One patient who had a visual field defects at visit 1 did not have a visual 
field defects at visit 2. These results suggest that perimetry is largely unchanged in the ex-
Vigabatrin group (testing patients at least one year of stopping Vigabatrin and one year 
apart between visits). Certain patients do not seem to improve on discontinuing Vigabatrin 
and certain persons do. Although the numbers of patients who chnaged were small (one 
improved and one worsened). It may be useful following the Vigabatrin and ex-Vigabatrin 
groups longer term to establish if any of the Vigabatrin group stop taking the drug if their 
visual fiedl defects improve.     
 
In previous studies on the ERG results with Vigabatrin, some studies have shown that 
photopic  b-wave  latency  has  improved  on  stopping  Vigabatrin(138)  without  a 
corresponding reduction in visual field defects.  In our data set there is a link between 
visual field defects and oscillatory potential amplitudes, cone b-wave amplitude and flicker 
amplitude when all patients with visual field defects are examined (see Table 10.5.1). 
However  there  is  no  statistical  significant  variation  in  these  parameters  between  the 
Vigabatrin group and the ex-Vigabatrin group in our study (see Tables10.5.2 and 10.5.3). 
Therefore  in  our  data  set  there  is  no  change  in  ERG  parameters  between  being  on 
Vigabatrin or off Vigabatrin. 
 
We have already discussed the poor specificity of visual field defects and ERG parameters 
in monitoring Vigabatrin associated retinal dysfunction. The WF-mfERG is a better tool at 
monitoring these changes.   169 
 
In the Vigabatrin group, 13 patients had an abnormal WF-mfERG on visit 1 and 2. One 
patient who had a normal WF-mfERG on visit 1 had an abnormal WF-mfERG on visit 2. 
There  were  no  patients  with  abnormal  WF-mfERG  on  visit  1  who  did  not  have  an 
abnormal WF-mfERG on visit 2. 15 patients did not have an abnormal WF-mfERG on 
visit 1 or 2. In 1 year, one patient’s visual function worsened in our data set. It seems that 
progression of retinal dysfunction is slow. 
 
In the ex-Vigabatrin group, 4 patients had an abnormal WF-mfERG on visit 1 and 19 
patients did not have an abnormal WF-mfERG on visit 1 and 2. No patient improved after 
at least three years off the drug suggesting that Vigabatrin has a permanent effect on the 
peripheral retina. These changes are chronic and pathological.  
 
11.7 What factors are important in the development and progression of disease of the 
visual system associated with Vigabatrin use?  
 
In our data set the influence of baseline patient and clinical characteristics on visual field 
defects were examined using logistic regression models. Each of the variables were added 
into  the  model  univariately  and  then  a  multivariate  stepwise  model  was  constructed 
retaining only variables significant at p<0.05. Odds ratios, 95% confidence intervals and 
corresponding p-values were reported. Predictors of visual field defects were shown in 
Table 10.7.1. Predictors of abnormal bilateral WF-mfERG were shown in Table 10.7.2. 
 
Some authors claim that there is no association with age, gender, duration of treatment or 
cumulative dosage/kg and the severity of visual field defects that could be demonstrated in 
patients on Vigabatrin.(130);
 (134;138) 
 
Some studies have found an increased incidence in male patients tested with up to 2:1 
relative  risk(130)
,  (126;128;140).  One  study  found  a  correlation  between  number  of 
cigarettes smoked and visual field defects.(139) 
 
Authors claim those patients with the largest cumulative dose (>5kg) had a slightly higher 
incidence of visual field defects.(135) One study showed a correlation with visual field 
defects once a total ingested dose of at least 1.5kg(139) was achieved. The author theorised 
that there  was a certain  minimum  load  that needed to  be  achieved before  visual  field 
defects occurred. Others have claimed that there is a correlation between the daily dose and   170 
visual field defects.(134) The prevalence of bilateral abnormalities in the WF-mfERG is 
compared to the drug load of Vigabatrin in Groups 1 & 2 in Table 10.2.7. The results show 
that in both Group 1 and Group 2 patients who developed bilateral abnormal WF-mfERG 
had a higher median load of Vigabatrin. Group 1 patients with abnormal WF-mfERG had a 
median  dose  of  9416g  whereas  those  patients  with  normal  WF-mfERG  had  a  median 
dosage was 5201g. Group 2 patients with abnormal WF- mfERG had a median dose of 
7690g whereas patients with normal WF-mfERG had a median dosage of 4745g. This 
result  was  statistically  significant.  Group  2  patients  with  abnormal  WF-mfERG  had  a 
median dose of 7690g whereas patients with normal WF-mfERG had a median dosage of 
4745g.  
 
Vigabatrin cumulative dose is compared to dose duration for normal and abnormal WF- 
mfERG in Vigabatrin group in Figure 11.7.1. 
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Figure 11.7.1 Vigabatrin cumulative dose versus dose duration for normal and abnormal 
WF-mfERG. 
 
The data from Figure 11.7.1 was used for Receiver Operator Characteristic Curve analysis 
(ROC) and this data is presented in Figure 11.7.2. 
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Figure 11.7.2 ROC Curve showing the effect of accumulated dose on peripheral retinal 
function. 
 
The  sensitivity  is  the  fraction  of  abnormal  WF-mfERG  results  above  a  threshold 
accumulated dose and the x-axis shows (1-specificity) values or the fraction of normal 
WF-mfERG results below a threshold of accumulated dose. Assuming equal importance 
for sensitivity and specificity, the ROC curve shows an optimum sensitivity of 79.3% and a 
specificity of 68% and this correspond to an accumulated dose of 5,580 Grams. 
 
Therfore cumulative dose seems to be an important factor in the development of retinal 
toxicity 
 
11.8 Do patients accept Vigabatrin associated visual field defects? 
 
In  summary,  all  groups  have  visual  field  defects  and  ERG  abnormalities.  These 
abnormalities are worse in patients who have been exposed to Vigabatrin. The peripheral 
retina seems to be selectively affected in patients exposed to Vigabatrin. WF-mfERG is the   172 
most  sensitive  and  specific  test  to  determine  those  patients  with  Vigabatrin  specific 
pathology that is chronic. Those patients with a higher cumulative load of Vigabatrin seem 
to  have  higher  incidence  of  visual  dysfunction.  Defects  are  slowly  progressive  and 
permanent. 
 
Two questionnaires were given to patients: QOLIE-31 P and VFQ-25. The Quality of Life 
in  Epilepsy  Inventory  (QOLIE-31  P)  contains  seven  multi-item  scales  that  tap  the 
following  health  concepts:  emotional  well-being,  social  functioning,  energy/fatigue, 
cognitive  functioning,  seizure  worry,  medication effects,  and overall quality  of  life.  A 
QOLIE-31 P overall score was obtained using a weighted average of the multi-item scale 
scores.  A  high  score  confers  good  qulaity  of  life.  The  Visual  Function  Questionnaire 
(VFQ-25)  generates  the  following  vision-targeted  sub-scales:  global  vision  rating, 
difficulty with near vision activities, difficulty with distance vision activities, limitations in 
social functioning due to vision, role limitations due to vision, dependency on others due to 
vision,  mental  health  symptoms  due  to  vision,  driving  difficulties,  limitations  with 
peripheral and color vision, and ocular pain. Additionally, the VFQ-25 contains the single 
general health rating question which has been shown to be a robust predictor of future 
health and mortality in population-based studies. 
 
Table 10.8.1 showed overall QOLIE-31 P and energy scores are highest in Vigabatrin and 
the non GABA groups suggesting that these patients are happier with their quality of life 
than the other groups. Surprisingly, seizure worry and medicine effects scored highest in 
these two groups as well. These scores suggest that even though patients are aware of the 
side  effects  of  Vigabatrin  they  have  a  better  quality  of  life  on  Vigabatrin  than  off. 
Supporting this theory emotional well being scores were the highest in the non GABA 
group and lowest in the ex-Vigabatrin group.  
 
Table 10.8.3 shows the scores in patients with abnormal WF-mfERG and with normal WF-
mfERG. Scores were higher in patients with abnormal WF-mfERG in the categories of 
seizure  worry,  energy  and  medicine  effects.  These  patients  would  mainly  be  in  the 
Vigabatrin and ex-Vigabatrin groups. 
 
In Vigabatrin group all patients had higher QOLIE-31 P scores in all categories if they had 
bilateral  abnormal  WF-mfERG.  See  Table  10.8.5.  These  patients  therefore  on  average 
thought that their lives were better even though they had visual dysfunction. 
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In ex-Vigabatrin patients, QOLIE-31 P showed medicine effects and seizure worry were 
scored higher in patients with abnormal bilateral WF-mfERG than patients without. All 
other parameters were scored higher in the group without visual field defects. See Table 
10.8.6. 
 
The ex-Vigabatrin group is made up of patients who tend to have less control of their 
epilepsy  (see  Table 1).  These patients had a  worse opinion on  their quality  of life as 
compared to patients on Vigabatrin.  
 
Interestingly in the GABA-ergic and non GABA-ergic groups all QOLIE-31 P  categories 
were scored lower if there were visual field defects. No patients in GABA and non-GABA 
groups had abnormal WF-mfERG. Visual field defects may be just one more manifestation 
of poor epilepsy control or increased numbers of anti-epileptic drugs. 
 
Overall  VFQ-25  scores  were  similar  between  all  groups  (see  Table  10.8.9).  This  is 
surprising because we know visual dysfunction is higher in groups 1 and 2, secondary to 
Vigabatrin. Patients, on average in each group, may have similar VFQ scores because 
peripheral  retinal  dysfunction  (leading  to  peripheral  visual  field  defects)  can  often  be 
symptomatic until very severe. 
 
A different picture emerges on examining scores group by group. Scores were lower in 
patients that were on Vigabatrin with visual field defects in the categories of near activities 
and mental health. Overall visual function in patients that were on Vigabatrin with visual 
field defects was lower than patients on Vigabatrin with no visual field defects though this 
result was not significant (see Table 10.8.12). Scores were lower in the categories of ocular 
pain, near and distance activities, peripheral vision and overall visual function in patients 
with abnormal bilateral WF-mfERG as compared with normal bilateral WF-mfERG (see 
Table  10.8.15).  Peripheral  vision  was  not  scored  lower  in  the  Vigabatrin  group  with 
abnormal visual field defects but was scored lower in those patients with abnormal WF-
mfERG. This may be confirmation that the WF-mfERG is more specific to Vigabatrin 
associated peripheral retinal toxicity than visual field defects. 
 
Patients  on  Vigabatrin  with  abnormal  WF-mfERG  noticed  poor  peripheral  vision. 
However the QOLIE-31 P and VFQ-25 suggest the majority were happy on Vigabatrin and 
as their seizures are controlled. This was also the clinical impression.  It therefoer seems   174 
that patients were happy to stay on vigabatrin despite their visula problemsd they have 
better seizure control and a better overall quality of life. 
 
11.9 Clinical features 
 
11.9.1 Colour vision 
 
Some studies have reported colour defects  ranging from 33% to 66% of people using 
various colour vision tests such as Isihara 38, Farnsworth D15-2 and Hardy Rand Rittler 
(161) (165) (129) while others have reported no change in colour vision on Vigabatrin with 
visual field defects(130). 
 
Using Hardy Rand Rittler colour vision test there were no patients with acquired colour 
vision defects. 
 
11.9.2 Clinical features 
 
Studies have found up to 71% of subjects on Vigabatrin with abnormal findings including 
retinal  artery  narrowing,  epiretinal  membrane,  abnormal  sheen  or  pigmentation  in  the 
macula, optic atrophy and a decrease in peripapillary nerve fiber layer(44;126;165). Other 
studies have reported that there has not been any ophthalmological abnormality that could 
explain visual field loss(135).  
 
There were 2 patients in our data set with attenuated vessels and one patient with white 
dots in the periphery with visual field defetcs and abnormal bilateral WF-mfERG..  
 
 
 
11.9.3 Optic atrophy 
 
Several  papers  have  reported  incidences  of  optic  atrophy  with  Vigabatrin  use(11;44). 
Indeed one of the few pathological reports available has documented loss of ganglion cells 
and  optic  atrophy(95).  However  it  is  not  clear  if  loss  of  ganglion  cells  is  a  primary 
phenomenon or secondary one to other retinal pathology.  Other studies have found no 
significant observable changes. No patient had optic atrophy in our data set. 
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11.10 Conclusion 
 
Visual field defects occur in patients with epilepsy irrespective of Vigabatrin exposure. 
The pattern of visual field loss in groups other than those on Vigabatrin (pattern of visual 
field loss is mainly bi-nasal) is generally concentric. There are abnormal ERG results in all 
groups with positive correlation with visual field defects and abnormal WF-mfERG. The 
WF- mfERG is a sensitive (100%) and specific (81%) tool we have to monitor Vigabatrin 
associated neuro-retinal toxicity. It is also much easier for patients to perform than visual 
field tests. It is objective and therefore attractive to monitor patients with epilepsy who 
may  have  difficulty with concentration and attention. The WF-mfERG has shown  that 
Vigabatrin drug load is significant in the development of retinal toxicity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter12    
 
The Future 
 
12.1 Introduction   176 
This completed two year prospective study examined patients for a maximum of two visits.  
 
12.2 Repeat Wide Field Multi-focal ERG (WF-mfERG) 
 
 An ongoing prospective study is being carried out by the Electrodiagnostic Imaging Unit, 
Glasgow  and  Epilepsy  Unit,  Glasgow.  Investigations  include  ophthalmic  history  and 
examination, Humphrey visual field examination, ISCEV standard ERG and WF-mfERG. 
The aim is to test 50 patients in the Vigabatrin and ex-Vigabatrin groups on at least two 
further occasions.  
 
It is hoped that repeat examinations in patients on Vigabatrin will give a better idea of 
disease progression hence improving management of patients. 
 
12.3 Optical Coherence Tomography (OCT) 
 
There has been a recent publication on OCT changes in the retinal nerve fiber layer in 
patients on Vigabatrin.(97) OCT is a relatively new imaging technique that permits in-vivo 
cross sectional imaging of biological tissue and is very useful in imaging the retina.  
 
The authors concluded that OCT of the retinal nerve fiber layer can identify Vigabatrin-
induced damage. OCT measurement of optic nerve is difficult. There is wide variation in 
sizes of optic nerves and therefore an accurate normal range has not been fully elucidated. 
A  prospective  study  is  being  carried  out  by  the  Electro-diagnostic  Imaging  Unit  and 
Epilepsy Unit, Glasgow. OCT will be performed of the optic nerve head in 50 patients on 
Vigabatrin on at least two visits. There are initial results in 23 patients on Vigabatrin (13 
patients on Vigabatrin with visual field defects, 10 patients on Vigabatrin without visual 
field  defects).  The  thickness  of  the  retinal  nerve  fiber  layer  in  patients  on  Vigabatrin 
compared to controls is statistically significant (p=0.0019) in determining patients with 
visual field defects. However, there is no statistically significantly difference in patients on 
Vigabatrin with and without visual field defects (p=0.0953). 
  
There does not seem to be a role for OCT in monitoring patients with visual field defects to 
monitor retinal toxicity. Due to attention deficits there may be a role in testing compliance. 
 
12.4 Acute toxicity 
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A recent study has been done to identify factors contributing to acute Vigabatrin neuro-
retinal  toxicity.  Sprague-Dawley  (albino)  rats  were  used  for  in  vivo  and  ex  vivo 
experiments in light and dark environments.  Retinas incubated with Vigabatrin under light 
had degeneration of photoreceptor outer segments, loss of photoreceptors and structural 
disruption of outer limiting membrane and damage to Muller cells in all areas of the outer 
retina (i.e. not only in the periphery) and seemed to be time and dose dependent. Retinas 
incubated with no light with Vigabatrin and retinas incubated in the light or dark with 
GABA showed no change. This is a surprising result suggesting that photo-toxicity may be 
the main underlying pathological mechanism for Vigabatrin associated visual field defects 
and is unrelated to GABA. Wearing dark glasses may protect patients from the photo-toxic 
effects and needs to be further investigated. 
 
12.5 Vigabatrin in the treatment of drug addiction 
 
Vigabatrin is being used in increasing frequency in the treatment of drug addiction(229) 
because of its effect on the reward circuitry of the brain. There may be an expanding role 
of the WF-mfERG of these patients. At the moment approval for Vigabatrin is being fast 
tracked through the U.S. Food and Drug Administration (FDA). 
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Chapter 13 
 
Summary 
 
One of the problems of previous studies was comparing the results of visual testing against 
appropriate controls. The patients in this study were matched closely for age, sex, AED 
and seizure control as far as possible. Although visual field abnormalities were found to be 
higher in the Vigabatrin (59%) and the ex-Vigabatrin group (46%), there were significant 
visual field abnormalities in non-Vigabatrin groups (25%). On the assessment of spatial 
retinal function alone however the results were different. Abnormal bilateral WF-mfERG 
responses were found in the Vigabatrin group (48%) and the ex-Vigabatrin group (22%) 
but no bilateral WF-mfERG abnormalities were found in any other groups investigated. 
The study suggests that there are probably different causes of visual field abnormalities in 
these patients. As anti epileptic drugs generally act to dampen the physiological response 
in the brain and in the retina, they are likely to cause transient visual field abnormalities. 
However as the WF-mfERG abnormalities are present in only those patients who have 
been exposed to Vigabatrin including those no longer on the treatment it would indicate a 
pathologic (toxic) effect on the retina that remains beyond usage of the drug. 
  
The study indicates that the WF-mfERG is the key investigation to identify retinal toxicity 
associated with the drug Vigabatrin. A comprehensive analysis of the main demographic 
factors identified duration of epilepsy/treatment and accumulated load of  
 
Vigabatrin seems to be the only significant risk factor for developing retinal toxicity. The 
results  of  the  Quality  of  Life  in  Epilepsy  (QOLIE-31  P)  and  Visual  Function 
Questionnaires (VFQ-25) in the various groups indicated that people in the Vigabatrin 
group  are  more  concerned  with  effective  seizure  control  than  with  retinal  toxicity 
associated with the drug. Surprisingly the patient group that was most concerned with 
visual field abnormalities was the non GABA-ergic group. 
 
The  study  results  indicate  that  visual  field defects  in patients  with epilepsy  may  have 
different underlying causes. Some visual field defects are probably related to physiological 
dampening caused by the drug action. However, there is clear evidence of retinal toxicity   179 
in those patients exposed to Vigabatrin. Therefore, the existing recommended method for 
assessing visual field or using conventional electrophysiology as an assessment of toxicity 
is  unlikely  to  be  sufficiently  specific  to  identify  Vigabatrin  associated  retinal  toxicity. 
Additionally, the results show that visual field assessment tends to be poorly repeatable in 
patients with epilepsy (table 5). The benefit of the WF-mfERG is that it is objective and 
appears only to be influenced by pathologic damage rather than synaptic dampening. An 
additional benefit is that pre-existing neurological abnormalities that would produce a field 
defect in patients with epilepsy will not influence the WF-mfERG responses. Thus it is 
more  likely  to  give  the  true  extent  of  retinal  toxicity  and  less  likely  to  produce  false 
positives. This is important for assessing patients on Vigabatrin and for the management of 
the drug in general.  
 
The study results make it clear that only patients exposed to Vigabatrin appear to be at risk 
of developing bilateral retinal defects and these defects may be slowly progressive with 
continued  Vigabatrin  treatment  in  some  patients  although  this  study  has  limited 
longitudinal data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   180 
 
 
 
 
 
 
 
 
 
Acknowledgements 
 
Stuart Parks: for his invaluable contribution to this project and his continuing advice  
 
David Keating: for his guidance 
 
Martin Brodie: for his supervision of the patients with epilepsy, his advice on medical 
management and his supervison 
 
Kevin Kelly: for tirelessly recruiting patients from the Epilepsy Unit, Glasgow 
 
Graeme Sills and John Paul Leach for advice and help with presentations 
 
Angela McCall and Ann McQuiston: who did the electrophysiology tests on most of the 
patients 
 
Sinead Dudgeon: who helped with presentations and data analysis  
 
Gordon Dutton: for his advice and review. 
 
Alison Foulis: who has taken on the longitudinal project and is re-testing patients on 
Vigabatrin 
 
Elizabeth McClure and the staff of the Optometry Department: for the provision of visual 
fields as well as clerical and nursing staff of Tennent Institute who helped with tests   181 
 
Iain Bryce, William Wykes, Peter Kyle and Charles Diaper: for teaching me 
Ophthalmology 
 
I would also like to thank the following organizations for their help in funding this project 
and attendance at meetings. 
The Chief Scientist Office, Scottish Office 
Vision Science Research, Glasgow University 
Singapore Eye Research Institute 
Scottish Ophthalmological Club 
International Society for Clinical Electrophysiology of Vision (ISCEV) 
The Faculty of Medicine, University of Glasgow 
Robertson Centre Statistics, University of Glasgow 
 
I am indebted to the patients who participated in this study and without whom this project 
would not have been possible. These patients were all recruited from the Epilepsy Unit at 
the Western Infirmary, Glasgow, UK. 
 
I am grateful for all the support my family (Shelisa, Elsie, Rita, Agnes, Arthur, Joshua, 
Elizabeth and Gill) has provided. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   182 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 1 – Ethical application, patient recruitment and patient information sheet 
 
WEST GLASGOW HOSPITALS UNIVERSITY NHS TRUST 
 
THE WEST ETHICAL COMMITTEE 
APPLICATION TO THE ETHICAL COMMITTEE FOR APPROVAL OF A 
CLINICAL RESEARCH PROJECT 
 
Please read these guidelines before completing the proforma.  You are also advised to refer to the document “Working 
with your Ethics Committee”. * 
 
1.   One typed copy of this application must be submitted to Secretary, West Ethics 
Committee, Western Infirmary, no later than 4pm on the Monday two weeks 
preceding the meeting of the Committee:  the Committee meets on the first 
and  third  Tuesday  of  each  month.    Late  arriving  protocols  will  not  be 
considered until the next meeting. 
 
2.  All of the numbered headings must be addressed.  Protocols must be presented in 
a concise manner with additional pages only being used if absolutely essential.  
Protocols presented in any other format or which deviate substantially from our 
guidelines in Working with your Ethics Committee will not be considered. 
 
3.  All investigators must sign the supporting Declaration Section 10). Copies of the 
complete Declaration of Helsinki are available from the Secretary West Ethics 
Committee. The principal investigator must complete Section 11 if the research 
project  involves  participation  of  healthy  volunteers.  Copies  of  the  Report 
“Research on Healthy Volunteers”, Royal College of Physicians of London, are 
available from the Administrator’s office. 
 
4             A patient/volunteer consent form must accompany all protocols and must pay 
heed to the advice given by the Committee on the inclusion of certain standard 
phrases. 
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5.  The investigators must not recruit medical and nursing students to participate as 
research volunteers. 
 
6.  Protocols will fall from the agenda if information is not forthcoming within 3 
months of requests being made by the Committee. 
 
7.   Grants/Charges:    See Attached Sheet 
 
                                     Company ?          Charity ?  Yes          Non-funded ? 
 
8.           Is this Project Multi-centred i.e. taking place in 5 or more UK centres ? No          
 
 
 
 
 
 
 
 
 
 
 
 
 
1.  Brief Title of Project: 
              Assessing retinal toxicity of vigabatrin and other GABA-ergic drugs in patients 
with refractory  
             epilepsy. 
 
2.  Name, Grade and Personal Qualifications of Investigators. 
              Dr Elaine A. Wilson, Associate Specialist, MBChB, MRCGP 
              Dr S Parks, Principal Clinical Scientist, BSc, PhD, MInstP, CPhys, SRCS 
              Dr D Keating, Consultant Electrophysiologist, PhD, FinstP, Fipemb, CEng, 
CPhys, SRCS   
              Professor Martin J Brodie, Consultant Clinical Pharmacologist, MD, FRCP 
              Professor Gordon Dutton, Consultatn Ophthalmologist, MD, FRCS, FRCOphth  
              Dr Roderick Duncan, Consultant Neurologist, MD, FRCP 
               
  Approved by: (If none of the investigators is a Consultant in the appropriate 
    department) 
 
 
 
  Signature of approving Consultant 
 
 
 
 
* Copies should be available in your department and the hospital libraries.  Further 
copies can       be obtained from the West Ethics Committee Secretary 
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3.  Purpose  of  Study:  (Please  outline  the  background  of  the  work,  what 
information you hope to obtain and what you believe will be benefit to the 
patient and/or to medical science) 
 
             Vigabatrin is an antiepileptic drug (AED), which was licensed in the UK in 
1989. The drug is indicated for the treatment of partial seizures with or without 
secondary generalisation
1 and for infantile spasms
2-5. It increases the level of the 
inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the brain and 
retina
6.  The  effectiveness  of  vigabatrin  as  treatment  for otherwise  intractable 
seizures  is  well-documented  and  around  8,000  prescriptions  are  dispensed 
annually in Scotland. 
 
              In  1997  Eke  and  colleagues  described  three  patients  with  severe  peripheral 
bilateral visual field defects associated with the use of vigabatrin
7. Although a 
number of studies have confirmed this initial report, the prevalence of visual 
field  abnormalities  in patients on  treatment  remains poorly  defined  (0.14%  - 
80%)
8-12. There is  also contradictory evidence on whether other GABA-ergic 
AEDs give rise to similar defects
13-14. 
 
             The  discrepancies  in  study  results  are  generally  considered  to  be  due  to 
limitations in evaluation techniques. The two principal techniques currently used 
to  assess  visual  function  in  these  patients  comprise  perimetry  (a  subjective 
technique  with  poor  reproducibility  in  this  patient  group)  and  the 
electroretinogram (ERG) (an objective technique which lacks spatial resolution 
and which is affected by the transient physiological effects of the antiepileptic 
agents  themselves).  Thus  visual  field  assessment  can  be  unreliable  or  even 
unobtainable  and  electroretinographic  abnormalities  alone  are  insufficient  to 
assume a vigabatrin related retinal pathology in this group. 
 
              Management is further complicated as many of those with visual field defects 
are  asymptomatic
15-17,  and  there  appears  to  be  no  correlation  of  these 
abnormalities with accumulated dose
18. Withdrawal of treatment in seizure-free 
individuals  is  not  a  preferred  option  as  complications  arise  from  failure  to 
adequately  manage  these  patients  on  alternative  AEDs.  Epilepsy  control  is 
important because uncontrolled seizures increase the risk of sudden unexpected 
death  in  epilepsy  (SUDEP)
19.  Recently  a  fatality  has  been  reported  as  a 
consequence of withdrawal from vigabatrin
20.  
 
             However, with over 200,000 patients worldwide currently receiving vigabatrin 
therapy and since GABA-ergic antiepileptic drugs are currently used in a variety 
of indications including manic depression, pain syndromes and the treatment of 
drug  addiction
21-24,  information  for  the  effective  management  of  vulnerable 
patients taking these agents needs to be identified as a matter of urgency. 
 
             The Electro-Diagnostic Imaging Unit at Gartnavel General Hospital is one of three groups in the 
world  to  have  developed  a  non-invasive  investigation,  with  superior 
repeatability/reproducibility
25-26,  called  the  Multi-focal  Electroretinogram  (mfERG).  mfERG 
provides  direct  topographical  information  on  retinal  health  using  a  non-invasive  technique 
performed in less than 8 minutes. The group in Glasgow is unique in that it has developed the 
technique  to  assess  peripheral  retinal  function
27,  whereas  other  groups  have  concentrated  on 
central retinal function. A small pilot study performed in Glasgow demonstrated that eight out of   185 
eleven  patients  taking  vigabatrin  had  significant  visual  field  defects.  A  further  pilot  study 
matched patients taking vigabatrin with a control group (matched for age, sex, seizure type and 
epilepsy duration), with no history of vigabatrin exposure, produced the following results: 65 
patients were enrolled, 12 of whom could not complete visual field testing or were lost to follow-
up. Nineteen patients (59%) taking vigabatrin, but none of the control group were found to have 
significant peripheral retinal dysfunction consistent with field defects. The results indicated that 
Wide  Field-mfERG  is  the  most  sensitive  objective  technique  at  identifying  visual  field 
abnormalities (100% sensitivity, 89% specificity)
28. 
         
              The aim of this study is to provide essential data to improve the management of patients taking 
vigabatrin.  This  will  include  accurately  quantifying  the  extent  of  retinal  defects  in  patients, 
assessing visual and epilepsy-related quality of life and identifying possible factors that may 
increase an individual’s risk of developing retinal defects (i.e. polytherapy, status epilepticus, site 
of epileptiform activity, smoking, alcohol etc.). The study also seeks to establish whether other 
GABA-ergic AEDs are implicated in the causation of retinal toxicity
29. 
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5.  Facilities and Personnel to support the work: Indicate here how the facilities 
and personnel you have available will enable the project to be adequately executed). 
 
The ElectroDiagnostic Imaging Unit at Gartnavel General Hospital is staffed by three 
medical physicists, three research assistants, one optometrist and one ophthalmologist. 
The multi-focal ERG is now performed on several hundred patients per annum. 
              
 An  experienced  ophthalmologist  (funded  for  2  years  by  the  CSO  grant)  will  be 
responsible  for  performing  the  following  investigations:  ophthalmic  assessment 
(fundoscopy,  visual  acuity  etc),  automated  static  perimetry,  WF-mfERG,  conventional 
electrophysiology and digital fundus photography.  
 A research nurse (also funded for two years by the CSO grant) will identify and contact 
suitable patients from the Western Infirmary Epilepsy Unit database and from the 
Epilepsy Service at the Institute of Neurological Sciences. He/she will document clinical 
details of the patient’s epilepsy and compile investigative and management details for 
each patient. In addition, he or she will collect information from two health related quality 
of life questionnaires.    186 
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6.   Patient/Volunteers:  (Please  indicate  how  patients  and/or  volunteers  are 
chosen giving the numbers chosen and justification for these numbers with 
power calculations where appropriate. Entry and exclusion criteria should be 
clearly stated. 
  Particular regard should be paid to the status of women of childbearing age. 
 
 
Three hundred patients, aged 16 years or over, with partial-onset seizures attending either 
the Epilepsy Unit (Western Infirmary) or the Institute of Neurological Sciences (Southern 
General Hospital) will be invited to participate in the study. Each will be taking, or will 
have previously taken, vigabatrin, an alternative GABA-ergic or non-GABA based AEDs 
for at least one year. 
 
The following groups will be excluded from participation in this study: 
 
•  Patients with photosensitive epilepsy. 
•  Patients who have significant retinal and/or optic disc abnormalities not associated 
with vigabatrin therapy. 
•  Patients with glaucoma. 
•  Patients at risk of developing angle closure glaucoma. 
•  Patients with a previous temporal lobectomy. 
•  Patients who are pregnant. 
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               Based on our previous pilot study, we can expect a drop-out rate of 20% from 
patients who have agreed to participate (either due to unreliable visual field test 
results or failure to attend). This would reduce the vigabatrin-based patient group 
to  120  and  our  estimate  on  those  with  retinal  abnormalities  to  70  (59%).  
Following  previous  comparative  studies  undertaken  by  our  group,  statistical 
methods will include Bland & Altman techniques
30. The proportion of patients 
with  toxicity  will  be  tabulated  in  various  sub-groups  of  interest.  This  will  be 
repeated for each of the treatment groups separately. The probability of having an 
event  will  be  modelled  by  logistical  regression,  both  univariably  and  multi-
variably.  The  current  study  has  been  designed  to  provide  sufficient  power  to 
address the main questions of the study (i.e. prevalence of vigabatrin toxicity and 
possible GABA-ergic toxicity).  Sufficient power  will  only be available for the 
main  demographic  factors  (e.g.  sex,  smoking,  polytherapy,  status  epilepticus). 
Interactions between other demographic parameters  (alcohol, genetics etc.) will 
also  be  of  interest,  however,  given  the  limited  population  base,  may  only  be 
quantified  as  an  odds  ratio.  Full  analysis  will  be  performed  by  the  Robertson 
Centre  for  Biostatistics,  where  staff  have  extensive  experience  of  major 
international multi-centre clinical trials for both the pharmaceutical industry and 
academic clinical research groups. Results will be presented in the form of odds-
ratios, 95% confidence intervals and p-values. 
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7.    Drugs, dosages and non-standard products  (Please include all drugs.  If a 
new drug is to be used a copy of the Clinical Trials Certificate or Clinical 
Trials Exemption Certification from the Committee on Safety of Medicines 
must be attached). 
 
               Eye drops used for ophthalmic examination and standard electroretinogram will 
be: 
 
              Tropicamide 1% – mydriatic  
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8.  Safety:  (Please  state  briefly  the  known  pharmacology  of  the  drugs  used 
indicating side effects and toxicity, together with hazards of any invasive 
procedure performed).  The minimum information would be that contained 
in the British Formulary  
 
               Tropicamide 1% is a short acting, relatively week mydriatic, which facilitates 
examination of the fundus of the eye. It may be associated with a mild stinging 
sensation of the eye for a few seconds after application and a rise in intra-ocular 
pressure. It will not be used in any patient found to be at significant risk of 
developing angle closure glaucoma during clinical assessment. Tropicamide may 
cause short-lived mild impairment of accommodation and irritation with bright 
lights.  
 
               In  a  small  number  of  cases,  the  scleral  electrode  can  cause  some  minor 
irritation. This is only a short lasting effect, similar to having a speck of dust in 
the eye. 
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9.  Radioactive  Substances:  (If  radioisotopes  are  to  used,  details  of  premises 
clearance by Radiation Protection Officer should be given and certificate of 
registration  with  the  DHSS  must  be  attached.    The  approximate  dose  of 
radioactivity administration should be stated). 
 
              Not applicable 
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10.   Grant or Financial Support (ALL sources of support for the work should be 
stated including details of all payments to be made to investigators, patients 
and healthy volunteers. 
 
               The project is being funded by a Chief Scientist Office grant. 
               
               The total amount of the grant is £152,422.00: £73,575 will be paid in year 1 and 
£78,847 in year 2, 
               which will cover staffing costs, indirect costs and consumables. 
 
               No payments will be made to the investigators or to patient participants. 
               
11.   Supporting Declaration (ALL named investigators must sign). 
 
 
  “I  certify  that  I  have  considered  the  declaration  of  Helsinki  and  this  protocol 
adheres to the principles contained therein”. 
 
 
12.   Research  on  Healthy  Volunteers  (Must  be  signed  by  the  principal 
investigator/s). 
 
  “I certify that I have considered the report of the Royal College of Physicians and 
this protocol adheres to the principles contained in that report.  I confirm that 
healthily  volunteers  will  have  their  legal  position  fully  explained  to  them, 
particularly  in  respect  of  the  ability  to  claim  for  damages  should  anything 
untoward occur to them as a result of their participation in research trails”. 
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  Signature................................................................................... 
 
 
  Designation............................................................................... 
 
 
  Date........................................................................................... 
 
Approved by the Ethical Committee 
 
  Date........................................... 
 
 
 
 
 
 
THIS SHEET HAS BEEN APPROVED BY THE WEST ETHICS COMMITTEE 
INFORMATION SHEET FOR PATIENTS/VOLUNTEERS IN CLINICAL RESEARCH 
PROJECT 
 
Brief Title of Project 
Assessing retinal toxicity of vigabatrin and other GABA-ergic drugs in patients with 
refractory epilepsy. 
 
Patient’s Summary (Purpose of study, nature of procedure, discomfort and possible risks in terms 
which the  
patient or volunteer can understand). 
 
We would like to invite you to take part in a study looking at vigabatrin (Sabril) and visual fields. 
It has been suggested that some people taking vigabatrin for their epilepsy may have problems with 
their visual fields (how wide you can see). It is not known, however, how many people this affects   192 
WEST ETHICS COMMITTEE 
 
FORM OF CONSENT FOR PATIENTS/VOLUNTEERS IN CLINICAL RESEARCH 
PROJECT 
 
 
Title of Project: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
By signing this form you give consent to your participation in the project whose title is at 
the top of this page.  You should have been given a complete explanation of the project to 
your satisfaction and have been given the opportunity to ask questions.  You should have 
been  given  a  copy  of  the  patient  information  sheet  approved  by  the  West  Ethics 
Committee to read and to keep.  Even though you have agreed to take part in the research 
procedures you may withdraw this consent at any time without the need to explain why 
and without any prejudice to your care. 
 
 
Consent: 
 
 
I,......................................................................................................................(PRINT) 
 
 
Of...................................................................................................................... 
 
give my consent to the research procedures above, the nature, purpose and possible 
consequences  
of which have been described to me 
 
 
by...................................................................................................................... 
 
 
Patient’s signature.............................................................Date....................... 
 
 
Doctor’s signature............................................................................................. 
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GREATER GLASGOW HEALTH BOARD 
 
THE WEST ETHICAL COMMITTEE 
 
PATIENT’S SUMMARY - GUIDELINES FOR INVESTIGATORS 
 
 
 
A)  The  following  information  must  be  included  in  the  Patients’  Summary 
unless obviously inappropriate: - 
 
  It should be noted that your participation in this study may not be of direct 
benefit  to  you,  but  could  help  in  the  development  of  treatment  for  the 
benefit of future patients. 
 
  If you do not wish to participate in this study, or wish to withdraw at any 
time after commencing the trial, your care will in no way be affected. 
 
  If you wish to take part in  this study, your General Practitioner will be 
advised  of  your  participation  and the clinical management  that  you  will 
undergo. 
   
  If you are, or are likely to become, pregnant you should not participate in 
the trial. 
   
 
B)  Written informed consent must always be obtained from patients/healthy 
volunteers. 
 
 
C)  Investigators must not recruit medical and nursing students to participate as 
research  volunteers                   West Research Office 
Ground Floor, Room 9, 
Admin Building 
Western Infirmary 
Glasgow, G11 6NT 
 
Tel. 0141 211 6281 
 
North Glasgow University Hospitals NHS Trust 
 
West Glasgow Sites 
 
West Project Registration Form 
 
 
R&D PROJECT I.D. NO:       
     (office use only) 
 
 
THIS FORM MUST BE TYPED. 
 
 
SECTION I:  PROJECT DETAILS 
 
I.  Project Title 
 
Assessing retinal toxicity of vigabatrin and other GABA-ergic drugs in patients with refractory epilepsy. 
 
 
 
 
 
I.  Name, Relevant Grade and Qualifications of Investigators  
 
Name 
 
Grade 
 
Department 
Employ Org 
Trust/Uni/ 
Other 
Do you have 
an  
Honorary 
NHS 
Contract? 
Telephone No. 
/ 
Email 
Prof M J Brodie 
 
(Principal Investigator) 
Consultant  Epilepsy Unit  Trust  No  0141 211 2572 
 
Dr Elaine A. 
Wilson 
 
Associate 
Specialist 
Epilepsy Unit  Trust (Grant 
funded) 
Yes  0141 211 1925 
EWILSONEU
@aol.com 
 
Dr Stuart Parks 
 
Principal 
Clinical 
Scientist 
Dept of 
Ophthalmolog
y 
Trust  No  0141 211 0091 
s.w.parks@cli
nmed.gla.ac.uk  
Dr D Keating 
 
 
Consultant 
Electrophysiolo
gist 
Dept of 
Ophthalmolog
y 
Trust  No  0141 211 2758 
d.keating@clin
med.gla.ac.uk 
Prof. G Dutton 
 
 
Consultant  Dept of 
Ophthalmolog
y 
Trust  No  0141 211 2090 
 
Dr Roderick 
Duncan 
 
 
Consultant  Institute of 
Neurological 
Sciences 
South Glasgow 
Trust 
No  r.duncan@clin
med.gla.ac.uk 
 
 
I.  Consultant, Head of Department or equivalent person within NGT giving authorisation to this study.   
 
 
Name 
 
Job Title 
 
Department 
 
Employed by 
 
Tel.  No. / email 
Prof. M J 
Brodie 
 
Professor of 
Clinical 
Pharmacology 
Epilepsy 
Unit 
North 
Glasgow 
Trust 
0141 211 2572 
Martin.J.Brodie@clinmed.gla.a
c.uk 
 
 
I.  Please name all NGT sites in which this study will take place – Western Infirmary and 
Gartnavel General Hospitals 
 
I.  Is the study being conducted with a sponsor?               No 
If ‘yes’, state name and details below: 
(a) 
 
Name of the Sponsor: 
 
Contact details of the person you are dealing with: 
   
Name: 
 
Address: 
 
 
 
 
Tel: 
Fax: 
E-mail: 
 
 
(b)  Does the Sponsor accept liability?     
        Yes/No      
Contact Commercial/Non-Commercial Research Co-ordinator who will arrange for a Form of Indemnity, 
if   required. 
 
 (c)  Is the Principal Investigator conducting the study as part of a course requirement of an undergraduate or      
postgraduate course, other than MD or PhD?     
             No 
 
If  ‘yes’,  state  course 
name:………………………………………………………………………………………………..  
 
 
I.  Principal Research Question 
 
 
 
 
       
 
 
 
I.   Proposed Start Date (day/month/year)     …1
st May 2003…………………………. 
 
Proposed End Date (day/month/year)     …1
st May 2005…………………………. 
 
 
II.  Methodology 
 
      Study type (you may tick more than one) 
Re-analysis of original data    Randomised controlled trial   
Laboratory study    Controlled trial without randomisation   
Case note review    Before-after study   
Dose-finding study    Case-control  ￿ 
Questionnaires / interviews    Cohort observation   
Economic evaluation    Cross-sectional study   
Other (please specify)   
 
 
I.  Outcome Measure Description 
 
 
 
 
 
10.  Sample Group 
 
(a)  Number of subjects being recruited locally 
 
SITE 
 
 
 
GRI  STOBHILL  WESTERN  GARTNAVEL  DENTAL  OTHER  
(Please Specify) 
TOTAL 
NUMBER 
 
 
 
    150      150-  Institute of 
Neurological 
Sciences  – South 
Glasgow Trust 
300 
 
 
(b)   Subject inclusion criteria 
 
- Aged 16 years of age and over 
The aim of this study is to accurately quantify the extent of retinal defects in epilepsy patients exposed to 
vigabatrin, and therefore provide essential data to improve the management of these patients.  
 
Quantification of the extent of retinal defects in patients and assessment of visual and epilepsy-related 
quality of life.  
- Male and female 
- Currently taking vigabatrin or previously taken vigabatrin for more than one year, or taking an alternative GABA-ergic drug 
and never exposed to vigabatrin or taking a non-GABA-ergic drug and never exposed to vigabatrin 
 
 
 
 
 
(c)   Subject exclusion criteria 
 
- Patients with photosensitive epilepsy 
- Patients with significant retinal and/or optic disc abnormalities not associated with vigabatrin therapy 
- Patients with glaucoma 
- Patients at risk of developing acute angle closure glaucoma 
- Patients with previous temporal lobectomy 
- Patients who are pregnant or intending to become pregnant during the study 
 
 
 
 
 
 
 
 
(d)   Source of sample group 
 
Patients who are registered with either the Epilepsy Clinics at the Western Infirmary or the Institute of Neurological Sciences.  
 
 
 
 
 
11.  Does the research go beyond the subjects' standard treatment?   
                 Yes  
 
 
 
 
 
12.  Has statistical advice has been sought on the size, power and design of the project?            
     Yes  
If ‘Yes’, from whom? Give justification for numbers. 
The current study has been designed to provide sufficient power to address the main questions of the study (i.e. prevalence of 
vigabatrin toxicity and possible GABA-ergic toxicity). Sufficient power will only be available for the  main demographic 
factors,  (e.g.  sex, smoking,  polytherapy,  status epilepticus).  Full analysis will  be  performed  by the  Robertson Centre  for 
Biostatistics. Results will be presented in the form of odds-ratios, 95% confidence intervals and p-values. 
 
13.  Provide details of the literature search carried out.  
 
See Key References attached to LREC submission. 
 
 
 
14.  Activity Areas (please tick more than one if appropriate) 
 
Cancer  
 
Vascular (includes Respiratory; Diabetes; Stroke) 
Ageing and Neurology (includes Geriatric Medicine; Mental Health; Clinical Neurological Science; Anaesthetics; Epilepsy) 
 
Maternal, Neonatal & Developmental  (includes Paediatric; Genetic Disease; Obstetrics & Gynaecology) 
 
Renal & Urology   
 
Dental (includes Oral Surgery) 
 
Infection & Inflammation (includes Laboratories; Bacteriology; Immunology) 
 
Gastroenterology, ENT & Ophthalmology 
 
Orthopaedics, Muscle & Trauma (includes Accident & Emergency; General Surgery; Rheumatology) 
 
Healthcare & Diet (includes Nutrition; Nursing; PAMs; General Practice; Primary Care; Health Economics) 
 
Skin (includes Dermatology; Burns; Plastic Surgery) 
 
Therapeutics & Devices (includes Pharmacology) 
 
 
 
 
15. NHS Priority Areas (please tick) 
 
Cancer 
 
CVD/Stroke 
 
Mental Health 
 
Public Health 
 
SECTION 2a:  USE OF HUMAN BIOLOGICAL MATERIAL   
 
I.  Will the research involve the analysis of existing stored samples of human biological 
materials?          No 
If ‘yes’, please complete this section and also Section 3b.   
 
II.  Will the research involve the collection and/or analysis of new samples of human 
biological 
materials obtained during the course of this study?                                                                                
   No 
If’ ‘Yes’ give details  
 
 
What samples will be collected and/or analysed, and by whom will they be collected? 
 
 
 
Are samples taken solely for research purposes (or are they a by-product of those taken primarily for 
clinical purposes i.e. surplus to clinical requirements)? 
 
 
 
 
3.    How will the samples be identified? 
Indicate if samples can be considered to be identified, coded, de-identified, anonymised or anonymous, 
and at what stage identifiers are removed.  (see guidance notes for definitions.)  
 
 
 
 
 
 
 
 
 
 
 
4. (a)   How long will the sample(s) be stored for during the course of the study? 
 
Months                           Years 
 
Give details. 
 
 
 
 
 
 
4. (b)   Will samples be stored after the study has ended?     
  N/A  
If ‘Yes’, for how long? 
 
Months                           Years 
 
Give details. 
 
 
 
 
 
 
5.   Will the research participant retain any rights to the sample(s)?                                                      
  N/A 
If ‘Yes’, give details. 
 
 
 
 
 
 
 
 
 
 
 
6.   Is it known how the samples will be used in the future?       
  N/A 
Give details and indicate if consent has been obtained for the future use of the samples (broad categories 
of future use may be acceptable in some cases), and how this will be safeguarded. 
 
 
 
 
 
 
 
 
 
7.   Does the research involve the analysis or use of genetic material from human biological 
materials?     No  
 
 
8.   Is it possible and/or intended to link the results of any genetic analysis back to 
individuals?    N/A 
If ‘No’, explain what safeguards are in place to ensure that this will not happen. 
 
 
 
If ‘Yes’, give details. 
 
  
 
 
 
 
 
 
SECTION 2b:  USE OF EXISTING STORED SAMPLES 
 
Complete Section 3b only if the study involves the use of stored or existing samples of 
human bodily materials (including those held in tissue banks). 
 
 
1.  What samples will be included in the study? 
 
 
 
 
 
2.   What tests/techniques will be carried out on the samples? 
 
 
 
 
3.   How will the samples be identified? 
Indicate if the samples can be considered to be identified, coded, de-identified, anonymised or 
anonymous, and at what stage identifiers are removed (see guidance notes for definitions).  
 
 
 
4.   Has specific consent been obtained previously to use stored samples for this purpose? 
  Yes / No 
If ‘Yes’, give details. 
 
 
 
If ‘No’, please justify. 
 
 
 
 
 
5.   Does the research involve the analysis or use of genetic material?   
  Yes / No 
If ‘Yes’, will it be possible to link the results of any genetic analysis back to individuals? 
 
 
 
If ‘No’, please explain why not. 
  
 
 
 
  
SECTION 3:  PHARMACY and FINANCE 
PHARMACY  (Non-commercial projects only.  For commercial projects, the company will form an                                   
                          agreement with Pharmacy) 
 
I.  Pharmaceutical aspects and the dispensing of drugs must be discussed with your local Pharmacy 
representative, 
       at least 6 weeks before commencing the study. 
 
Site Pharmacists who 
may approve a clinical 
trial 
Site                                                                    Contact No. 
Eileen Conkie  Western Infirmary                  Clinical Trials Pharmacist  Ext. 52756 
Jonathon Allan  Gartnavel General Hospital   Dispensary Pharmacist  Ext. 53316 
Carla Forte  Beatson Oncology Centre      Oncology Pharmacist  Ext. 52740 
Graham Conkie  Western Infirmary                 Production Pharmacist  Ext. 52882 
Linda Johnstone  Glasgow Royal Infirmary      Dispensary/Clinical Trials 
Pharmacist  
Ext. 21188 / 24081 
Linda Johnstone    Dental Hospital and School   Dispensary/C Trials 
Pharmacist          
Ext. 21188 / 24081 
Steven Leadbetter  Glasgow Royal Infirmary      Aseptic Services 
Pharmacist  
Ext 24265 
Sally McKendrick  Glasgow Royal Infirmary      Oncology Pharmacist 
                                            
Ext 24265 
Lesley Brown  Stobhill Hospital                    Dispensary Pharmacist  Ext 13579 
 
For further information, please contact Mrs F McMillan Clinical Governance Development 
Pharmacist: WIG Ext. 52706 
 
2.  All medicinal products to be administered as part of study: 
  Drug 1  Drug 2  Drug 3  Drug 4 
Generic Name 
 
Tropicamide 1%       
Proprietary name 
 
Minims   Tropicamide 
or Mydriacyl 
     
Dosage form 
 
Drops       
Strength 
 
1%       
Route 
 
Intra-ocular       
Dosage & frequency 
 
1 drop each eye       
Treatment Duration 
 
1 stat dose       
Standard Drug or 
Trial Drug (please 
indicate) 
Standard drug       
Total (Standard + 
Trial) Drug Cost 
Total trial 400 minims 
£107.60 
     
  
3.  Authorised and signed on behalf of Pharmacy Department by:   
   (Please note that only staff detailed above may sign this section.) 
  West Site  East Site 
Name     
Job Title     
Signature     
Date     
FINANCE 
 
Is this project COMMERCIAL           NON-COMMERCIAL              ￿ ￿ ￿ ￿           
(Please tick appropriate box) 
 
Definitions 
Commercial:           Where the study is sponsored by a Pharmaceutical Company 
Non-Commercial :  Where the study is funded by charities, research councils or Trust Endowment 
Funds etc. 
 
Commercial Projects 
If you have identified your project as Commercial you do not have to complete the Pharmacy and 
Finance  Section.    Instead,  please  contact  Dr  Gillian  Martin,  Commercial  Research  Co-
ordinator, on Tel. No. 0141 211 1813, to provide details of the Clinical Research Associate.   
 
Non-Commercial Projects 
• • • •  Please contact Elizabeth Stirling / Brenda Dougan in the Finance Department, Trust 
Headquarters, if you have any queries (Tel No : 201 9748 / 9705). 
•  No part of this form should be left blank - where no costs are incurred please state that 
there are no costs. 
•  This section must be signed by Head of Department/Clinical Director and any other heads 
of support department as required.  
 
1.  Is this project being submitted for any internal or external funding?        
Awarded 
 
 
 
2. If yes, is the funding:  
Research Council    Charity   
University    Department of Health / NHS  ￿ 
Endowment fund    Endowment fellowship   
 
Other (please state) 
 
 
  
3. Funding details 
Source of external funding 
 
  COSTS COVERED  Please indicate value  
Name of Funder / Funding Body 
 
CSO  Staffing  £107,462 
 
Funding – awarded/pending  Awarded  Facilities  £ 
Grant Ref. No.    Laboratory  £ 
Duration   26 months  Radiology  £ 
Proposed Start Date   1/5/03  PAMS  £ 
Proposed End Date   30/6/05  Drugs  £ 
Value   £156,576  Pharmacy Sundries  £3,000 
    Other (statistical consultancy)  £3,129 
    Other (indirects)  £42,985 
    TOTAL  £156,576 
Administered By 
 
 
North Glasgow University Hospitals NHS Trust   
Endowment  (Greater Glasgow Health Board)   
University  Glasgow University 
Other (Please State)   
 
 
4.Please provide details of any drugs, equipment etc being provided free for use in this study, 
including details of the donor.   
 
 
5. Costs summary 
  Staffing 
 Please detail all staff involved in project regardless of employer / funder and indicate if new staff 
are required. Please indicate grade of staff if name of individual not yet known. 
Name  Site  Employed by   Funded by   Estimated hours on 
project per patient 
Dr Elaine A. Wilson         
Dr S Parks  GGH  Trust    0.5 
Dr D Keating  GGH  Trust    0.2 
Professor Martin J 
Brodie 
       
Professor Gordon 
Dutton 
GGH  Trust    0.1 
Dr Roderick Duncan         
 
Note:  Estimated hours per patient includes set up and hours involved on project.  Set up time 
should include “thinking time” along with preparation time for Ethics & Grant submissions. 
 
  NHS Service support costs: 
All NHS tests / samples taken beyond routine patient care should be listed below.  
       
Laboratories  Name of test  Volume  
per patient 
Authorised and signed by head of 
support department 
Biochemistry       
  Haematology 
 
     
Pathology/Cytology 
 
     
Microbiology 
 
     
Virology 
 
     
Other 
 
     
 
 
Radiology / 
Cardiology 
 
Description  Volume 
 per patient 
Authorised and signed by head of 
support department 
CT       
MRI       
X RAY       
Ultrasound       
ECG       
EEG       
Endoscopy       
Other       
Theatre  Description of procedure  Volume 
 per patient 
Authorised and signed by head of 
support department 
In Patient 
Procedure 
     
Day Case 
Procedure 
     
Out Patient 
Procedure 
     
Other       
 
 
 
PAMs / other 
support 
Description  Total 
mins. per 
patient 
Authorised and signed by head of 
support department 
Dietetics       
Occupational 
Therapy 
     
Physiotherapy       
Speech Therapy       
Medical Records       
Library       
Other       
  
 
  Additional patient stays / visits 
Type of Stay  Clinic/Ward/Department Used  Length of Additional Stay/Attendance per 
patient 
Inpatient 
 
   
Day case 
 
   
Outpatient 
 
   
Follow-up visits 
 
   
 
Note:  Use of accommodation to facilitate a trial, e.g. use of an outpatient clinic to screen patients, 
should be included above. 
 
  Additional pharmacy costs 
Please make clear how the drugs / sundries are being funded 
 
Description  Dosage per patient  Unit cost  Total cost per patient 
       
       
       
       
 
 
 
 
 
 
 
(e)    Will the trial patient population be recruited from other Health Board areas? 
  Yes / No 
 
 
 
  Will the project patient population be recruited from other Health Board Areas ?    
No 
If yes, please provide details. 
 
  Supplies and equipment 
       Please include purchase cost and running cost 
Department  Item  Volume  Unit cost  Total cost 
 
         
         
         
 
 
  Additional costs not covered above 
Please state any other financial implications, e.g. will patients be prescribed drugs from the Trust when 
they would normally receive them from their G.P. or another hospital?  Will there be any drug costs at end 
of study? 
 
  
Department  Item  Volume  Unit cost  Total cost 
 
Stationary         
Postage         
Patient Travel         
Patient Meals         
Other         
         
 
6.  Implications on patient care service and costs 
(a)  Will the project impact on waiting lists?                                                                                                           
Yes / No 
       If yes, state how 
 
 
 
 
 
 
(b)  Are there any other implications on service costs as a result of this project?                                                
Yes / No     If yes, please provide details 
 
 
Note:  Include here any savings that may result.  If the project has implications on future service 
developments please   
           describe the impact on treatment and costs / savings. 
 
 
 
 
 
 
7.Project authorisation by Clinical Director or Head of Department 
 
 
I confirm that the above accurately represents the resources required for this project and 
that the project has my authorisation. 
 
 
Name  
 
 
Job title 
 
 
Department 
 
 
Signature 
 
 
Date 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 2 – Quality of life in epilepsy questionnaire (QOLIE-31P) 
 
 
 
 
Visit Number: 
└─┴─┘ └─┴─┘ └─┴─┘ 
D          M           Y 
└─┴─┘ 
 
Patient’s Name (Patient’s Initials): 
Sex: 
_________________________________________________   □  Male 
□  Female 
Patient’s ID Number:  Date of birth: 
_________________________________________________   └─┴─┘ └─┴─┘ └─┴─┘ 
D          M           Y 
 
 
 
 
 
 
NOTE:   If you experienced a simple or complex partial seizure within the previous four hours, or a generalized tonic-
clonic seizure within the previous 24 hours, please delay completing this questionnaire 
 
 
  
INSTRUCTIONS:  
This questionnaire asks about your health and daily activities.  Answer each question by circling the appropriate number 
(1, 2, 3…). 
If you are unsure about how to answer a question, please give the best answer you can and write a comment or explanation 
in the margin.  Please feel free to ask someone to help you if you have difficulty reading or completing the form. 
 
 
 
 
 
 
 
Part A.  
These questions are about how you have been FEELING during the past 4 weeks. For each question, please give the one 
answer that comes closest to the way you have been feeling. 
 
 
 
 
Reviewing only questions in Part A, consider the overall impact of these issues on your life in the past 4 weeks. 
 
 
1.  Overall, how would you rate your quality of life? 
(Circle one number only on the scale below) 
 
   
                           
                       
  10  9  8  7  6  5  4  3  2  1  0   
     
How much of the time during the past 4 weeks… 
(Circle one number on each line) 
 
 
 
All 
of the 
time 
Most 
of the 
time 
A good bit 
of the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
 
2.  Did you feel full of life? 
 
1  2  3  4  5  6 
 
3.  Did you have a lot of energy? 
 
1  2  3  4  5  6 
 
4.  Did you feel worn out? 
 
1  2  3  4  5  6 
 
5.  Did you feel tired? 
 
1  2  3  4  5  6  
(Circle one number) 
  Not at all  Somewhat  Moderately  A lot  Very much 
 
6.  How much do the above problems and worries about energy 
distress you overall? 
 
1  2  3  4  5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part B.  
These questions are about how you have been FEELING during the past 4 weeks. For each question, please give the one 
answer that comes closest to the way you have been feeling. 
 
 
 
 
 
 
 
Reviewing only questions in Part B, consider the overall impact of these issues on your life in the past 4 weeks. 
 
How much of the time during the past 4 weeks… 
(Circle one number on each line) 
 
 
All 
of the 
time 
Most 
of the 
time 
A good bit 
of the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
 
7.  Have you been a very nervous person? 
 
1  2  3  4  5  6 
 
8.  Have you felt so down in the dumps that nothing could 
cheer you up? 
 
1  2  3  4  5  6 
 
9.  Have you felt calm and peaceful? 
 
1  2  3  4  5  6 
 
10. Have you felt downhearted and low? 
 
1  2  3  4  5  6 
 
11. Have you been a happy person? 
 
1  2  3  4  5  6  
(Circle one number) 
  Not at all  Somewhat  Moderately  A lot  Very much 
 
12. How much do the above problems and worries about 
emotions distress you overall? 
 
1  2  3  4  5 
 
 
 
 
 
 
  
 
Part C.  
The following questions are about how you FEEL and about problems you may have with daily ACTIVITIES during the past 
4 weeks. For each question, please give the one answer that comes closest to the way you have been feeling. 
 
The following question asks about how you FEEL and how things have been going for you. 
 
How much of the time during the past 4 weeks… 
(Circle one number) 
 
 
All 
of the 
time 
Most 
of the 
time 
A good bit 
of the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
 
13. Has your health limited your social activities (such as 
visiting friends or close relatives)? 
 
1  2  3  4  5  6 
 
The following questions ask about problems you may have with certain ACTIVITIES. 
 
How much of the time during the past 4 weeks your epilepsy or antiepileptic drugs have 
caused trouble with… 
 
(Circle one number on each line) 
  A great deal  A lot  Somewhat  Only a little  Not at all 
 
14. Leisure time (such as hobbies, going out) 
 
1  2  3  4  5 
 
15. Driving (or other transport) 
 
1  2  3  4  5 
 
 
 
Not at all 
bothersome       
Extremely 
bothersome
 
16. How much do your work limitations bother you? 
 
1  2  3  4  5 
 
17. How much do your social limitations bother you? 
 
1  2  3  4  5 
 
Reviewing only questions in Part C, consider the overall impact of these issues on your life in the past 4 weeks. 
 
(Circle one number) 
  Not at all  Somewhat  Moderately  A lot  Very much 
 
18. How much do the above problems and worries about daily 
activities distress you overall? 
 
1  2  3  4  5 
 
Part D.  
These questions are about thinking, reading, concentrating and memory problems you may have had during the past 4  
weeks. For each question, please give the one answer that comes closest to the way you have been feeling. 
 
How much of the time during the past 4 weeks… 
 
(Circle one number) 
 
All 
of the 
time 
Most 
of the 
time 
A good bit 
of the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
 
19. Did you have difficulty reasoning and solving problems 
(such as making plans, making decisions, learning new 
things)? 
 
1  2  3  4  5  6 
 
 
Yes, 
a lot 
Yes, 
somewhat 
Only 
A little 
No, 
not at all 
 
20. During the past 4 weeks, have you had any trouble with your memory? 
 
1  2  3  4 
 
During the past 4 weeks, how often have you had… 
 
(Circle one number on each line) 
 
All 
of the 
time 
Most 
of the 
time 
A good bit 
of the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
 
21. Trouble remembering things people told you? 
 
1  2  3  4  5  6 
 
22. Trouble concentrating on reading? 
 
1  2  3  4  5  6 
 
23. Trouble concentrating on one thing at a time? 
 
1  2  3  4  5  6 
 
 
 
Not at all 
bothersome       
Extremely 
bothersome
 
24. How much do your memory difficulties bother you? 
 
1  2  3  4  5 
 
Reviewing only questions in Part D, consider the overall impact of these issues on your life in the past 4 weeks. 
 
(Circle one number) 
  Not at all  Somewhat  Moderately  A lot  Very much 
 
25. How much do the above problems and worries about 
psychological functioning distress you overall? 
 
1  2  3  4  5 
 
Part E.  
These questions are about problems you may have related to your epilepsy or antiepileptic drugs. 
 
 
  
During the past 4 weeks… 
 
(Circle one number on each line) 
 
Not at all 
bothersome       
Extremely 
bothersome
 
26. How much do physical effects of antiepileptic drugs bother you? 
 
1  2  3  4  5 
 
27. How much do psychological effects of antiepileptic drugs 
bother you? 
 
1  2  3  4  5 
 
 
 
 
 
Very 
worried 
Somewhat 
worried 
Not very 
worried 
Not worried
at all 
 
28. How worried are you that the drugs you are taking may be 
bad for you if you have to take them for a long time? 
 
1  2  3  4 
 
 
 
Reviewing only questions in Part E, consider the overall impact of these issues on your life in the past 4 weeks. 
 
(Circle one number) 
  Not at all  Somewhat  Moderately  A lot  Very much 
 
29. How much do the above problems and worries about the effects of 
drugs distress you overall? 
 
1  2  3  4  5 
 
 
 
 
 
 
 
 
 
 
 
 
Part F.  
These questions are about how you FEEL about your fits during the past 4 weeks. For each question, please give the one 
answer that comes closest to the way you have been feeling. 
 
 
How much of the time during the past 4 weeks… 
 
(Circle one number) 
 
All 
of the 
time 
Most 
of the 
time 
A good bit 
of the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time  
How much of the time during the past 4 weeks… 
 
(Circle one number) 
 
All 
of the 
time 
Most 
of the 
time 
A good bit 
of the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
 
30. Have you worried about having another fit? 
 
1  2  3  4  5  6 
 
 
Very 
afraid 
Somewhat 
afraid 
Not very 
afraid 
Not afraid 
at all 
 
31. How afraid are you of having a fit during the next 4 weeks? 
 
1  2  3  4 
 
 
    Worry a lot  Worry a little 
Don’t worry 
at all 
 
32. Do you worry about hurting yourself during a fit? 
 
  1  2  3 
 
 
 
Very 
worried 
Somewhat 
worried 
Not very 
worried 
Not  worried 
at all 
 
33. How worried are you about embarrassment or other social problems due to a fit 
during the next 4 weeks? 
 
1  2  3  4 
 
 
 
 
Not at all 
bothersome       
Extremely 
bothersome
 
34. How much do your fits bother you? 
 
1  2  3  4  5 
 
 
Reviewing only questions in Part F, consider the overall impact of these issues on your life in the past 4 weeks. 
 
(Circle one number) 
  Not at all  Somewhat  Moderately  A lot  Very much 
 
35. How much do the above problems and worries about fits 
distress you overall? 
 
1  2  3  4  5 
 
 
Part G.  
The following question asks about how you FEEL about your overall quality of life. Please give the one answer that comes 
closest to the way you have been feeling. 
 
 
36. How has your QUALITY OF LIFE been during the past 4 weeks 
(that is, how have things been going for you)? 
  
     
(Circle one number 
only) 
  Very good: 
could hardly have been better    1 
       
  Pretty good    2 
       
  Good & bad about equal    3 
       
  Pretty bad    4 
       
  Very bad: 
could hardly have been worse    5 
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Reviewing only questions 1 and 36 in Part G (on page 1 and this page), consider the overall impact of your quality of life in 
the past 4 weeks. 
 
(Circle one number) 
  Not at all  Somewhat  Moderately  A lot  Very much 
 
37. How much does the state of your quality of life distress 
you overall? 
 
1  2  3  4  5 
 
Part H.  
 
 
 
 
 
38. How good or bad do you think your HEALTH is?  
On the thermometer scale below, the best state of health imaginable is 100 and the worst state imaginable is 0. Please 
indicate how you feel about your health by circling one number on the scale. Please consider your epilepsy as being 
part of your overall health when you answer this question. 
  
 
       
Best Health State 
Imaginable  
  100    =   
 
  90 
 
 
  80 
 
 
  70 
 
 
  60 
 
 
  50 
 
 
  40 
 
 
  30 
 
 
  20 
 
 
  10 
 
 
 
   0  =     
 
   
 
       
     
 
 
 
Worst Health State 
Imaginable  
 
Part I. 
Considering ALL the questions you have answered, please indicate the areas related to your epilepsy that are most 
IMPORTANT to you NOW. 
 
 
39.  Number the following topics from ‘1’ to ‘7’ with ‘1’ corresponding to 
the most important topic and ‘7’ to the least important one. Please use 
each number only once. 
 
└──┘  A.  Energy (tiredness) 
└──┘  B.  Emotions (mood) 
└──┘  C.  Daily activities (work, driving, social) 
└──┘  D.  Mental activity (thinking, concentrating, memory) 
└──┘  E.  Medication effects (physical, mental) 
└──┘  F.  Worry about fits (impact of fits) 
└──┘  G.  Overall quality of life 
 
 
 
 
 
 
 
 
 
 
  Please check to be sure you have answered every question on every page.   
 
THANK YOU FOR COMPLETING THIS QUESTIONNAIRE 
ABOUT LIVING WITH EPILEPSY. 
   
 
 
 
 
 
 
SCORING MANUAL FOR THE QUALITY OF LIFE IN EPILEPSY INVENTORY-31 (QOLIE-31) 
 
CONTENT OF THE QOLIE-31  
The Quality of Life in Epilepsy Inventory (QOLIE-31) contains seven multi-item scales 
that tap the following health concepts: emotional well-being, social functioning,  
energy/fatigue, cognitive functioning, seizure worry, medication effects, and overall 
quality of life. A QOLIE-31 overall score is obtained using a weighted average of the 
multi-item scale scores. The QOLIE-31 also includes a single item that assesses 
overall health.  
 
SCORING RULES  
Precoded numeric values for responses on some QOLIE-31 items are in the direction 
such that a higher number reflects a more favorable health state. For example, a 
circled response of '10' for item 1 corresponds to "Best Possible Quality of Life", while 
a circled response of '0' corresponds to "Worst Possible Quality of Life." However, 
precoded numeric values for some other items on the uOLIE-31 are in the direction 
such that a lower number reflects a more favorable health state. For example, a 
circled response of '1' for item 14 corresponds to more favorable quality of life, while a 
value of '5' on this item corresponds to less favorable quality of life. As these 
examples also demonstrate, different items in the QOLIE-31 have different ranges of 
precoded numeric values. Higher scores always reflect better quality of life (Table 2). 
To perform this step, write in the converted score for each item in the column labeled 
"Subtotal" in Table 2. Next, sum the subtotal scores for each scale and write in these 
values in the places marked "Total." Finally, divide each "Total" by the from 0 to 100 
points. Higher scores reflect better quality of life; lower ones, worse quality of life. 
Note that Table 1 shows the divisors to be used only in situations where every item 
within a given scale has been answered. For example, if item 11 in the Seizure Worry 
scale was left blank and the other four items in the scale were answered, then the 
"Total" score for Seizure Worry would be divided by '4' (instead of '5') to obtain the 
"Final Score:'  
 
OVERALL SCORE  
A QOLIE-31 overall score can be derived by weighting and summing QOLIE-31 scale 
scores (Table 4). QOLIE-31 scale weights were derived from a regression analysis 
that used a summary score from the OOLIE-89.  The QOLIE-31 overall score is 
calculated by summing the product of each scale score times its weight and summing 
over all scales (Table4).  
 
Following are Scoring Tables 2 and 4. 
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The following is a survey with statements about problems which involve your vision or 
feelings that you have about your vision condition.  After each question please choose the 
response that best describes your situation. 
 
Please answer all the questions as if you were wearing your glasses or contact lenses (if 
any). 
 
Please take as much time as you need to answer each question.  All your answers are 
confidential.  In order for this survey to improve our knowledge about vision problems 
and how they affect your quality of life, your answers must be as accurate as possible.  
Remember, if you wear glasses or contact  lenses, please answer all of the following 
questions as though you were wearing them. 
 
INSTRUCTIONS: 
 
1.  In general we would like to have people try to complete these forms on their own.  
If you find that you need assistance, please feel free to ask the project staff and 
they will assist you. 
 
2.  Please answer every question (unless you are asked to skip questions because they 
don’t apply to you). 
 
3.  Answer the questions by circling the appropriate number. 
 
4.  If you are unsure of how to answer a question, please give the best answer you can 
and make a comment in the left margin. 
 
5.  Please complete the questionnaire before leaving the center and give it to a 
member of the project staff.  Do not take it home. 
 
6.  If you have any questions, please feel free to ask a member of the project staff, 
and they will be glad to help you. 
 
STATEMENT OF CONFIDENTIALITY: 
 
All information that would permit identification of any person who completed this 
questionnaire will be regarded as strictly confidential.  Such information will be used 
only for the purposes of this study and will not be disclosed or released for any other 
purposes without prior consent, except as required by law.  
 
 
   
Visual Functioning Questionnaire - 25 
   
PART 1 - GENERAL HEALTH AND VISION 
 
 
1.  In general, would you say your overall health is:  
  (Circle One) 
 
  Excellent..................................  1   
  Very Good...............................  2 
  Good........................................  3 
  Fair..........................................  4 
  Poor.........................................  5 
   
 
 
 
2.  At the present time, would you say your eyesight using both eyes (with glasses or 
contact lenses, if you wear them)  is excellent, good, fair, poor, or very poor or are you 
completely blind? 
  (Circle One) 
 
  Excellent..................................  1   
  Good........................................  2 
  Fair..........................................  3 
  Poor.........................................  4 
  Very Poor................................  5 
  Completely Blind....................  6 
 
 
  
 
 
   
 
3.  How much of the time do you worry about your eyesight? 
 
            (Circle One) 
  None of the time..................................  1   
  A little of the time...............................  2 
  Some of the time.................................  3 
  Most of the time..................................  4 
  All of the time?....................................  5 
 
 
4.  How much pain or discomfort have you had in and around your eyes (for example, 
burning, itching, or aching)?  Would you say it is: 
 
            (Circle One) 
  None........................................  1   
  Mild.........................................  2 
  Moderate .................................  3 
  Severe, or.................................  4 
  Very severe?............................  5 
 
 
PART 2 - DIFFICULTY WITH ACTIVITIES 
 
The next questions are about how much difficulty, if any, you have doing certain activities 
wearing your glasses or contact lenses if you use them for that activity. 
 
5.  How much difficulty do you have reading ordinary print in newspapers?  Would you say 
you have:  
   
   
          (Circle One) 
  No difficulty at all.............................................................   1   
  A little difficulty................................................................  2 
  Moderate difficulty............................................................  3 
  Extreme difficulty.............................................................  4 
  Stopped doing this because of your eyesight....................  5 
  Stopped doing this for other reasons or not  
       interested in doing this  6 
  
 
 
   
6.  How much difficulty do you have doing work or hobbies that require you to see well up 
close, such as cooking, sewing, fixing things around the house, or using hand tools? 
Would you say: 
   
          (Circle One) 
  No difficulty at all.............................................................   1   
  A little difficulty................................................................  2 
  Moderate difficulty............................................................  3 
  Extreme difficulty.............................................................  4 
  Stopped doing this because of your eyesight....................  5 
  Stopped doing this for other reasons or not  
       interested in doing this  6 
 
 
7.  Because of your eyesight, how much difficulty do you have finding something on a 
crowded shelf? 
    
          (Circle One) 
  No difficulty at all.............................................................   1   
  A little difficulty................................................................  2 
  Moderate difficulty............................................................  3 
  Extreme difficulty.............................................................  4 
  Stopped doing this because of your eyesight....................  5 
  Stopped doing this for other reasons or not  
       interested in doing this  6 
 
 
8.  How much difficulty do you have reading street signs or the names of stores?    
     
          (Circle One) 
  No difficulty at all.............................................................   1   
  A little difficulty................................................................  2 
  Moderate difficulty............................................................  3 
  Extreme difficulty.............................................................  4 
  Stopped doing this because of your eyesight....................  5 
  Stopped doing this for other reasons or not  
       interested in doing this  6 
 
 
 
 
 
  
 
 
   
9. Because of your eyesight, how much difficulty do you have going down steps, stairs, or 
curbs in dim light or at night?  
   
          (Circle One) 
  No difficulty at all.............................................................   1   
  A little difficulty................................................................  2 
  Moderate difficulty............................................................  3 
  Extreme difficulty.............................................................  4 
  Stopped doing this because of your eyesight....................  5 
  Stopped doing this for other reasons or not  
       interested in doing this  6 
 
 
 
10.  Because of your eyesight, how much difficulty do you have noticing objects off to the 
side while you are walking along? 
     
          (Circle One) 
  No difficulty at all.............................................................   1   
  A little difficulty................................................................  2 
  Moderate difficulty............................................................  3 
  Extreme difficulty.............................................................  4 
  Stopped doing this because of your eyesight....................  5 
  Stopped doing this for other reasons or not  
       interested in doing this  6 
 
 
11.  Because of your eyesight, how much difficulty do you have seeing how people react to 
things you say? 
 
          (Circle One) 
  No difficulty at all.............................................................   1   
  A little difficulty................................................................  2 
  Moderate difficulty............................................................  3 
  Extreme difficulty.............................................................  4 
  Stopped doing this because of your eyesight....................  5 
  Stopped doing this for other reasons or not  
       interested in doing this  6 
 
  
 
 
   
12.  Because of your eyesight, how much difficulty do you have picking out and matching 
your own clothes? 
   
           (Circle One) 
  No difficulty at all.............................................................   1   
  A little difficulty................................................................  2 
  Moderate difficulty............................................................  3 
  Extreme difficulty.............................................................  4 
  Stopped doing this because of your eyesight....................  5 
  Stopped doing this for other reasons or not  
       interested in doing this  6 
 
 
 
13.  Because of your eyesight, how much difficulty do you have visiting with people in their 
homes, at parties, or in restaurants ? 
 
          (Circle One) 
  No difficulty at all.............................................................   1   
  A little difficulty................................................................  2 
  Moderate difficulty............................................................  3 
  Extreme difficulty.............................................................  4 
  Stopped doing this because of your eyesight....................  5 
  Stopped doing this for other reasons or not  
       interested in doing this  6 
 
 
 
14.  Because of your eyesight, how much difficulty do you have going out to see movies, 
plays, or sports events? 
   
          (Circle One) 
 
  No difficulty at all.............................................................   1   
  A little difficulty................................................................  2 
  Moderate difficulty............................................................  3 
  Extreme difficulty.............................................................  4 
  Stopped doing this because of your eyesight....................  5 
  Stopped doing this for other reasons or not  
       interested in doing this   6 
 
 
15.  Are you currently driving, at least once in a while? 
  (Circle One)  
 
 
   
  Yes ........................  1  Skip To Q 15c   
  No..........................  2     
 
 
15a.  IF NO:  Have you never driven a car or have you given up driving? 
  (Circle One) 
  Never drove...........  1  Skip To Part 3, Q 17   
  Gave up.................  2     
 
 
15b.  IF YOU GAVE UP DRIVING:  Was that mainly because of your eyesight, 
mainly for some other reason, or because of both your eyesight and other 
reasons? 
   
        (Circle One) 
 
  Mainly eyesight.........................................  1  Skip To Part 3, Q 17   
  Mainly other reasons.................................  2  Skip To Part 3, Q 17 
  Both eyesight and other reasons................  3  Skip To Part 3, Q 17 
 
 
15c.  IF CURRENTLY DRIVING:  How much difficulty do you have driving during 
the daytime in familiar places?  Would you say you have: 
 
        (Circle One) 
  No difficulty at all.....................................  1   
  A little difficulty........................................  2 
  Moderate difficulty....................................  3 
  Extreme difficulty.....................................  4 
  
 
 
   
16.  How much difficulty do you have driving at night?  Would you say you have:  
            (Circle One) 
  No difficulty at all...........................................  1   
  A little difficulty..............................................  2 
  Moderate difficulty..........................................  3 
  Extreme difficulty...........................................  4 
  Have you stopped doing this because 
       of your eyesight..........................................  5 
  Have you stopped doing this for other  
       reasons or are you not interested in  
       doing this....................................................  6 
 
 
16A. How much difficulty do you have driving in difficult conditions, such as in bad weather, 
during rush hour, on the freeway, or in city traffic?  Would you say you have: 
             
            (Circle One) 
  No difficulty at all...........................................  1   
  A little difficulty..............................................  2 
  Moderate difficulty..........................................  3 
  Extreme difficulty...........................................  4 
  Have you stopped doing this because 
       of your eyesight..........................................  5 
  Have you stopped doing this for other  
       reasons or are you not interested in  
       doing this....................................................  6 
 
 
  
 
 
   
PART 3:  RESPONSES TO VISION PROBLEMS 
       
The next questions are about how things you do may be affected by your vision.  For each one, 
please circle the number to indicate whether for you the statement is true for you all, most, 
some, a little, or none of the time. 
 
        (Circle One On Each Line) 
READ CATEGORIES:  All of the 
time 
Most of 
the time 
Some of 
the time 
A little 
of the 
time 
None of 
the time 
 
 
 
17.  Do you accomplish less than 
you would like because of your 
vision? 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
18.  Are you limited in how long 
you can work or do other 
activities because of your 
vision?..................................  
 
 
 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
19.   How much does pain or 
discomfort in or around your 
eyes, for example, burning, 
itching, or aching, keep you 
from doing what you’d like to 
be doing?  Would you say: 
 
 
 
      1 
 
 
 
      2 
 
 
 
       3 
 
 
 
       4 
 
 
 
      5 
 
 
 
 
 
 
  
 
 
   
For each of the following statements, please circle the number to indicate whether for you the 
statement is definitely true, mostly true, mostly false, or definitely false for you or you are not 
sure. 
 
  (Circle One On Each Line) 
 
  Definitely  Mostly  Not  Mostly  Definitely 
  True  True  Sure  False  False 
 
 
20.  I stay home most of the time  
  because of my eyesight............  1  2  3  4  5   
 
21.  I feel frustrated a lot of the  
  time because of my  
  eyesight. ...................................  1  2  3  4  5   
 
22.  I have much less control  
  over what I do, because of  
  my eyesight..............................  1  2  3  4  5   
 
23.  Because of my eyesight, I  
  have to rely too much on  
  what other people tell me.........  1  2  3  4  5   
 
24.  I need a lot of help from  
  others because of my  
  eyesight. ...................................  1  2  3  4  5 
 
25.  I worry about doing things 
  that will embarrass myself 
  or others, because of my 
  eyesight. ...................................  1  2  3  4  5 
 
 
 
 
 
 
 
Appendix of Optional Additional Questions  
 
 
   
 
SUBSCALE: GENERAL HEALTH   
A1.  How would you rate your overall health, on a scale where zero is as bad as death and 10 
is best possible health? 
 
(Circle One) 
 
  0  1  2  3  4  5  6  7  8  9  10   
  Worst  Best 
 
SUBSCALE: GENERAL VISION  
 
A2.  How would you rate your eyesight now (with glasses or contact lens on, if you wear 
them), on a scale of from 0 to 10, where zero means the worst possible eyesight, as bad 
or worse than being blind, and 10 means the best possible eyesight? 
 
(Circle One) 
 
  0  1  2  3  4  5  6  7  8  9  10   
  Worst  Best 
 
SUBSCALE:  NEAR VISION 
 
A3.  Wearing glasses, how much difficulty do you have reading the small print in a telephone 
book, on a medicine bottle, or on legal forms?  Would you say: 
   
  (Circle One) 
 
  No difficulty at all.............................................................   1   
  A little difficulty................................................................  2 
  Moderate difficulty............................................................  3 
  Extreme difficulty.............................................................  4 
  Stopped doing this because of your eyesight....................  5 
  Stopped doing this for other reasons or not  
       interested in doing this  6  
 
 
   
 
A4.  Because of your eyesight, how much difficulty do you have figuring out whether bills 
you receive are accurate? 
   
          (Circle One) 
  No difficulty at all.............................................................   1   
  A little difficulty................................................................  2 
  Moderate difficulty............................................................  3 
  Extreme difficulty.............................................................  4 
  Stopped doing this because of your eyesight....................  5 
  Stopped doing this for other reasons or not  
       interested in doing this  6 
 
 
A5.  Because of your eyesight, how much difficulty do you have doing things like shaving, 
styling your hair, or putting on makeup? 
   
          (Circle One) 
  No difficulty at all.............................................................   1   
  A little difficulty................................................................  2 
  Moderate difficulty............................................................  3 
  Extreme difficulty.............................................................  4 
  Stopped doing this because of your eyesight....................  5 
  Stopped doing this for other reasons or not  
       interested in doing this  6 
 
 
SUBSCALE:  DISTANCE VISION 
 
A6.  Because of your eyesight, how much difficulty do you have recognizing people you 
know from across a room? 
   
          (Circle One) 
  No difficulty at all.............................................................   1   
  A little difficulty................................................................  2 
  Moderate difficulty............................................................  3 
  Extreme difficulty.............................................................  4 
  Stopped doing this because of your eyesight....................  5 
  Stopped doing this for other reasons or not  
       interested in doing this  6 
 
A7.  Because of your eyesight, how much difficulty do you have taking part in active sports 
or other outdoor activities that you enjoy (like golf, bowling, jogging, or walking)?  
    
 
 
   
 
           (Circle One) 
  No difficulty at all.............................................................   1   
  A little difficulty................................................................  2 
  Moderate difficulty............................................................  3 
  Extreme difficulty.............................................................  4 
  Stopped doing this because of your eyesight....................  5 
  Stopped doing this for other reasons or not  
       interested in doing this  6 
 
A8.  Because of your eyesight, how much difficulty do you have seeing and enjoying 
programs on TV?  
   
          (Circle One) 
  No difficulty at all.............................................................   1   
  A little difficulty................................................................  2 
  Moderate difficulty............................................................  3 
  Extreme difficulty.............................................................  4 
  Stopped doing this because of your eyesight....................  5 
  Stopped doing this for other reasons or not  
       interested in doing this  6 
 
 
SUBSCALE:  SOCIAL FUNCTION 
 
A9.  Because of your eyesight, how much difficulty do you have entertaining friends and 
family in your home? 
   
           (Circle One) 
  No difficulty at all.............................................................   1   
  A little difficulty................................................................  2 
  Moderate difficulty............................................................  3 
  Extreme difficulty.............................................................  4 
  Stopped doing this because of your eyesight....................  5 
  Stopped doing this for other reasons or not  
       interested in doing this  6 
 
 
 
SUBSCALE:  DRIVING 
 
A10.  [This item, “driving in difficult conditions”, has been included as part of the 
base set of 25 items as item 16a.] 
   
 
 
   
 
 
SUBSCALE:  ROLE LIMITATIONS 
 
A11. The next questions are about things you may do because of your vision.  For each item, 
please circle the number to indicate whether for you this is true for you all, most, some, a 
little, or none of the time. 
   
    (Circle One On Each Line) 
 
  All of the 
time 
Most of 
the time 
Some of 
the time 
A little 
of the 
time 
None of 
the time 
 
 
a.  Do you have more help from 
others because of your vision?
.............................................  
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
 
b.  Are you  limited in the kinds of 
things you can do because of 
your vision?..........................  
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
  
 
 
   
 
SUBSCALES:  WELL-BEING/DISTRESS (#A12) and DEPENDENCY (#A13) 
 
The next questions are about how you deal with your vision.  For each statement, please circle 
the number to indicate whether for you it is definitely true, mostly true, mostly false, or 
definitely false for you or you don’t know. 
     
      (Circle One On Each Line) 
 
  Definitely  Mostly  Not  Mostly   Definitely
  True  True  Sure  False  False 
 
A12. I am often irritable because  
  of my eyesight..........................  1  2  3  4  5   
 
 
A13. I don’t go out of my home  
  alone, because of my  
  eyesight. ...................................  1  2  3  4  5   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
   
Version 2000 
The National Eye Institute 25-Item 
Visual Function Questionnaire (VFQ-25)   
 
Version 2000    
 
 
 
   
This final version of the VFQ-25 differs from the previous version 
in that it includes an extra driving item from the appendix of 
supplementary questions as part of the base set of items. Also, the 
revised scoring algorithm excludes the single-item general health 
rating question from the calculation of the vision-targeted composite 
score. Because of these 2 changes, the base set of items actually 
includes 26 questions, however, only 25 are vision-targeted and 
included in the composite score. Please see the “Frequently Asked 
Questions” or FAQ section for additional clarifications of these 
changes. 
 
Background 
The National Eye Institute (NEI) sponsored the 
development  of  the  VFQ-25  with  the  goal  of 
creating  a  survey  that  would  measure  the 
dimensions  of  self-reported  vision-targeted 
health status that are most important for persons 
who have chronic eye diseases.  Because of this 
goal, the survey measures the influence of visual 
disability and visual symptoms on generic health 
domains such as emotional well-being and social 
functioning, in addition to task-oriented domains 
related  to  daily  visual  functioning.  Questions 
included  in  the  VFQ-25  represent  the  content 
identified  during  a  series  of  condition-specific 
focus groups with patients who had age-related 
cataracts,  glaucoma,  age-related  macular 
degeneration,  diabetic  retinopathy,  or  CMV 
retinitis.
 1 
 
The VFQ-25 is the product of an item-reduction 
analysis of  the longer field test version of the 
survey  called  the  51-item  National  Eye 
Institute  Vision  Function  Questionnaire 
(NEI-VFQ).
2  The longer version contains 
51 questions which represent 13 different sub-
scales.  The NEI-VFQ Field Test Study collected 
the data needed  to examine  the reliability  and 
validity of the survey  across all of the above-
mentioned ocular diseases.  Also, reliability and 
validity was assessed in a heterogeneous group 
of patients with low vision from any cause and a 
group  of  age-matched  persons  with  normal 
vision.  A  published  report  describes  the 
psychometric properties of the longer field test 
version of the survey.
 3  Additional a number of 
clinical studies have used either the 51 or the 25-
item version of the NEI-VFQ across a number of 
chronic ocular conditions.
 4-8 Despite the success 
of the longer field test version and its continued 
use, to enhance feasibility a short-form version 
was  planned  since  the  earliest  developmental 
phase. 
 
The VFQ-25 consists of a base set of 25 vision-
targeted questions representing 11 vision-related 
constructs, plus an additional single-item general 
health  rating  question.  The  VFQ-25  also 
includes  an  appendix of additional  items  from 
the 51-item version that researchers can use to 
expand the scales up to 39 total items.  All items 
in the VFQ-25 are from the 51-item field test 
version; no new items were developed for use in 
the  VFQ-25.  Unless  otherwise  specified,  the 
remainder  of  this  document  will  use  the  term 
VFQ-25 to refer to the base set of items. 
 
The VFQ-25 takes approximately 10 minutes 
on  average  to  administer  in  the  interviewer 
format.  There  is  also  a  self-administered 
version of the survey, however, psychometric 
testing of the self-administered version has not 
been  done.  The  VFQ-25  generates  the 
following  vision-targeted  sub-scales:  global 
vision  rating  (1),  difficulty  with  near  vision 
activities  (3),  difficulty  with  distance  vision 
activities (3), limitations in social functioning 
due to vision (2), role limitations due to vision 
(2),  dependency  on  others  due  to  vision  (3), 
mental  health  symptoms  due  to  vision  (4), 
driving  difficulties  (3),  limitations  with 
peripheral (1) and color vision (1), and ocular 
pain (2). Additionally, the VFQ-25 contains the 
single general health rating question which has 
been shown to be a robust predictor of future 
health  and  mortality  in  population-based 
studies. Please see the FAQ section for more 
information  about  the  general  health  rating 
question. 
 
Development of the NEI VFQ-25 
The guiding principles for the selection of the 
short-form  items  included:  1)  low  item-level 
missing  data  rates;  2)  normal  distribution  of 
response choices; and 3) retention of items that 
explained the greatest proportion of variance in 
the 51-item sub-scales. The items retained in the 
VFQ-25 and the optional items (provided in the 
appendix to the survey) are listed on Table 1. A 
report describing the performance of the VFQ-25 
relative  to  the  Field  Test  version  is  currently 
under review.
 2  The reliability and validity of the    
 
 
 
   
VFQ-25 is similar to that observed for the 51-
item  version  of  the  survey.  On  average,  each 
VFQ-25 sub-scale predicts 92% of the variance 
in the corresponding 51-item sub-scale score. 
 
Optional Items 
Appendix 1 consists of additional questions that 
users may add to a specific sub-scale. Inclusion 
of these may be helpful if a particular sub-scale 
represents the primary domain of vision-targeted 
HRQOL that is felt to be most important for the 
condition under study. For example, if a user is 
testing  a  new  treatment  for  macular 
degeneration,  by  adding  near  vision  questions 
A3, A4, and A5 to VFQ-25 questions 5, 6, and 7, 
the  investigator  would  have  a  six-item  near 
vision scale rather than a three-item scale. The 
addition  of  these  items  would  enhance  the 
reliability  of  the  near  vision  sub-scale  and  is 
likely to improve the responsiveness of the sub-
scale to the intervention over time (Table 6). If 
items from the appendix are used, the VFQ-25 
developers would encourage users to incorporate 
all  optional  items  for  a  given  sub-scale.  This 
strategy will enhance the comparability of results 
across studies. 
 
Scoring  
Scoring VFQ-25 with or without optional items 
is a two-step process:  
 
•  First,  original  numeric  values  from  the 
survey  are  re-coded  following  the  scoring 
rules  outlined  in  Table  2.  All  items  are 
scored so that a high score represents better 
functioning. Each item is then converted to a 
0 to 100 scale so that the lowest and highest 
possible scores are set at 0 and 100 points, 
respectively. In this format scores represent 
the achieved percentage of the total possible 
score, e.g. a score of 50 represents 50% of 
the highest possible score.  
 
•  In  step 2,  items  within  each  sub-scale  are 
averaged together to create the 12 sub-scale 
scores.  Table  3  indicates  which  items 
contribute to each specific sub-scale. Items 
that  are  left  blank  (missing  data)  are  not 
taken  into  account  when  calculating  the 
scale  scores.  Sub-scales  with  at  least  one 
item answered can be used to generate a sub-
scale  score.  Hence,  scores  represent  the 
average for all items in the sub-scale that the 
respondent answered. 
 
Composite Score Calculation 
To calculate an overall composite score for the VFQ-25, simply 
average the vision-targeted sub-scale scores, excluding the general 
health rating question.  By averaging the sub-scale scores rather 
than the individual items we have given equal weight to each sub-
scale, whereas averaging the items would give more weight to 
scales with more items. 
    
 
 
 
   
 
 
 
 
 
 
 
 
 
 
Table 1. Item Number Translation from the 51-Item Field Test Version to the VFQ 25 
 
S = retained in the VFQ-25, A = retained in the appendix should be used for the VFQ-39, 
 --- = deleted from the VFQ-25 & VFQ-39 
 
Field Test 
Version 
Ques.# 
 
Sub-scale 
 
Status 
VFQ-25 
Ques. # 
Field Test 
Version 
Ques.# 
 
Sub-scale 
 
Status 
VFQ-25 
Ques. # 
1  general health  S  1  29  social fx  ---  --- 
2  general health  A  A1  30  social fx  A  A9 
3  general vision  S  2  31  social fx  S  13 
4  expectations  ---  ---  32  distance vision  A  A8 
5  well-being/ 
distress 
S  3  33  distance vision  A  A7 
6  well-being/ 
distress 
---  ---  34  distance vision  S  14 
7  ocular pain  S  19  35  driving  
(filter item) 
S  15 
8  expectations  ---  ---  35a  driving  
(filter item) 
S  15a 
9  expectations  ---  ---  35b  driving  
(filter item) 
S  15b 
10  expectations  ---  ---  35c  driving  S  15c 
11  well-being/ 
distress 
S  25  36  driving  ---  --- 
12  ocular pain  S  4  37  driving  S  16 
13  well-being/ 
distress 
---  ---  38  driving  S  16a * 
14  general vision  A  A2  39a  role limitations  S  17 
15  near vision  S  5  39b  role limitations  A  A11a 
16  near vision  A  A3  39c  well-being/ 
distress 
---  --- 
17  near vision  S  6  39d  role limitations  ---  --- 
18  near vision  ---  ---  39e  role limitations  A  A11b 
19  near vision  S  7  39f  role limitations  S  18 
20  distance vision  S  8  40  well-being/ 
distress 
A  A12 
21  distance vision  ---  ---  41  dependency  S  20 
22  distance vision  S  9  42  well-being/ 
distress 
S  21 
23  peripheral vision  S  10  43  well-being/ 
distress 
S  22 
24  distance vision  A  A6  44  dependency  ---  --- 
Comment [DS1]:     
 
 
 
   
25  social fx  S  11  45  dependency  A  A13 
26  near vision  A  A4  46  dependency  S  23 
27  color vision  S  12  47  dependency  S  24 
28  near vision  A  A5         
* VFQ-25 item 16a was listed in previous versions as part of the appendix of supplemental items (#A10).   
 
 
 
   
 
Table 2.  Scoring Key: Recoding of Items 
 
Item Numbers  Change original response category 
(a)  To recoded value of: 
1,3,4,15c
(b)  1 
2 
3 
4 
5 
100 
75 
50 
25 
0 
2  1 
2 
3 
4 
5 
6 
100 
80 
60 
40 
20 
0 
5,6,7,8,9,10,11,12,13,14,16,16a 
A3,A4,A5,A6,A7,A8,A9
(c) 
 
1 
2 
3 
4 
5 
6 
100 
75 
50 
25 
0 
* 
17,18,19,20,21,22,23,24,25, 
A11a,A11b,A12,A13        
1 
2 
3 
4 
5 
0 
25 
50 
75 
100 
A1,A2  0 
to 
10 
0 
to 
100 
 
(a)  Precoded response choices as printed in the questionnaire. 
 
(b)  Item 15c has four-response levels, but is expanded to a five-levels using item 15b. 
  Note:  If 15b=1, then 15c should be recoded to “0” 
  If 15b=2, then 15c should be recoded to missing. 
  If 15b=3, then 15c should be recoded to missing.
 
 
(c)  “A” before the item number indicates that this item is an optional item from the Appendix.  If optional 
items are used, the NEI-VFQ developers encourage users to use all items for a given sub-scale.  This 
will greatly enhance the comparability of sub-scale scores across studies. 
 
*  Response choice "6" indicates that the person does not perform the activity because of non-vision 
related problems.  If this choice is selected, the item is coded as "missing."    
 
 
 
   
Table 3. Step 2: Averaging of Items to Generate VFQ-25 Sub-Scales 
 
 
Scale 
 
Number of items 
Items to be averaged  
(after recoding per Table 2) 
General Health 
General Vision 
Ocular Pain 
Near Activities 
Distance Activities 
Vision Specific: 
    Social Functioning 
    Mental Health 
    Role Difficulties 
    Dependency 
Driving 
Color Vision 
Peripheral Vision 
1 
1 
2 
3 
3 
 
2 
4 
2 
3 
3 
1 
1 
1 
2 
4, 19 
5, 6, 7 
8, 9, 14 
 
11, 13 
3, 21, 22, 25 
17, 18 
20, 23, 24 
15c, 16, 16a 
12 
10 
 
 
 
 
 
Table 4. Step 2: Averaging of Items to Generate VFQ-39 Sub-Scales (VFQ-25 + Optional Items) 
 
 
Scale 
 
Number of items 
Items to be averaged  
(after recoding per Table 2) 
General Health 
General Vision 
Ocular Pain 
Near Activities 
Distance Activities 
Vision Specific: 
    Social Functioning 
    Mental Health 
    Role Difficulties 
    Dependency 
Driving 
Color Vision 
Peripheral Vision 
2 
2 
2 
6 
6 
 
3 
5 
4 
4 
3 
1 
1 
1, A1 
2, A2 
4, 19 
5, 6, 7, A3, A4, A5 
8, 9, 14, A6, A7, A8 
 
11, 13, A9 
3, 21, 22, 25, A12 
17, 18, A11a, A11b 
20, 23, 24, A13 
15c, 16, 16a 
12 
10 
 
 
    
 
 
 
   
Figure 1.  Example of VFQ-25 Scoring Algorithm for Near Activities Sub-Scale 
 
 
 
5.  How much difficulty do you have reading ordinary print in newspapers?  Would you say 
you have: 
 
No difficulty at all..................................................................... 1  
A little difficulty....................................................................... 2  
Moderate difficulty................................................................... 3  
Extreme difficulty...................................................................(4) 
Stopped doing this because of your eyesight........................... 5  
Stopped doing this for other reasons or not 
     interested in doing this......................................................... 6 
 
 
6.  How much difficulty do you have doing work or hobbies that require you to see well up 
close, such as cooking, sewing, fixing . . . ?  Would you say you have: 
 
No difficulty at all...................................................................(1) 
A little difficulty....................................................................... 2  
Moderate difficulty................................................................... 3  
Extreme difficulty..................................................................... 4 
Stopped doing this because of your eyesight........................... 5  
Stopped doing this for other reasons or not 
     interested in doing this......................................................... 6 
 
 
7.  Because of your eyesight, how much difficulty do you have finding something on a crowded 
shelf?  Would you say you have: 
 
No difficulty at all..................................................................... 1  
A little difficulty....................................................................... 2  
Moderate difficulty................................................................... 3  
Extreme difficulty...................................................................(4) 
Stopped doing this because of your eyesight........................... 5  
Stopped doing this for other reasons or not 
     interested in doing this......................................................... 6   
 
 
 
    
 
 
 
   
Scoring example - Figure 1    
 
 
 
   
Items 5, 6, and 7 are used to generate the near 
activities sub-scale score (Table 3).  Each of the 
items has 6 response choices.  Response choice 
6 indicates that the respondent does not perform 
the activity because of reasons that are unrelated 
to vision.  If a respondent selects this choice, the 
answer is treated as missing and an average of 
the  remaining  items  is  calculated.    Response 
choice 5 indicates that an activity is so difficult 
that  the  participant  no  longer  performs  the 
activity.    This  extremely  poor  near  vision 
response choice is recoded to “0” points before 
taking an average of all three items.  To score all 
items in the same direction, Table 2 shows that 
responses  1  through  5  for  items  5,  6,  and  7 
should be recoded to values of 100, 75, 50, 25, 
and 0 respectively.  If the respondent is missing 
one of the items, the person's score will be equal 
to the average of the two non-missing items.    
 
 
 
   
 
 
 
 
Formula:                                                                                  
 
  Mean  =   (Score for each item with a non-missing answer)   
               Total number of items with non-missing answers 
Example:    
 
  With responses converted:  =   (25 + 100 + 25)    =    50 
            3 
 
Note:   100 = Best, 0 = Worst possible score. 
 
 
 
 
      
 
 
 
   
Psychometric properties of  
VFQ-25 sub-scales     
 
 
 
   
Psychometric data for VFQ-25 reported in the 
earlier  pre-publication  version  of  the  scoring 
manual  have  been  updated  and  submitted  for 
peer-reviewed publication.
2 The values reported 
in this document are identical to those reported 
in  the  future  publication  and  should  be  used 
when citing the performance characteristics of 
the VFQ-25. 
 
Statistical Power Calculations 
Tables 8, 9, and 10 are provided to estimate 
statistical power when using the VFQ-25 and 
VFQ-39. These tables estimate the number of 
subjects needed per group to attain 80% power 
(alpha = 0.05, two-tailed) depending on the 
anticipated difference in scores between 
groups. Table 8 contains power calculations for 
changes over time between two experimental 
(i.e. randomized) groups using a repeated-
measures design. For example, if one were 
interested in being able to detect a 5-point 
difference for the VFQ-25 General Vision sub-
scale, one would need 271 subjects per group. 
Table 9 shows power calculations for two 
experimental groups using a single, post-
intervention measurement design. Such a 
design is not as precise as a design that uses a 
baseline and post-intervention measurement 
points (i.e., more subjects are needed per group 
to detect the same difference). Table 10 
provides corresponding sample size 
information for a non-experimental (i.e. non-
randomized) repeated-measures design where 
subjects self-select into the two groups. One 
sees that the number of subjects needed per 
group is more than that needed for a 
randomized experiment (Table 8) and less than 
the number needed for a randomized, post-
intervention-only measurement design (Table 
9).    
 
 
 
   
    
 
 
 
   
Table 8.  Sample sizes needed per group to detect differences in change over time between 
two experimental groups for the VFQ-25, repeated measures design 
 
          Number of Points Difference   
Scale Name      SD  2  5  10  20 
 
VFQ-25: 
General Health      26.00  1696  271  68  17 
General Vision      21.00  1106  177  44  11 
Ocular Pain      17.00  725  116  29  7 
Near Activities      29.00  2110  338  84  21 
Distance Activities    29.00  2110  338  84  21 
Social Functioning    27.00  1829  293  73  18 
Mental Health      27.00  1829  293  73  18 
Role Difficulties    29.00  2110  338  84  21 
Dependency      28.00  1967  315  79  20 
Driving       35.00  3073  492  123  31 
Color Vision      23.00  1327  212  53  13 
Peripheral Vision    27.00  1829  293  73  18 
VFQ-25 Composite    20.00  1004  161  40  10 
 
VFQ-39: 
General Health      21.00  1106  177  44  11 
General Vision      19.00  906  145  36  9 
Ocular Pain      17.00  725  116  29  7 
Near Activities      28.00  1967  315  79  20 
Distance Activities    26.00  1696  271  68  17 
Social Functioning    25.00  1568  251  63  16 
Mental Health      26.00  1696  271  68  17 
Role Difficulties    28.00  1967  315  79  20 
Dependency      27.00  1829  293  73  18 
Driving       35.00  3073  492  123  31 
Color Vision      23.00  1327  212  53  13 
Peripheral Vision    27.00  1829  293  73  18 
VFQ-39 Composite    21.00  1106  177  44  11 
 
 
Note: Scales are all scored on 0-100 possible range. Estimates assume alpha = 0.05, two-tailed t-test, 
power = 80%, and an inter-temporal correlation between scores of 0.60. 
 
    
 
 
 
   
Table 9.  Sample sizes needed per group to detect differences between two experimental 
groups for the VFQ-25, post-intervention measures only.  
 
          Number of Points Difference   
Scale Name      SD  2  5  10  20 
 
VFQ-25: 
General Health      26.00  2650  424  106  26 
General Vision       21.00  1729  277  69  17 
Ocular Pain      17.00  1133  181  45  11 
Near Activities      29.00  3297  527  132  33 
Distance Activities    29.00  3297  527  132  33 
Social Functioning    27.00  2858  457  114  29 
Mental Health      27.00  2858  457  114  29 
Role Difficulties    29.00  3297  527  132  33 
Dependency      28.00  3073  492  123  31 
Driving       35.00  4802  768  192  48 
Color Vision      23.00  2074  332  83  21 
Peripheral Vision    27.00  2858  457  114  29 
VFQ-25 Composite    20.00  1568  251  63  16 
 
VFQ-39: 
General Health      21.00  1729  277  69  17 
General Vision      19.00  1415  226  57  14 
Ocular Pain      17.00  1133  181  45  11 
Near Activities      28.00  3073  492  123  31 
Distance Activities    26.00  2650  424  106  26 
Social Functioning    25.00  2450  392  98  25 
Mental Health      26.00  2650  424  106  26 
Role Difficulties    28.00  3073  492  123  31 
Dependency      27.00  2858  457  114  29 
Driving       35.00  4802  768  192  48 
Color Vision      23.00  2074  332  83  21 
Peripheral Vision    27.00  2858  457  114  29 
VFQ-39 Composite    21.00  1729  277  69  17 
 
 
Note: Scales are all scored on 0-100 possible range. Estimates assume alpha = 0.05, two-tailed t-test, 
and power = 80%. 
 
 
    
 
 
 
   
Table 10.  Sample sizes needed per group to detect differences between two self-selected 
groups for the VFQ-25, repeated measures design 
 
          Number of Points Difference   
Scale Name      SD  2  5  10  20 
 
VFQ-25: 
General Health      26.00  2120  339  85  21 
General Vision      21.00  1383  221  55  14 
Ocular Pain      17.00  906  145  36  9 
Near Activities      29.00  2637  422  105  26 
Distance Activities    29.00  2637  422  105  26 
Social Functioning    27.00  2286  366  91  23 
Mental Health      27.00  2286  366  91  23 
Role Difficulties    29.00  2637  422  105  26 
Dependency      28.00  2459  393  98  25 
Driving       35.00  3842  615  154  38 
Color Vision      23.00  1659  265  66  17 
Peripheral Vision    27.00  2286  366  91  23 
VFQ-25 Composite    20.00  1254  201  50  13 
 
VFQ-39: 
General Health      21.00  1383  221  55  14 
General Vision      19.00  1132  181  45  11 
Ocular Pain      17.00  906  145  36  9 
Near Activities      28.00  2459  393  98  25 
Distance Activities    26.00  2120  339  85  21 
Social Functioning    25.00  1960  314  78  20 
Mental Health      26.00  2120  339  85  21 
Role Difficulties    28.00  2459  393  98  25 
Dependency      27.00  2286  366  91  23 
Driving       35.00  3842  615  154  38 
Color Vision      23.00  1659  265  66  17 
Peripheral      27.00  2286  366  91  23 
VFQ-39 Composite    21.00  1383  221  55  14 
 
 
Note: Scales are all scored on 0-100 possible range.Estimates assume alpha = 0.05, two-tailed t-test, 
power = 80%, and an inter-temporal correlation between scores of 0.60. 
 
    
 
 
 
   
Frequently Asked Questions (FAQ) 
    
 
 
 
   
Q. What kind of permissions are required  to 
use the VFQ-25 in a research study? 
 
The VFQ-25 is a public document available without charge for 
all researchers to use provided they identify the measure as such 
in all publications and cite the appropriate developmental papers. 
Users do not need to notify the developers or the NEI that they 
intend to use the measure. However, there are some specific 
permissions for using the VFQ-25 that are detailed on the cover 
page of the questionnaire itself. These include acknowledging in 
all publications that the VFQ-25 was developed by RAND and 
funded by the NEI, and that any changes made to the measure for 
your particular study will be identified as such. 
  
Q. Can I change the format of the VFQ-25 to 
suit my study? 
 
Any  change  to  the  wording  or  order  of  the 
items would constitute a change to the measure 
and  should  be  specified  as  such  in  any 
published papers. Other than this, it is expected 
that researchers may need to change the format 
or appearance of items to suit their purposes. 
 
As  of  August  2000,  to  our  knowledge  no 
studies  have  reported  on  the  effect  of  item 
order on responses to VFQ-25 or other similar 
vision-targeted  surveys.  That  is,  whether 
responses  change  depending  where  particular 
items appear in the questionnaire. However, to 
ensure  the  comparability  of  scores  across 
studies, it is our position that the order of items 
should not be changed. 
 
Q.  Has  the  VFQ-25  been  translated  into 
any other languages? 
 
As of August 2000, the developers are aware of 
translation into approximately 9 languages. For 
the  cost  of  distribution,  a  Spanish  language 
version  for  Mexican-American  populations  is 
available  from  the  UCLA  and  RAND  based 
developers.    The  developers  will  provide 
researchers with the names of other persons to 
contact for other language translations. Should 
researchers wish to translate the VFQ-25, the 
same  permissions  apply,  with  the  additional 
requirement  that  all  publications  specify 
responsibility  for  the  translation  along  with 
instructions  for  obtaining  a  copy  of  the 
translated version. 
 
Q. Do you have any additional normative 
information for specific populations? 
 
The  developers  currently  are  not  conducting 
studies  for  the  express  purpose  of  further 
investigating the psychometric properties of the 
VFQ-25  or  producing  normative  data. 
However, many researchers are currently using 
the  VFQ-25  as  an  endpoint  or  outcome  in  a 
number of health services and clinical studies. 
It is likely that as these studies are completed, 
results that are relevant to better understanding 
the  performance  of  the  VFQ-25  will 
accompany the main results of each study.  The 
developers and staff at the NEI are aware of 
other researchers who are collecting condition-
specific  normative  data  on  population-based 
samples with the VFQ-25 and when possible 
will  provide  contact  information  for  these 
investigators to new users. 
 
Q.  How  relevant  is  the  normative  data 
provided  in  the  scoring  manual  to  my 
sample? 
 
The means, standard deviations, and statistical power values 
shown in this document were estimated using cross-sectional 
data from the Field Test Study.  Participants recruited for the 
Field Test were not randomly sampled, but rather were identified 
for enrollment based on clinical criteria biased towards persons 
with moderate to severe forms of each target disease. Further, 
because it was our desire to enroll a broad spectrum of patients 
based on disease severity, we did not take into consideration 
treatment status. Please see references #3 for a full description of 
the NEI-VFQ field test study sample. 
 
Q. Why is a single-item general health item 
included in the VFQ-25? 
 
During the developmental phase of the NEI-VFQ, vision-
targeted health-related quality of life (HRQOL) was a relatively 
new concept. For this reason, we included this question to insure 
that researchers had a minimal amount of information about a 
person’s general health status to use as a benchmark against 
other published samples or cohorts. 
    
 
 
 
   
This  general  health  rating  question  has  been 
widely used in studies and is a robust predictor 
of  future  health  and  mortality.  However,  to 
fully  measure generic HRQOL,  many quality 
of  life  measurement  experts  recommend 
including  a  separate  generic  measure  of 
HRQOL such as the SF-36 or SF-12.
9 In such a 
situation  the  single-item  VFQ-25  general 
health rating question is not needed because the 
identical  question  is  asked  as  part  of  these 
surveys.
10, 11 
 
Q. Should we be looking at the sub-scales 
or the composite score? 
 
The VFQ-25 sub-scales are grouped by theme 
or domain. So, for example, items having to do 
with near vision are differentiated from items 
having  to do  with other  vision  activities like 
distance  vision or ocular pain. This does not 
mean that the items are not highly correlated or 
that they are psychometrically distinct. What it 
does  mean  is  that  researchers  should 
beforehand  carefully  consider  which  vision-
specific  domains  are  most  likely  to  be 
influenced  by  a  particular  disease  and/or 
treatment  and  then  focus on  the results  from 
those sub-scales to support their findings. 
 
The composite score is best used in situations 
where  an  overall  measure  of  vision-targeted 
health  related  quality  of  life  is  desired.  For 
example, in studies where it is not clear what 
the specific impact of ocular disease or a new 
treatment might be. Also, in situations where 
differences  can  be  hypothesized  between 
groups  beforehand  across  multiple  sub-scales 
but  the  overall  sample  size  of  the  study  is 
relatively  small,  because  it  is  likely  that  the 
error term for the composite score is likely to 
be smaller than for any given sub-scale, it may 
be more efficient to represent these differences 
as a single score. 
 
Q. What benefit is there to using the VFQ-
25  over  a  measure  more  specific  to  a 
particular  disease,  like  the  Activity  of 
Daily Vision Scale (ADVS)
10 for persons 
with age-related cataracts? 
 
The  VFQ-25  contains  items  that  are  very 
similar to items found in other vision-targeted 
measure  like  the  ADVS  that  are  more  task 
oriented.  However,  whereas  the  ADVS  was 
designed  specifically  to  assess  a  set  of 
activities most relevant to patients undergoing 
cataract  surgery,  the  VFQ-25  expands  the 
range  of  activities  to  measure  the  impact  of 
ocular  disease  on  broader  domains  of  health 
such  as  social  and  emotional  well-being. 
Serious ocular diseases that lead to irreversible 
loss of vision are likely to impact dimensions 
of a person’s life beyond simple tasks such as 
driving  or  reading  the  newspaper,  and 
similarly,  by  preserving  vision,  many 
successful  interventions  also  will  impact 
persons’  lives  at  this  more  global  level. 
Especially in these situations, use of the VFQ-
25 should be considered. 
 
Q.  Why  does  the  response  to  item  15b, 
“stopped  driving  due  to  vision  and  other 
reasons”,  generate  a  missing  score  for  the 
subsequent driving items? 
 
Driving  items  15,  15a,  and  15b  are  filter 
questions designed to specify whether a person 
has ever driven a car, and if so, whether they 
are currently driving or if they have stopped.  If 
people have never driven a car, then, of course, 
their answers should be set to missing for all 
driving  items.  Similarly,  this  also  applies  to 
people  who  have  stopped  driving  for  other 
reasons  not  due  to  vision.  However,  in  the 
course of pilot testing the field test participants 
wanted this additional mixed response option. 
It was our decision that although persons did 
indeed report not driving due to vision, it was 
not clear how much of a role the “other” reason 
also played in this decision.  Therefore, we set 
the  scoring  criteria  for  this  response  to  be 
missing for all subsequent driving items to be 
absolutely  sure  that  all  driving  responses 
reflected  only  problems  with  vision.  Should 
researchers wish to change this response option 
to allow persons to answer subsequent driving    
 
 
 
   
items (currently there is a skip to  item  #17), 
this  change  should  be  noted  in  subsequent 
publications. 
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